European Neuropsychopharmacology (v.19, #S3)
P.3.c.044 Use of concomitant medication in the treatment of schizophrenia by F. Oosthuizen; J.B. Bodenstein; R. Reddy (S535-S536).
P.3.c.043 Cardio-metabolic risk profiles of community psychiatric patients in North Tyneside, United Kingdom by A. Nulkar; H.M.O. Watkinson; A. Waton; P. Mackin (S535).
P.3.c.045 Treatment efficacy and concomitant benzodiazepine use with aripiprazole versus olanzapine in acute bipolar mania by M. Singh (S536).
P.3.c.046 Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia by H. Meltzer; M. Cohen; L. Snow-Adami; M. Mackle; J. Zhao; A. Szegedi; J. Panagides (S536-S537).
P.3.c.048 Attitudes concerning depot medication in the German general population: a representative telephone survey by J. Cordes; J. Thuenker; K. Hueckelheim; U. Müller; J. Kornischka (S538).
P.3.c.047 Obesity and antipsychotics drugs in patients with schizophrenia by D.G. Gugleta Dragoslava; S.V. Slavkovic Violeta; T.S. Tosic Golubovic Suzana; S.D. Stankovic Jankovic Dora (S537).
P.3.c.042 The comparison of therapeutic efficacy, metabolism of glucose and lipid and change in prolactin in antipsychotics by J.G. Kim; B.M. Choe (S534).
P.3.c.041 Does level of care, gender, age or choice of drug influence adherence to treatment with antipsychotics? by I. Castberg; A. Westin; O. Spigset (S533-S534).
P.3.c.036 Dose pattern and effectiveness of paliperidone in patients with schizophrenia by J-S. Lee; J. Ahn; J. Lee; J. Kim; I. Jung; C. Lee; J. Lee; S. Lee; C. Kim (S530-S531).
P.3.c.035 Effect of quetiapine on the subjective estimates of sleep in the 8 weeks treatment of patients with bipolar depression by B. Yoon; W. Bahk; D. Jon; K. Min; S. Park; H. Chung; Y. Shin (S530).
P.3.c.037 Cognitive functions and PANSS scores in a cohort of patients with schizophrenia treated with olanzapine by A. Borkowska; M. Bielinski; W. Drozdz (S531-S532).
P.3.c.038 Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia by S.T. Tosic Golubovic Suzana; Z.O. Zikic Olivera; N.G. Nikolic Gordana; S.V. Slavkovic Violeta; G.D. Gugleta Dragoslava; S.V. Sibinovic Vladica (S532).
P.3.c.040 Predictors for treatment response in patients with acute schizophrenia by A. Schreiner; M. Blanc; L. Bidzan; D. Hoeben; G. Badescu; M. Schmauss; M. Kotler (S533).
P.3.c.039 Audit of extrapyramidal symptoms in patients treated with long-acting injectable antipsychotics by A. Khan; S. Mustafa (S532-S533).
P.3.c.049 Short-term improvement by minocycline added to olanzapine antipsychotic treatment in schizophrenia by J. Hallak; C. Chaves; C. Marque; J. Crippa; I. Chaudhry; N. Husain; L. Wichert-Ana; J. Deakhi; A. Zuardi; S. Dursun (S538-S539).
P.3.c.050 Expression of the inflammatory cytokine mRNA in patients with schizophrenia treated with quetiapine by S. Kawashige; H. Kikuyama; A. Tsutsumi; T. Kanazawa; T. Hori; M. Nishiguchi; A. Hokyo; J. Koh; H. Yoneda (S539).
P.3.c.060 Changes in hyperprolactinaemia and related adverse events after switching antipsychotic treatment to quetiapine by A.L. Montejo; S. Majadas; M. Franco; N. Prieto; P. Álvarez; R. Gordo; X.A. Espina; T. Martín; J. Guijarro; G. Medina (S544-S545).
P.3.c.059 Association between antipsychotic treatment and clinical and economic outcomes in schizophrenia and bipolar disorder by M. Mychaskiw; K. Sanders; J. Alvir; L. Montejano; G. Lenhart; C. O'Gorman (S544).
P.3.c.061 Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder by T. Suppes; E. Vieta; U. Gustafsson; B. Paulsson (S545-S546).
P.3.c.062 Low doses of antipsychotic in aggressive men: evaluation of cases from the family violence service by M. Mateus; C. Silva; J. Redondo (S546).
P.3.c.064 Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia by K. Grootens; N.M.J. van Veelen; M.M. Sitskoorn; R.J. Verkes; R.S. Kahn (S547).
P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine by S. Porcelli; M. Bosia; F. Cocchi; E. Marino; E. Smeraldi; R. Cavallaro (S546-S547).
P.3.c.058 Theoretical and clinical implications of drug-drug interactions in the psychotic population: an evidence based review by P. Chue; R. Procyshyn; D. Chan (S543-S544).
P.3.c.057 Double-blind, placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia by M. Mackle; L. Snow-Adami; J. Zhao; A. Szegedi; J. Panagides (S543).
P.3.c.052 Higher prevalence of metabolic syndrome in patient with bipolar disorder and schizophrenia in Korean population by N.Y. Lee; H.Y. Yu; D.C. Jung; S.H. Kim; Y.S. Kim; Y.M. Ann (S540).
P.3.c.051 Metabolic screening in serious mental illness outpatients in Function Assertive Community Treatment (FACT) in the Netherlands by D. Cohen; R. Keet (S539-S540).
P.3.c.053 Lithium-neuroleptic neurotoxicity, delirious-extrapyramidal reactions, and neuroleptic malignant syndrome by J.W. Lee (S540-S541).
P.3.c.054 Effect of diagnosis and treatment on cardio-metabolic risk in community psychiatric patients by P. Mackin; A. Nulkar; H.M.O. Watkinson; A. Waton (S541).
P.3.c.056 Population pharmacokinetics of asenapine in patients with schizophrenia or bipolar disorder by M. Prohn; R. De Greef; S. Chapel; T. Kerbusch (S542-S543).
P.3.c.055 Paliperidone-induced obsessive compulsive symptoms by E. Tzavellas; T. Paparrigopoulos; D. Karaiskos; R. Zaloni; X. Stachtea; J. Liappas (S542).
P.3.c.034 Eufest: the moderating impact of metabolic co-morbidities on treatment outcomes in first-episode schizophrenia by W. Fleischhacker; R. Kahn; O. Karayal; C. Siu; E. Pappadopulos (S529-S530).
P.3.c.033 Function assertive community treatment: treatment of severe mental illness in the Netherlands by R. Keet; J.R. van Veldhuizen; A. Nugter (S529).
P.3.c.013 Hospital utilisation and long-acting injectable risperidone: a mirror image study with a national claim-based database by K. Su; H.C. Chang; C.H. Tang; K.P. Su (S518).
P.3.c.012 Use of atypical antipsychotic determines good compliance to medication in a teaching hospital in Malaysia by N.Z. Zainal; C.G. Ng (S517).
P.3.c.014 Effects of long-acting injectable risperidone on cognitive function in patients with schizophrenia by S.W. Kim; Y.H. Lee; J.H. Lee; K.H. Chung; J.A. Yoo; J.H. Ryu; J.S. Yoon; J.M. Kim; I.S. Shin; S.J. Yang (S518).
P.3.c.015 Dose response side effects of risperidone versus convenient antipsychotics by I. Popovic; V. Popovic (S519).
P.3.c.017 Performance of the Spanish version of the TOOL questionnaire: impact of adverse events of antipsychotics on patients by A.L. Montejo; J. Correas Lauffer; J. Cuervo; L. Cordero; T. Diez; J. Maurino (S520).
P.3.c.016 Assessment of efficacy and metabolic effects in schizophrenic patients switched from risperidone to ziprasidone by J.H. Lee; J.O. Song; S.J. Lee; K.H. Lee (S519-S520).
P.3.c.011 Short term treatment responsiveness of cognitive impairments in first episode of schizophrenia by I. Miclutia; R. Macrea; C.A. Popescu (S516-S517).
P.3.c.010 Severity of negative symptoms in schizophrenic patients treated with atypical neuroleptic risperidone – follow-up by M. Krzystanek; E. Krzystanek; I. Krupka-Matuszczyk (S516).
P.3.c.005 Paliperidone in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability by P. Bozzatello; S. Bellino; C. Rinaldi; F. Bogetto (S513).
P.3.c.004 The effect of intramuscular olanzapine in the treatment of acute agitation in patient with psychotic symptoms by J.C. Shim; B.G. Kong; S.G. Lee; Y.H. Kim (S512-S513).
P.3.c.006 Life satisfaction, psychopathology and functional level in chronic schizophrenia undergoing antipsychotic treatment by H. Jung; S. Hwang; J. Yi; Y. Kim; Y. Kim (S514).
P.3.c.007 Efficacy of atypical antipsychotics in chronic daily headache by N. Kouroumalos; M. Foutouli; K. Kalamafkianaki; E. Nikolakaki (S514-S515).
P.3.c.009 Positive and negative symptoms reduction follow-up in patients treated with olanzapine by M. Krzystanek; E. Krzystanek; I. Krupka-Matuszczyk (S515-S516).
P.3.c.008 Efficacy and tolerability of aripiprazole in outpatients with schizophrenia or schizoaffective disorder by D. Shin (S515).
P.3.c.018 Add on of another antipsychotic vs switch to a different antipsychotic: effect on QTc interval by G. di Sciascio; S. Calo; G. Amodio; S. D'Onofrio; R. Pollice (S520-S521).
P.3.c.019 Coronary heart disease risk in schizophrenic patients by J. Castaño; B. Diaz; C. Gamier; A. Navarro; P. Alvaro; R. Sanchis; H. Schroder; L.M. Martin; A. Bulbena (S521-S522).
P.3.c.028 Schizophrenic patients treated with quetiapine perform better than haloperidol on theory of mind tasks by H. Jia; R. Gao; H. Zhu; L. Bu; Y. Zhang (S526-S527).
P.3.c.027 Therapeutic adherence and readmissions in schizophrenic patients treated with paliperidone a 6-month follow-up by J.A. Blanco; J.A. Aguado; G. Medina; O. Segurado; J.I. Franch; J.J. Madrigal (S526).
P.3.c.029 Results from the monitoring system for clozapine in Slovakia by J. Pecenak; V. Novotny; P. Janik (S527).
P.3.c.030 Low dose versus standard dose of antipsychotics for relapse prevention in schizophrenia: a meta-analysis by H. Takeuchi; D.C. Mamo; T. Suzuki; T. Arenovich; H. Uchida (S527-S528).
P.3.c.032 Gender differences and risk of metabolic abnormalities in patients under long-term antipsychotic treatment by G. Cerveri; A. Mazzocchi; L.S. Volonteri; I. Netti; C. Mencacci (S528-S529).
P.3.c.031 Low daytime activity and increased night rest time during antipsychotic treatment of schizophrenia by A. Wichniak; E. Waliniowska; I. Musinska; K. Czasak; A. Wierzbicka; W. Jernajczyk; M. Jarema (S528).
P.3.c.026 Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis by B.G. Kong; J.C. Shim; S.K. Lee (S525-S526).
P.3.c.025 Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report by O. Saatcioglu; S. Gumus; K. Kamberyan; M. Yanik (S524-S525).
P.3.c.021 Plasma level monitoring of antipsychotics in two different clinics for court-order detention patients in The Netherlands by C. De Blecourt; T.I. Oei (S522-S523).
P.3.c.020 Paliperidone action on prolactin level in the real clinical practice: results by V. Fricchione Parise; G. Balletta; R. Ioime (S522).
P.3.c.022 Effect of olanzapine on serum insulin level and psychopathology profile in inpatients with schizophrenia by B. Konarzewska; A. Szulc; R. Poplawska; N. Waszkiewicz (S523).
P.3.c.023 Delirium psychoses caused by antiparkinsonian drugs by J. Santiago Sastre; A. Sánchez Peña (S523-S524).
P.3.c.024 Risperidone long-acting formulation in treatment-resistant schizophrenic patients: the predictive value of plasma levels in relation to clinical response and safety by G. Cerveri; L.S. Volonteri; I. De Gasperi; B. Papini; P. Papa; M.C. Mauri; C. Mencacci (S524).
P.3.c.065 Aripiprazole in the treatment of kleptomania: a case study by S. Mercan; O.G.U.Z. Karamustafalioglu; V. Karabulut; H. Sengul (S547-S548).
P.3.c.066 Treatment of cervical tardive dystonia with botulinum toxin type-A: two case reports by E. Marini; P. Georgila; N. Kouroumalos; V. Nikolopoulos; N. Tagaris; D. Sakkas (S548).
P.3.e.009 The role of social support and therapeutic alliance in promoting adherence to medication in first episode psychosis by A. Malla; M. Rabinovitch; C. Cassidy; R. Joober (S572-S573).
P.3.e.008 A programme for the emotional intelligence development of chronic mental patients by M.A. Sánchez Peña; J. De Santiago Sastre (S571-S572).
P.3.e.010 Assessing antipsychotics in practice: patients' views and experience by R. Hunter; S. Shankie; C. McMillan (S573).
P.3.e.01l Tobacco smoking and schizophrenia spectrum disorders in the CLAMORS study: a case-control analysis in the Spanish context by J. Rejas; J. Bobes; C. Arango; M. Garcia-garcia (S573-S574).
P.3.e.013 Psychiatric and non-psychiatric comorbidity in patients with psychotic disorders by M. Garcia Mahia; M. Vidal Millares; C. Armas Barbazan; L. Pérez Ramírez; J. Bajo Lema (S574-S575).
P.3.e.012 Validity of the Functional Remission On General Schizophrenia (FROGS) scale: second validation study by C. Lançon; F. Rouillon; P.M. Llorca; P. Gorwood; F.J. Baylé (S574).
P.3.e.007 Polarity of the first episode and predominant polarity in a cohort of bipolar outpatients by A. García-López; C. De Dios-Perrino; E. Ezquiaga (S571).
P.3.e.006 Diagnostic stability of schizophrenia in Korean patients according to the DSM-IV by W. Kim; Y.S. Woo; H.J. Seo; W.M. Bahk (S570-S571).
P.3.e.00l Initial motivation predicts long-term adherence to pharmacological treatment by I. García-Cabeza; M.S. Olmeda; M. Salgado (S567-S568).
P.3.d.023 Comparison of atypical antipsychotics on acute phencyclidine (PCP) treatment-induced social interaction deficit in rats by G. Imre; I. Gyertyán (S567).
P.3.e.002 Do patients follow advice from physical healthcare clinics in secondary care: an audit by R.E. Hodgson; S. Mendis (S568).
P.3.e.003 The relative association between four treatment-emergent adverse events and health-related quality of life by I. Ruiz; C. Adrianzen; C. Arango-Dávila; D. Martinez-Araujo; R. Walton; J. Maria-Haro; D. Novick; M. Dossenbach; J. Karagianis (S568-S569).
P.3.e.005 Factors influencing burden on the primary caregivers of remitted schizophrenic outpatients by C.K. Kim; B.M. Choe; M.J. Kim; H.C. Kim; J.H. Jang (S570).
P.3.e.004 Wellness program in the Czech Republic: evaluation of weight changes in schizophrenic patients related to medication by E. Kitzlerová; L. Motlová-Bankovská; E. Dragomirecká (S569-S570).
P.3.e.014 Membrane fatty acid levels as a predictor of treatment response in schizophrenia by T. Sumiyoshi; M. Matsui; Y. Higuchi; T. Itoh; H. Itoh; H. Arai; C. Takamiya; Y. Kawasaki; M. Suzuki; M. Kurachi (S575).
P.3.e.015 Impact of smoking tobacco on healthy life-style habits and 10-year cardiovascular risk in schizophrenia disorders by C. Arango; J. Bobes; M. García-García; J. Rejas (S575-S576).
P3.e.024 Social cognition: response to treatment in first episode psychosis by R. Schoeman; P.P. Oosthuizen; R. Emsley (S580-S581).
P3.e.023 Statistical approaches in a global era: integrating multi-regional studies by B. Parsons; C. Siu; N. Schooler; S. Potkin; G. Cohen (S580).
P.3.f.001 Compliance over 8 year of follow-up in first psychotic episodes by S. Barbeito; P. Vega; A. Ugarte; B. Fernandez de Corres; P. López; A. González-Pinto (S581).
P.3.f.002 Effect of MK-801 on lipopolysaccharide (LPS)-induced sensorimotor gating impairments in neurodevelopmental model of schizophrenia in rats by A. Basta-Kaim; B. Budziszewska; M. Leskiewicz; M. Kubera; W. Lason (S582).
P.3.f.004 Regulation of the GABA cell phenotype in neurodevelopmental model of schizophrenia in rats by A. Basta-Kaim; B. Budziszewska; M. Leskiewicz; M. Kubera; K. Fijal; W. Lason (S583).
P.3.f.003 Prenatal immune activation induces primary defects in dopaminergic development relevant to schizophrenia by J. Feldon; S. Vuillermot; U. Meyer (S582-S583).
P.3.e.022 Schizophrenia and pregnancy: long-term study of a women-on-treatment sample in the community by M.L. Zamarro; D. Crespo; A. Cordero; R. Gutierrez; J. Ramos (S579-S580).
P.3.e.021 Effective treatment for schizophrenic patients with history of neuroleptic malignant syndrome by A.M. Ciobanu; A.A. Ciucu; S. Mihalascu (S579).
P.3.e.017 Brain activation preceding auditory verbal hallucinations by I. Sommer; K.M. Diederen; R.S. Kahn (S576-S577).
P.3.e.016 Effectiveness of repetitive transcranial magnetic stimulation repetitive TMS for depression in schizophrenia by N. Maslenikov; E. Tsukarzi; S. Mosolov (S576).
P.3.e.018 The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia by D.C. Jung; S.S. Hwang; S.H. Kim; N.Y. Lee; H.Y. Jung; Y.M. Ahn; Y.S. Kim (S577).
P.3.e.019 The impact of once-daily quetiapine fumarate on length of hospitalisation in patients with mental illness by K. Järbrink; J. Locklear; D. Hayflinger (S578).
P.3.e.020 Early medication adherence and insight change in first episode psychosis by M. Lepage; M. Bodnar; L. Buchy; R. Joober; A.K. Malla (S578-S579).
P.3.d.022 The effects of quetiapine, olanzapine and haloperidol on human plasma lipid peroxidation in vitro by A. Dietrich-Muszalska; J. Rabe-Jablonska; B. Kontek (S566-S567).
P.3.d.02l Long-term treatments with low and high-dose olanzapine changed hepatocyte numbers in rats by E. Odaci; H. Bilen; A. Hacimuftuoglu; O.N. Keles; I. Can; M. Bilici (S566).
P.3.d.001 In-vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors by Y. Tadori; A. Forbes; R. McQuade; T. Kikuchi (S554).
P.3.c.075 A randomized controlled, pilot study of aripiprazole in the treatment of delirium by S.W. Jung; K.S. Kim (S553-S554).
P.3.d.002 Hyperglycemia and antipsychotic treatment in patients on methadone maintenance by L. Barbadillo; E. Zapirain; A. Lopez; E. Usoz; A.V. Gil; A. Calvo (S554-S555).
P.3.d.003 Metabolic syndrome and antipsychotic treatment in patients on methadone maintenance by E. Zapirain; L. Barbadillo; O. Eizaguirre; A.L. Odriozola; A. Álvarez; M.P. Aizpuru (S555-S556).
P.3.d.005 Effects of typical and atypical antipsychotics on choline acetyltransferase expression in rats by Z. Sui; G. Huang; Y. Chung (S556-S557).
P.3.d.004 Retrospective case note study of use of antimuscarinic prescribing in modern in patient psychiatric setting by V. Agrawal; R. Rizwan; S. Agrawal (S556).
P.3.c.074 L-lysine as an add-on treatment in patients with schizophrenia by C. Wass; D. Klamer; E. Katsarogiannis; K. Fejgin; E. Palsson; J. Svensson; I. Bogren; J.A. Engel; M. Berglund; B. Rembeck (S553).
P.3.c.073 Relation of the change in symptoms and cognitive functions in schizophrenia with the change in cortical inhibition by I. Yildiz; A. Ertugrul; C. Temucin (S552-S553).
P.3.c.068 Efficacy outcomes of risperidone long acting injection in patients previously on oral atypicals versus conventional depots by A. Lam; P. Chue; L. Lígate; K. Akhras; A. Jacobs (S549-S550).
P.3.c.067 The effects of amisulpride on weight and metabolic parameters in psychotic patients with surcharge weight by J. Monreal Ortiz; D. Chesa Vela; E. Surribas Leza; C. Franquelo Cruz (S548-S549).
P.3.c.069 Association study of plasma aripiprazole level and psychopathology among people with schizophrenia by T. Lan; H. Chiu; H. Chen; C. Chan (S550).
P.3.c.070 Substance abuse does not compromise improvements in Spanish patients treated with risperidone long-acting injection by A. Lam; J.M. Olivares; K. Akhras; A. Jacobs (S550-S551).
P.3.c.072 Clinical differences between classical and atypical long acting antipsychotics in a community setting by J.M. Pelayo-Teran; O. Fernández-Torre; P. Trabajo-Vega; J. Martínez-Diez; C. Ordóñez-Prieto; R. Casado-Martínez; N. Varela-Aller; M. Álvarez-Bermejo; V. Quintana-González; C. Villaverde-Amieva (S552).
P.3.c.071 Catechol-o-methyltransferase val158met in first episode psychosis: prognostic factor or negative trait marker? by J.M. Pelayo-Teran; R. Pérez-Iglesias; I. Mata; J. Vázquez-Bourgon; E. Carrasco-Marín; X.L. Vázquez-Barquero; B. Crespo-Facorro (S551).
P.3.d.006 Effects of postnatal intermittent hypoxia on prepulse inhibition and locomotor activity in rats by R. Barbosa da Silva; K. Yamada; S. Satake; J.C. Perry; V. D'Almeida (S557).
P.3.d.007 The pattern of use and outcome of Asian patients with schizophrenia treated with risperidone over five years by J.S. Gill; S.T. Jambunathan; J.H. Ting; O.H. Koh; N.Z. Zainal (S558).
P.3.d.016 Effect of olanzapine on MK-801-induced impairment of memory in the radial-arm maze test in mice by I. Komsuoglu; O. Mutlu; G. Ulak; F. Yildiz Akar; F. Erden (S563).
P.3.d.015 Enhanced cortical dopaminergic and glutamatergic transmission and antipsychotic-like effect of risperidone by idazoxan by M.M. Marcus; C. Wiker; O. Frånberg; A. Konradsson-Geuken; X. Langlois; K. Jardemark; T.H. Svensson (S562-S563).
P.3.d.017 Behavioural and molecular effects of N-desmethylclozapine and clozapine in an animal model of schizophrenia by A. Ertugrul; E. Saka; H. Ozdemir; A. Vural; Y. Ozdemir; H.Y. Meltzer; T. Dalkara (S563-S564).
P.3.d.018 GABAergic intemeurons are involved in the excitatory action of 8-OH-DPAT on prefrontal cortex pyramidal neurons by L. Lladó-Pelfort; F. Artigas; P. Celada (S564).
P.3.d.020 Characterization of [3H]asenapine binding in sections of rat brain by M. Shahid; B. Henry (S565-S566).
P.3.d.019 Asenapine improves cognition and cortical serotonergic function in monkeys with phencyclidine-induced impairment by J. Jentsch; J. Elsworth; M. Shahid; H. Marston; R. Roth (S565).
P.3.d.014 Modification of cortical inhibition by paliperidone or risperidone: preliminary results by L. Ustohal; R. Prikryl; H. Kucerova; L. Havlaskova; E. Ceskova (S561-S562).
P.3.d.013 Reboxetine enhances cortical dopaminergic and glutamatergic transmission and the antipsychotic-like effect of olanzapine by T.H. Svensson; K. Jardemark; A. Malmerfelt; C. Bjorkholm; M.M. Marcus (S561).
P.3.d.009 Effects of olanzapine and sertindole on MK-801 induced visual memory deficit in mice by O. Mutlu; I. Komsuoglu; G. Ulak; F. Erden; F. Yildiz Akar (S559).
P.3.d.008 Translating antipsychotic efficacy across species based on free (unbound) drug concentrations by C. Bundgaard; C.K. Olsen; C. Sveigaard; B. Steiniger-Brach (S558).
P.3.d.010 Pharmachological treatment in first psycotic episodes: glutamate and BDNF levels by S. Ruiz De Azua Garcia; S. Barbeito; S. Alberich; J.R. Pecina; M. Hernanz; A. González-pinto (S559-S560).
P.3.d.01l The immunomodulatory effects of atypical neuroleptics quetiapine and amisulpride in the dynamics of 6-week treatment by O.A. Lobacheva; T.P. Vetlugina; A.V. Semke (S560).
P.3.d.012 The effects of single dose aripiprazole and haloperidol on resting blood flow in healthy volunteers by R. Handley; F. Zelaya; A.A.T.S. Reinders; T. Marques; S. Kapur; R. Murray; P. McGuire; S. Williams; C. Paríante; P. Dazzan (S560-S561).
P.3.c.003 An open label study of the use of aripiprazole in the treatment of chronic PTSD: preliminary findings by M. Hopwood; J. Wardell; P. Chen; K. Wallace; I. Krivonos (S512).
P.3.c.002 Comparison of risperidone, olanzapine and quetiapine for body weight, serum blood glucose and prolactin levels by H. Chaudhry; N. Arshad; S. Niaz; T. Suleman; K. Mufti (S511-S512).
P.2.e.027 Do mood stabilizers protect patients with bipolar disorders from negative effects of life events? by S. Ben Nasr; Y. El Kissy; G.H. Amara; R. Hamdi; B. Ben Hadj Ali (S463-S464).
P.2.e.026 Valproate for acute bipolar depression: systematic review and meta-analysis by A.H. Young; J.M. Azorin; G. Perugi; E. Vieta; C. Bowden; V. Cornelius; L.A. Smith (S463).
P.2.e.028 Prevalence and correlates of obesity and overweight during treatment in patients with bipolar I disorder by A. Mechri; A. Ezzaher; D. Haj Mouhamed; W. DouM; M.E. Najjar; L. Gaha (S464-S465).
P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial by A. Saricicek; K. Maloney; B. Lorberg; A. Muralidharan; B. Ruf; H. Blumberg; J. Hu; B. Pittman; G. Sanacora; Z. Bhagwagar (S465).
P.2.e.031 Metabolic syndrome in bipolar disorders in Spain: findings from the population-based case-control BIMET-VIVA study by R. Gabriel-Sánchez; L. Lorenzo-Carrascosa; M. Alonso-Arroyo; A. González-Pinto; E. Vieta; J.M. Montes; J. Rejas; F. Mesa (S466).
P.2.e.030 Creatine kinase level may not be associated with motor activity but with simple mood state in Korean unmedicated bipolar patients by S. Chung; M.S. Choi; T.S. Ha; J.C. Yang; T.W. Park; Y.C. Chung; A.J. Jung (S465-S466).
P.2.e.025 Ziprasidone with adjunctive mood stabilizer in maintenance treatment of bipolar disorder: metabolic profiles by O. Karayal; K. Ice; P. Chappell; J. Schwartz; C. Siu; E. Pappadopulos (S462-S463).
P.2.e.024 The effect of mania on cytokine status in bipolar illness by A. Remlinger; P. Wojciak; J. Karczewski; A. Kostrzewa; K. Wiktorowicz; J.K. Rybakowski (S462).
P.2.e.019 Predictors of recurrence in bipolar I disorder: a 2-year prospective study in a Tunisian sample by A. Mrad; L. Bouzgarrou; A. Mechri; W. Douki; M.F. Najjar; L. Gaha (S459).
P.2.e.018 Thyroid function index and recurrence in patients with bipolar disorders by J.M. Kang; D.H. Han; S.Y. Joo; J.W. Kim (S458-S459).
P.2.e.020 Effects of pharmacological treatment on the use of episodic memory storage and recall strategies in bipolar I disorder by C. Lopez-Jaramillo; J.P. Lopera-Vasquez; A. Gallo; J. Ospina-Duque (S459-S460).
P.2.e.021 Time with symptoms in a cohort of bipolar outpatients followed prospectively during 18 months by C. De Dios Perrino; E. Ezquiaga Terrazas; A. García López (S460).
P.2.e.023 Axis I psychiatric comorbidity in Korean patients with bipolar disorder: prevalence and response to treatment by B. Cha; E.S. Moon; C.Y. Jeong; K. Ha (S461-S462).
P.2.e.022 Effectiveness and safety of amisulpride's high dose in acute mania: an open label study by S. Arques; M.A. Pino; D. Villavicencio; P. Sierra; L. Livianos (S461).
P.2.e.032 Patterns in European and rest of world use of doctorate level raters in bipolar and schizophrenia clinical trials by D. Daniel; J. Bartko; N. Sartorius; E. Vieta; A. Butler; G. Moya (S466-S467).
P.2.e.033 Predictors of the development of cardiometabolic abnormalities in youth with bipolar disorder on ziprasidone or placebo by C. Correll; E. Pappadopulos; O. Karayal; F.S. Mandel (S467).
P.2.g.003 Backpain in patients with depressive disorder by J. Martinovic; A. Miljatovic; A. Brankovic (S473).
P.2.g.002 Mean platelet volume in patients with major depression: effect of escitalopram treatment by F. Canan; A. Ataoglu (S472-S473).
P.2.g.004 Effect of escitalopram treatment on white blood cells in patients with major depression by F. Canan; A. Ataoglu; A. Ozcetin (S473-S474).
P.2.g.005 A long term prospective study of mixed bipolar patients by A. González-Pinto; M.A. Jimeno; M. Gutiérrez; K. Haidar; M. Sainz (S474).
P.2.g.007 Interactions between cholesterol and serotonin transporter polymorphism on late-life depression by K.Y. Bae; J.A. Yoo; J.M. Kim; I.S. Shin; S.W. Kim; S.J. Yang; J.H. Ryu; T. Youn; I.S. Yoon (S475).
P.2.g.006 Effects of phosphatidylserine on depression in the elderly by T. Komori; T. Matsumoto; E. Motomura; T. Shiroyama (S474-S475).
P.2.g.001 Correlation between smoking and depression by I. Gabos Grecu; M. Gabos Grecu; T. Moica; A. Vesa; R. Crisan; M. Florea; G. Buicu; C. Gabos Grecu (S471-S472).
P.2.f.001 Mania-like behavioural abnormalities of diacylglycerol kinase β knockout mice by K. Kakefuda; A. Oyagi; K. Tsuruma; M. Shimazawa; K. Yokota; Y. Shirai; K. Horie; N. Saito; J. Takeda; H. Hara (S471).
P.2.e.035 Is bipolar affective disorder under-diagnosed in secondary care in the UK? by M. Agius; B. Iankov; L. Murphy; R. Zaman (S468-S469).
P.2.e.034 Personality disorder comorbidity among outpatients with bipolar disorder: impact on prognosis and quality of life by A. Frikha; G.H. Amara; S. Dridi; S. Ben Nasr; B. Ben Hadj Ali (S468).
P.2.e.036 Determination of a Young Mania Rating Scale severity threshold and of the minimally clinical significant difference in the EMBLEM cohort by M. Lukasiewicz; S. Gerard; A. Besnard; B. Falissard; E. Perrin; H. Sapin; M. Tohen; C. Reed; J.M. Azorin (S469).
P.2.e.037 The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial by M. Knesevich; K. Papadakis; A. Bose; G. Andor; I. Laszlovszky (S469-S470).
P.2.e.039 Prevalence and correlates of non-adherence with mood stabilisers in patients with bipolar I disorder by A. Mechri; L. Bouzgarrou; A. Mrad; W. DouM; M.F. Najjar; L. Gaha (S470-S471).
P.2.e.038 Mood disorders and obesity: quality of life and social functioning by E. Pierantozzi; L. Bossini; M. Roggi; L. Padula; R.N. Forgione; P. Castrogiovanni; A. Fagiolini (S470).
P.2.e.017 Aripiprazole combination with divalproex in patients with acute manic and mixed episode by W. Bahk; Y.S. Woo; M.Y. Chung; D.H. Kim; B.H. Yoon; J.H. Lee; Y.M. Ahn; S.K. Chung"; J.G. Kim; K.H. Lee (S458).
P.2.e.016 Sensitivity of a comprehensive rating scale for bipolar disorders to assess improvements with treatment by C. Bowden; J. Mintz; J. Gonzalez; V. Singh; P. Thompson; C. Bernardo (S457-S458).
P.2.d.029 The influence of mianserin on cytokines plasma levels in rats under chronic mild stress by K. Manikowska; P. Mikolajczak; M. Wojtys; T. Bobkiewicz-Kozlowska (S445-S446).
P.2.d.028 Influence of antidepressants on cytokines in lipopolysaccharide-stimulated primary rat mixed glial cell cultures by A.M. Bielecka; A. Pudelko; M. Paul-Samojedny; J. Kowalski; E. Obuchowicz (S445).
P.2.d.030 Glucocorticoid induced reduction in neural stem cell proliferation is counteracted by antidepressants by C. Anacker; P. Zunszain; L. Carvalho; S. Thuret; J. Price; C.M. Paríante (S446).
P.2.d.03l Trazodone increases extracellular serotonin levels in the frontal cortex of rats by B. Garrone; S. De Santi; D. D'Amico; A. di Matteo; L. Olivieri; M. Magnani; A. Comandini; A. Guglielmotti (S447).
P.2.d.033 Effect of desipramine and imipramine chronic administration on lipopolysaccharide-induced interleukin-1β levels in rat brain and plasma by E. Obuchowicz; A. Prymus; A. Bielecka; L. Drzyzga; M. Kot; W.A. Daniel; I. Krupka-Matuszczyk (S448).
P.2.d.032 Glycogen synthase kinase 3 (GSK-3β) an emerging target for neurological disease: in silico study to investigate the binding mode of trazodone by R. Ombrato; M.A. Alisi; N. Cazzolla; G. Corso; C. Manelfi; G. Mangano; M. Magnani; C. Milanese; L. Olivieri; L. Polenzani (S447-S448).
P.2.d.027 Psychopharmacological therapy of depressed patients requiring in-patient care by E. David; M. Bálint; E. Frey; R. Papp; G. Gazdag (S444-S445).
P.2.d.026 The role of GIRK channels on the inhibitory effect of antidepressants on noradrenergic neurotransmission by M. Torrecilla; I. Fernandez-Aedo; L. Ugedo (S444).
P.2.d.021 Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties by M. Mallei; S. Zappettini; L. Musazzi; E. Mocaer; C. Gabriel; M. Milanese; G. Bonanno; M. Popoli (S441-S442).
P.2.d.020 Administration of stressin I into the locus coeruleus induces noradrenaline release: a microdialysis study in rat by I. Horrillo; J.E. Ortega; J.J. Meana (S441).
P.2.d.022 CYP2D6 P34S polymorphisms and mirtazapine responses in Koreans with major depression by M.S. Lee; H.Y. Lee; H.S. Chang; J.H. Paik; B.J. Ham; R.H. Kang; S.O. Jeon; Y.J. Jeong; H.M. Kim (S442).
P.2.d.023 Synergic mechanisms in the modulation of BDNF and Arc following agomelatine administration by F. Calabrese; R. Molteni; S. Pisoni; C. Gabriel; E. Mocaer; G. Racagni; M.A. Riva (S442-S443).
P.2.d.025 Paroxetine treatment in women with menopausal depression by V.F. Filovska; M.J.K. Jakovcevska; O.D. Dimova; I.N. Nedzipi (S443-S444).
P.2.d.024 Modulation of the neurotrophin BDNF in serotonin transporter mutant rats by F. Calabrese; R. Molteni; A. Cattaneo; F. Macchi; G. Racagni; M. Gennarelli; B.A. Ellenbroek; M.A. Riva (S443).
P.2.e.00l Predominant polarity as an outcome predictor in a clinical trial for bipolar depression by I.P. Pacchiarotti; A.R. Rosa; L.M. Mazzarini; F. Colom; M. Tohen; E. Vieta (S448-S449).
P.2.e.002 Asenapine effects on individual items on the young mania rating scale in patients with bipolar I disorder by J. Zhao; J. Panagides (S449).
P.2.e.01l Characteristics of patients with bipolar disorder presenting a current major depressive episode: analysis in 8 countries by A.H. Young; J. Angst; J.M. Azorin; C.L. Bowden; G. Perugi; E. Vieta (S454-S455).
P.2.e.010 Nutritional, metabolic and endocrine disorders in patients with bipolar disorder: a systematic review by S. Jerónimo; J. Bobes; F. Rico-Villademoros; J.M. Montes; J. Mostaza; E. Vieta (S454).
P.2.e.012 The effect of genetic predisposition and COMT on sad facial information processing in bipolar disorder by S. Frangou; G. Lelli-Chiesa; M. Kempton (S455).
P.2.e.013 Seasonal variations in bipolar disorder admissions in Galiza by I. Veiga Ramos; P. De Usabel; M.J. Mota; A. Arauxo (S455-S456).
P.2.e.015 Brain structural changes associated with predisposition, resilience and disease expression in bipolar disorder by S. Frangou; M. Kempton (S457).
P.2.e.014 Memory and executive functions among siblings of patients with bipolar I disorder by M. Rabie; H.A. Rami (S456).
P.2.e.009 Gynaecological and obstetric comorbidities in patients with bipolar disorder: a systematic review by J. Bobes; J.M. Montes; J. Mostaza; F. Rico-Villademoros; E. Vieta; J. Saiz-Ruiz (S453-S454).
P.2.e.008 Cardiovascular and respiratory comorbidities in patients with bipolar disorder: a systematic review by J.M. Montes; J. Saiz-Ruiz; E. Vieta; J. Mostaza; F. Rico-Villademoros; J. Bobes (S452-S453).
P.2.e.004 Age at onset in bipolar disorder by I.H. Paik; W. Ham; Y.S. Woo; M.H. Park (S450-S451).
P.2.e.003 Mixed symptoms of bipolar disorder related to nicotine dependence but not current smoking in young men by C.B. Yeh; S.S.F. Gau; W.C. Mao; J.F. Shyu (S449-S450).
P.2.e.005 Factors affecting recovery from mania in bipolar disorder in patients treated with atypical antipsychotics by T. Treuer; F.D. Yang; D. Dikeos; G. Tapia; M. Blinc Pesek; C. Hudita; T. Okasha; M. Molnar; Y. D'Yachkova; G. Harrison (S451).
P.2.e.006 Prophylactic effect of lithium in maintenance treatment of bipolar disorder is associated with plasma levels >0.6 mEq/L by W.A. Nolen; B. Paulsson; R.H. Weisler (S451-S452).
P.2.e.007 Everyday practice of French psychiatrists in the drug treatment of bipolar disorders by L. Samalin; S. Guillaume; R.M. Llorca (S452).
P.2.g.008 Effects of lemon and valerian inhalation on autonomic nerve activity in depressed and healthy subjects by T. Komori; T. Matsumoto; E. Motomura; T. Shiroyama (S475-S476).
P.2.g.009 Effectiveness of prolonged-release melatonin in chronic insomnia concomitant with depression – naturalistic observation by M. Siwek; D. Dudek; K. Styczen; G. Nowak (S476).
P.3.a.034 A short term pilot group for patients with co-occurring psychosis in partial remission and substance use disorders by A. Uzmah Kucina; M. Delic; B. Avgustin (S499-S500).
P.3.a.033 Family association study in schizophrenia by P. Kapelski; P. Czerski; A. SzczepanMewicz; M. Skibinska; J. Rybakowski; J. Hauser (S499).
P.3.a.035 The Polish version of the InterSePT scale for suicidal thinking – reliability and validity by A. Mlodozeniec; M. Jarema; T. Szafranski; A. Leszczynska; K. Krysiak; K. Katarasinska-Pierzgalska (S500).
P.3.a.036 Drug-induced akathisia and suicidal ideation in schizophrenia inpatients by A. Mlodozeniec; M. Jarema; T. Szafranski; A. Leszczynska; K. Krysiak; A. Zebrowska (S501).
P.3.a.038 Computerized analyses of prosody in schizophrenia by S. Portuguese; S. Piantadosi; E. Gibson; B.M. Cohen; D. Ongur (S502).
P.3.a.037 Auto-antibodies in affective and schizophrenic disorders by I. Ganhao; E. Goncalves; P. Pedro (S501-S502).
P.3.a.032 The relationship between striatal dopamine function and frontal cortical function in the aetiology of psychosis by O. Howes; P. Fusar-Poli; P. Allen; R. Murray; P. Grasby; P. McGuire (S498-S499).
P.3.a.03l Comorbid depression and treatment attitude among out-patients with schizophrenia or schizoaffective disorder by A. Frikha; S. Brahem; A. Mhalla; S. Mlika; S. Ben Nasr; B. Ben Hadj Ali (S498).
P.3.a.026 Ziprasidone switching effects on metabolic syndrome in patients treated with others atypical antipsychotics by R. Grigorescu; V. Voicu; D. Vasile; G. Grigorescu; M. Staicu (S495).
P.3.a.025 Influence of knowledge of the Spanish consensus on physical health in schizophrenic patients in clinical practice by J. Bobes; J. Saiz-Ruiz; I. Barber; J. Luque (S494-S495).
P.3.a.027 Evaluation of clinical efficacy of social skills training in patients on continuous pharmacotherapy by E. Shimada; S. Niwa; N. Anzai; E. Ikebuchi; M. Nishizono (S495-S496).
P.3.a.028 Memantine precipitates psychosis in Kraepelinian's paraphrenia: case report and implications by B. Trancas; C. Vieira; A. Luengo; B. Pereira; J. Ribeiro; J. Ramos; A. Neto; M. Martins; G. Cardoso (S496).
P.3.a.030 A 6-month, double-blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder by E. Vieta; C. Bowden; K.S. Ice; J.H. Schwartz; P. Wang; M. Versavel; O. Karayal (S497-S498).
P.3.a.029 The importance of working through the trauma of psychosis – the role of group therapy by B. Avgustin; N. Perovsek Solinc; M. Blinc Pesek; H. Korosec Javornik (S496-S497).
P.3.a.039 Developing guidelines for the treatment of stable schizophrenia across primary and secondary care by M. Agius; S. Chapman; R. Zaman (S502-S503).
P.3.b.001 Predictors of social functioning in schizophrenia by A. Erol; E. Unal; E. Tune Aydin; L. Mete (S503).
P.3.b.010 Structural brain abnormalities and altered sensitivity to psychotomimetic drugs in neuregulin-1 knockout mice by C. O'Tuathaigh; G. O'Sullivan; C. O'Leary; O. Tighe; L. Desbonnet; D. Lai; R.P. Harvey; D.T. Croke; J.L. Waddington (S508-S509).
P.3.b.009 An fMRI study about verbal 'theory of mind' task in Korean schizophrenic patients by J. Son; S.I. Lee; C.J. Shin; S.K. Kim; I.K. Oh; H. Ghim; S.B. Lee; Y.R. Choi; Y.R. Kim; J.C. Yoo (S508).
P.3.b.01l Dysfunction of configural face processing in individuals at ultra-high risk for schizophrenia by H.S. Kim; N.Y. Shin; J.S. Choi; M.H. Jung; J.H. Jang; D.H. Kang; J.S. Kwon (S509).
P.3.b.012 Electrophysiological measures in schizophrenia and bipolar disorder by N. Domján; G. Csifcsåk; I. Szendi; Z. Janka (S509-S510).
P.3.c.001 Quality of life: sexual dysfunction in young people with schizophrenia treated with ziprasidone by C. Istikoglou; D. Vlissides; K. Michelidakis; O. Mikirditsian (S511).
P.3.b.013 Associations of 5HT2A receptor gene polymorphisms with symptoms of disorganisation in schizophrenia by L. Olajossy-Hilkesberger; B. Godlewska; M. Olajossy; H. Marmurowska-Michalowska (S510).
P.3.b.008 Dysbindin gene (DTNBP1) and schizophrenia in Korean population by J.J. Kim; C.U. Pae; T.Y. Jun; K.I. Jung; C.U. Lee; C. Lee; I.H. Paik (S507).
P.3.b.007 Homocystein and metabolic syndrome in schizophrenia by D. Cozman; M. Dronca; E. Craciun; M. Manea; B. Nemes (S506-S507).
P.3.b.003 The associations with apathy and neuropsychological deficits in schizophrenia by S. Kim; K.W. Yun; W.J. Lim; J.W. Choi; H.S. Park (S504-S505).
P.3.b.002 Patterns of event-related potentials reflecting dysfunctional facial affect processing in schizophrenia patients by S.H. Lee; Y.M. Park; K.J. Lee; H. Kim; Y.C. Chung (S504).
P.3.b.004 Abnormal behaviours of conditional heparin-binding epidermal growth factor-like growth factor knockout mice by H. Hara; A. Oyagi; Y. Oida; K. Kakefuda; M. Shimazawa; N. Shioda; K. Kitaichi; Y. Furuta; K. Fukunaga; S. Higashiyama (S505).
P.3.b.005 Glial fibrillary acidic protein (GFAP) and S100B protein serum levels in recent onset schizophrenia by D. Fekkes; N.J.M. van Beveren; C.H.R. Roder (S505-S506).
P.3.b.006 Hyperhomocysteinemia and individuality of psychotic disorders in childhood and adolescents by L. Kevere; S. Purvina; D. Bauze; M. Zeibarts; A. Rizevs; M. Caune; I. Purvins; R. Andrezina (S506).
P.3.a.024 Treatment-responsive arousal misattribution to neutral faces in psychosis: implications for psychopharmacology studies by E.S. Haralanova; R.C. Gur; G. Griinder (S493-S494).
P.3.a.023 What do large scale studies of medication in schizophrenia add to our management strategies? by M. Agius; R. Zaman; S. Chapman; M. Gilhooley (S493).
P.3.a.003 The revolving door patients – are they different? by V. Novak Grubic; B. Zalar; M. Saje (S481-S482).
P.3.a.002 Brief psychotic disorder induced by pramipexole: a five-case study by M. Marinescu; Y. Bescond; C. Bescond; S. Voillet; S. Bulteau; M. Lejoyeux (S481).
P.3.a.004 Sexual life and the view of marriage in the unmarried outpatients with schizophrenia by C.K. Kim; H.G. Kim; D.J. Kim; M.J. Kim (S482).
P.3.a.005 Expert rater assisted score evaluation: a new method to increase efficiency in drug development programs by J. Schoemaker; R. Gaur; V. Chawla; A. Szegedi (S482-S483).
P.3.a.007 Comparison of the effects between video-based contact and educational lecture on the stigma of mental illness by C.K. Kim; J.W. Kim; B.C. Kim; H. Chong (S484).
P.3.a.006 Psychological treatment in the first psychotic episode by P. Vega Perez; S. Ruiz De Azúa; M. Martinez; S. Ron; R. Gonzalez Oliveros; J. Asua; A. Gonzalez-Pinto (S483-S484).
P.3.a.001 Sequential IM/oral ziprasidone and haloperidol in agitated patients with Schizophrenia: A naturalistic comparison by C. Fernando; V. Pérez-Solá; M. Gutierrez-Fraile; J.R. Gutiérrez-Casares; F. Mesa (S480-S481).
P.2.h.004 Development of a new affective temperament scale associated with the s alíele of 5-HTTLPR by X. Gonda; K.N. Fountoulakis; A. Laszik; Z. Rihmer; H.S. Akiskal; G. Bagdy (S480).
P.2.g.011 Painful physical symptoms in major depressive Turkish outpatients by O. Karamustafalioglu; C. Korulsan Ogutcen; M. Akbiyik; N. Kahraman; G. Alpak (S477).
P.2.g.010 Dissociative symptoms in patients with mood and anxiety disorders and potential correlation to antidepressant response by M.M. Moscariello; F. Ratti; A. Quartini; F.E. Forcen; J.N. Munuera; G. Bersani (S476-S477).
P.2.g.012 Repetitive transcranial magnetic stimulation with EEG-dependent stimulus timing in the treatment of depression by J. Lee; G.W. Price (S478).
P.2.h.001 Controlled study of pulsed electro magnetic fields (PEMF) in medication-resistant major depression by K. Martiny; M. Lunde; P. Bech (S478).
P.2.h.003 Comparison of the stress factors' impact on HPA in patients with depression and neurosis – study with the use of the Dexamethasone Supression Test by B. Spila; H. Dubas-Slemp; A. Urbanska; R. Bartczuk; A. Grzywa-Celinska (S479-S480).
P.2.h.002 Neuropeptide S alters depression- and anxiety-like behaviors in the FSL/FRL rats, a genetic animal model of depression by G. Wegener; B.C. Finger; D.A. Slattery; I.D. Neumann; A.A. Mathé (S479).
P.3.a.008 Effects of cognitive remediation in schizophrenia patients by M. Rodriguez; R. Kawaciukova; L. Bankovska-Motlova; P. Mohr; E.V.A. Dragomirecka; T. Novak; M. Preiss; J. Sediva (S484-S485).
P.3.a.009 Schizophrenia Related NRG1 single nucleotide polymorphisms Lead to Smooth Eye Pursuit Dysfunction in a population of young men by N. Smyrnis; E. Kattoulas; N.C. Stefanis; D. Avramopoulos; G. Papadimitriou; I. Evdokimidis; C.N. Stefanis (S485).
P.3.a.018 Two patients with chronic psychotic disorders who completed interferon-alpha plus ribavirin therapy for hepatitis C by W. Drozdz; D. Kozielewicz; D. Dybowska; W. Halota; A. Borkowska (S490-S491).
P.3.a.017 Paliperidone extended-release for the treatment of bipolar mania by C. Leotsakou; A. Sardis; C. Labiris; F. Kapsali; K. Papadopoulos; P. Pelka; A. Kalogeropoulou; M. Giovanoglou; E. Datsi; P. Paterakis (S489-S490).
P.3.a.019 Modafinil's efficacy in treating clozapine-associated sedation and sleepiness in patients with schizophrenia by N. Kouroumalos; P. Georgila; E. Marini; D. Sakkas (S491).
P.3.a.020 Gender differences in hospitalised schizophrenic patients by M. Serrano Vazquez; M.M. Serrano Carton; M.C. Serrano Carton (S491-S492).
P.3.a.022 Executive function in deficit schizophrenia by P. Polgar; I. Bitter; S. Keri; P. Czobor (S492-S493).
P.3.a.02l Cannabis use and clinical presentation among a sample of first episode of schizophrenia patients by T. Moreno-Calle; R. Pérez-Iglesias; I. Mata; J. Mayoral-vanSon; J.M. Pelayo-Teran; O. Martinez-Garcia; G. Pardo; J.L. Vázquez-Barquero; B. Crespo-Facorro (S492).
P.3.a.016 Relation between psychopathology, insight, self-esteem, stigma, quality of life and cognition in women with schizophrenia by N. Ghirasim; I. Miclutia; C. Popescu (S489).
P.3.a.015 Switching to aripiprazole from atypical antipsychotics in patients with schizophrenia by S.W. Kim; J.H. Lee; Y.H. Lee; K.H. Chung; J.H. Ryu; J.S. Yoon; J.M. Kim; J.A. Yoo; T. Youn; K.Y. Bae (S488-S489).
P.3.a.01l The effect of stress and antipsychotic treatment on inflammatory and metabolic markers in first-episode psychosis by V. Mondelli; M. Aas; M. di Forti; H. Fisher; R. Handley; T. Reis Marques; H. Taylor; P. Dazzan; R.M. Murray; C.M. Paríante (S486).
P.3.a.010 Clinical outcome in first episode of schizophrenia by R. Macrea; I. Miclutia; C.A. Popescu (S485-S486).
P.3.a.012 A study of the clinical outcome following treatment discontinuation after remission in first-episode schizophrenia by R. Emsley; P. Oosthuizen; L. Koen; D. Niehaus; L. Martinez (S486-S487).
P.3.a.013 Insight and clinical outcome in first episode psychosis: 1-year follow-up study by C. Morelli; R. Ayesa-Arrióla; J.M. Pelayo-Teran; J.M. Rodriguez-Sanchez; R. Perez-Iglesias; I. Mata; B. Crespo-Facorro (S487-S488).
P.3.a.014 Psychotic disorder with underlying Graves disease: a case report by A.M. Zaharie; N. Racataianu; I. Miclutia; C. Ghervan (S488).
P.3.f.005 Corpus callosum abnormalities in schizophrenia: potential association to antipsychotic treatment by A. Quartini; A. Iannitelli; M. Paolemili; C. Di Biasi; G. Gualdi; G. Bersani (S583-S584).
P.3.f.006 NW-3509: a novel potent sodium channel blocker with antipsychotic potential by E. Iizzo; L. Faravelli; A. Ieraci; C. Sabido-David; C. Caccia; P. Melloni; K. Wedzony; M. Bortolato; R. Frau; P. Salvati (S584).
P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy by A.B. Sinyukhin; G.P. Timoshinov; V.A. Kornilov; P.D. Shabanov (S681-S682).
P.7.a.005 Repeated transcranial magnetic stimulation in Tourette's syndrome by M.H. Lim; H.W. Kim; K.K. Lee; K.C. Paik; S.B. Lee; J.H. Chae (S680-S681).
P.7.a.007 Is there a link between a history of childhood trauma and cognitive impairment in first-episode psychosis? by M. Aas; V. Mondelli; A. Reichenberg; M. Di Forti; B. Wiffen; R. Handley; H. Taylor; R. Murray; P. Dazzan; C.M. Pariante (S682).
P.7.a.008 Safety and efficacy of ziprasidone in pediatric bipolar disorder by R. Findling; M. DelBello; P. Wang; B. Gundapaneni; M. Versavel; O. Karayal (S682-S683).
P.7.b.00l Effects of 6-OHDA lesion of the mPFC on the open field activity and social interaction behavior in adolescent rats by Z. Sui; G. Huang; Y. Chung (S683-S684).
P.7.a.009 Negative life events and conduct disorder among adolescents by G.H. Amara; A. Frikha; S. Ben Nasr; B. Ben Hadj Ali (S683).
P.7.a.004 Relationship between mental disorders and suicidal behavior among children and adolescents in a psychiatric department by J. Balazs; G. Dallos; J. Gadoros (S680).
P.7.a.003 Efficacy of prolonged-release methylphenidate in a randomized controlled trial in adults with ADHD: secondary endpoints by B. Schaeuble; C. Orman; J.M. Palumbo (S679-S680).
P.6.f.004 Neurochemical aspects of possible therapeutic interventions of opiate medications in schizophrenia patients by A. Mititelu (S677).
P.6.f.003 Rimonabant repeated treatment inhibits behavioral sensitization previously developed to morphine in mice by E.A.V. Marinho; R. Santos; A.J. Oliveira-Lima; F.W. Silva; M.A. Baldaia; R. Wuo-Silva; A.W. Hollais; P.B. Sousa; H.A. Fernandes; R. Frussa-Filho (S676-S677).
P.6.f.005 Effects of different basal levels of anxiety on locomotion of mice in a novel environment by J.L.S. Cunha; R. Levin; D.F. Fukushiro; C.L. Parti; V.C. Abílio; R. Frussa-Filho (S677-S678).
P.6.f.006 Genotype-dependent effects of stress on opiate reward and GABAA receptor subtypes in C57BI/6J and DBA/2J mice by W. Solecki; A. Wawrzczak-Bargiela; J. Kubik; W. Bilecki; R. Przewlocki (S678).
P.7.a.002 A long-term safety study of prolonged-release methylphenidate in adults with ADHD by B. Schaeuble; J. Singh; L.A. Adler; C. Orman; G.J. Pandina; J.M. Palumbo (S679).
P.7.a.001 Changes in the developmental trajectories of striatum in autism by M. Langen; H.G. Schnack; H. Nederveen; D. Bos; B.E. Lahuis; M.V. de Jonge; H. van Engeland; S. Durston (S678-S679).
P.7.b.002 Fronto-striatal brain dysfunction in adults with ADHD during interference inhibition and attention allocation by A. Cubillo; R. Halari; E. Taylor; K. Rubia (S684).
P.7.b.003 Comparison of adolescent SHR, WKY and Wistar rats in different behavioural models by B. Langen; R. Dost (S685).
P.7.c.004 Clinical effects and tolerability of aripiprazole in children and adolescents with psychiatric disorders by R. Ramos-Ríos; A.M. Gago-Ageitos; M. Vidal-Millares; J.A. Mazaira-Castro; M.D. Dominguez-Santos (S691).
P.7.c.003 Somnolence and sedation in adolescents with schizophrenia treated with aripiprazole (acute and long term follow-up) by J.Y. Loze; S.J. Mathew; R.D. McQuade; W.H. Carson; M. Nyilas; R.A. Forbes; T. Iwamoto; R. Mankoski; A. Pikalov (S690-S691).
P.7.d.001 Impact of psychiatric comorbidity on quality of life in adolescents with epileptic disorder by E. Beyoglu; Y. Taneli; O. Ozdemir; M.S. Okan; S. Taneli (S691-S692).
P.7.e.001 The effect of adverse family relations and ADRA2A genotype on attention deficit and level of education in young adults by E. Kiive; T. Kurrikoff; J. Mäestu; J. Harro (S692).
P.7.e.003 The relationship between parental age and child psychopathology by T. Fidan; I. Esin; H. Ceyhun; S. Gürsoy (S693-S694).
P.7.e.002 Pharmacogenetics of acute treatment of depression and anxiety in children and adolescents by S. Kronenberg; A. Apter; M. Carmel; A. Frisch; A. Weizman (S693).
P.7.C.002 Effects of aripiprazole on glucose, lipids and weight in adolescent patients: a pooled analysis of 2 clinical trials by J.Y. Loze; A. Pikalov; R. Baker; S. Kaplita; W.H. Carson; R. Owen; R.A. Forbes; M. Nyilas; T. Iwamoto; J.W. Newcomer (S689-S690).
P.7.c,00l Emotional expression, ADHD-related difficulties and ADHD core symptoms: 6-month data from the COMPLY observational study by P.M. Wehmeier; A. Schacht; R.W. Dittmann; T. Banaschewski (S689).
P.7.b.005 Arginine vasopressin receptor gene-based single nucleotide polymorphism (SNP) analysis in ADHD by D. van West; J. Del-Favero; D. Deboutte; C. Van Broeckhoven; S. Claes (S686).
P.7.b.004 Neurobiological correlates of disruptive behaviour disorder in a normal population; differences between boys and girls by E. Platje; L.M.C. Jansen; R.R.J.M. Vermeiren; T.H.A.H. Doreleijers; P.A.C. van Lier; T. Frijns; J.M. Koot; W. Meeus (S685-S686).
P.7.b.006 Chronic methylphenidate or atomoxetine treatment alters BDNF expression in the brain of spontaneously hypertensive rats by A. Cattaneo; L. Caffino; A. Sesta; M. Ibba; E. Carboni; F. Fumagalli; M.A. Riva; M. Gennarelli (S686-S687).
P.7.b.007 Neurobiological factors as predictors for re-offending in adolescent males by M. De Vries-Bouw; A. Popma; L.M.C. Jansen; R. Vermeiren; T.H.A.H. Doreleijers (S687).
P.7.b.009 Effects of methylphenidate on electrical activity and Arc gene expression in the prefrontal cortex during development by J. Aston; C. Liauzun; T. Zetterstrom; B. Gronier (S688-S689).
P.7.0.008 Associations of risk-taking in traffic with markers of serotonin system and personality in a follow-up study by D. Eensoo; M. Saupõld; J. Harro (S687-S688).
P.6.f.002 The effects of inhalation exposure to toluene on spatial and object recognition memory in rats by L. Chilachava; G. Maglakelidze; M. Zhvania; M. Dashniani; L. Gelazonia (S676).
P.6.f.0Q11 Neuropeptide Y (NPY) or a NPY-Y5 selective agonist increase in vivo monoamine levels in mesocortical limbic projection areas by D. Quarta; C.P. Leslie; R. Carletti; E. Valerio; L. Caberlotto (S675).
P6.d.01l Comparison of behavioural consequences pre and postnatal morphine exposure in the rats offspring by Z. Gyarmati; J. Timár; M. Sobor; K. Király; Z. Furst (S663-S664).
P.6.d.010 Repeated (±)3,4-methylenedioxy-methamphetamine treatment enhances hippocampal long-term potentiation in Dark-Agouti rats by G. Baccini; R. Morini; R. Corradetti; B. Mlinar (S663).
P6.d.012 Effects of modafinil on cocaine-induced behavioral sensitization in mice by R. Wuo-Silva; H.A. Fernandes; R.P. Souza; L.H.F. Zanlorenci; L.T.C. Ribeiro; C.S. Oliveira; J.M.R. Maragno-Correa; L. Sanday; L.R. Bittencourt; R. Frussa-Filho (S664).
P6.d.013 The evaluation of the effect of food deprivation on the development of morphine dependence in rats by A. Nurten; A. Zengin; Z.G. Ozunal; E. Ozturk; N. Enginar (S664-S665).
P6.d.015 Effects of an environmental contra-conditioning strategy with aripiprazole in an animal model of cocaine dependence by A.J. Oliveira Lima; A.W. Hollais; E.A.V. Marinho; M.A. Baldaia; R. Wuo-Silva; R. Santos; H.A. Fernandes; C.A. Gerardi-Junior; L.A. Ferreira; R. Frussa-Filho (S666).
P6.d.014 MDMA self-administration is abolished in 5-HT2A receptor knockout mice by M.J. Orejarena; R. Maldonado; P. Robledo (S665).
P6.d.009 Inhibition of anandamide hydrolysis differentially modulates cocaine-induced effects on rat mesolimbic system by A. Luchicchi; S. Lecca; S. Carta; G. Pillolla; M. Pistis (S662-S663).
P6.d.008 CB1 receptors are involved in some but not all nicotine-motivated behaviours by V.C. Wing; M. Shoaib (S661-S662).
P6.d.003 Opposite regulation of FADD and nuclear poly (ADP-ribose) polymerase (PARP) in brains of cocaine addicts by M. Alvaro-Bartolome; R. La Harpe; J.J. Meana; J.A. Garcia-Sevilla (S658-S659).
P6.d.002 Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats by M. Charkhpour; B. Habibi-Asl; K. Hassanzadeh (S658).
P6.d.004 Depressive-like behaviour and aripiprazole increase the drug intake in iv self-administration model in rats by J. Kucerova; J. Pistovcakova; D. Vrskova; M. Nemecek; A. Sulcova (S659-S660).
P6.d.005 Ultrastructural alteration of cortical serotonergic fibers after MDMA (ecstasy) treatment using a new TpH2 antibody by C. Ádori; P. Löw; R.D. Andó; L. Gutknecht; D. Papp; Z. Frank; J. Takács; G.G. Kovács; P. Lesch; G. Bagdyf (S660).
P6.d.007 Differential effects of acute and repeated amphetamine on two animal models of human novelty-seeking behaviour by D.F. Fukushiro; L.P. Saito; C.F. Lima; G.P. Oliveira; L. Cupersmid; M.D.G.B. Tacconi; R. Frussa-Filho (S661).
P6.d.006 Association between the cell adhesion molecule gene, personality traits and addictive behaviour in methamphetamine abuse by B. Lee; D. Kwon; Y. Kim; S. Cho; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S660-S661).
P6.d.016 Long-lasting effects of transient food deprivation on an animal model of addiction by E. de Almeida; R.P. Souza; R. Wuo-Silva; A. Takatsu-Colleman; V.P. Ricardo; L.H.F. Zanlorenci; T.F. Trombim; A.J. Oliveira-lima; E.A.V. Marinho; R. Frussa-Filho (S666-S667).
P.6.d.017 Profile of the N-substituted benztropine analog, AHN-1055, as a candidate treatment for cocaine addiction by A. Ferragud; C. Velázquez-Sánchez; A. Arcusa; V. Hernández-Rabaza; H.G. Gumus; A. Nácher; V. Merino; J. Murga; M. Cardá; J.J. Canales (S667).
P.6.e.006 The effects on the human body from the cessation of smoking by J.S. Seo; S.S. Lee; D.J. Kim; B.W. Nam; S.W. Moon; H.J. Go (S672).
P.6.e.005 Validation study of Kim's smoking cessation motivation scale and its predictive implications for smoking cessation by J.W. Park; J.Y. Lee; K.H. Joe; S.H. Chai; D.J. Kim; H.J. Go (S671-S672).
P.6.e.007 Gender differences of nicotine dependence in South Korea by S.K. Kim; Y.R. Lee; M.J. Joe; H.J. Jeon; S.M. Chang; J.H. Lee (S673).
P.6.e.008 A study of the relationship between internet addiction tendency and personality disorders by B. Yeon (S673-S674).
P.6.e.010 Two years assessment in cocaine-addicted patients: linkage between alexithymia and pathological parental attachment by P. Vigezzi; G. Zita; E. Cozzolino (S674-S675).
P.6.e.009 Substance use during pregnancy and child outcomes: a longitudinal study by M. Imaz; E. Gelabert; L.L. García-Esteve; P. Navarro; J. Sanjuan; R. Guillamat; A. Gutierrez; M. Torrens; K. Langorh; R. Martin-Santos (S674).
P.6.e.004 Hostility and impulsivity of nicotine dependence by S. Min; J. Whang; J. Shin; K. Park; H. Lee (S671).
P.6.e.003 Effect of sigarette smoking on treatment of schizophrenia with clozapine by N. Zivkovic; D. Pavicevic; G. Djokic; J. Lekovic (S670-S671).
P6.d.019 Amygdaloid and hypothalamic mRNA expression for CRF and vasopressin after administration of psychoactive drugs in rats by P. Shabanov; A.A. Lebedev; V.P. Pavlenko (S668).
P.6.d.018 Serotonin transporter and 5-HT2A receptor binding in human ecstasy and hallucinogen users by D. Erritzoe; V. Frokjaer; M. Christoffersen; W. Baare; T. Jernigan; T. Ramshoy; C. Svarer; G.M. Knudsen (S667-S668).
P6.d.020 Do dopaminergic drugs induce a place preference in normal rat? by Y. Zengin; N. Authier; P.M. Llorca; F. Durif (S668-S669).
P.6.e.00l The relationship between the biogenetic charaters, the choice of game, and the severity of game addiction by J.W. Kim; D.H. Han; K.J. Min; C. Na; J.M. Kang; B.W. Nam (S669-S670).
P.6.e.002 Effectiveness of psychosocial rehabilitation program for pathologic gambling in Korea by Y.S. Choi (S670).
P.8.a.00l Relationship among the dissociation, ways of coping style, and hypnotisability in undergraduate students by J. Lee; H.S. Oh (S694).
P.8.a.002 The panel of selected genes involving in regulation of food intake in anorexia nervosa patients by M. Janas Kozik; M. Stachowicz; I. Krupka Matuszczyk; U. Mazurek; K. Krysta; I. Jelonek; A. Janas (S694-S695).
C.11.02 Emerging preclinical data and models – what's new? by J. Neill (S714).
C.11.01 Multidimensional approach to sensory gating functions and cognition in humans by F. Vollenweider (S713-S714).
C.11.03 The effect of antipsychotics on cognitive performance in schizophrenia: implication on clinical outcome by B. Gallhofer (S714).
C.12.01 Advances in the treatment for depression: an update on antipsychotics by E. Vieta (S715).
C.12.03 Understanding the mechanism of action: similarities and differences of current treatment by L. Yatham (S715-S716).
C.12.02 Anxiety: a common theme in psychiatric disorders? by S. Kasper (S715).
C.10.03 What is new in treating patients with major depressive disorder who show inadequate response to antidepressants by A.H. Young (S713).
C.10.02 Treating mania and managing long-term treatment of bipolar disorder by C. Arango (S713).
C.06.04 Can switching antipsychotics improve patient outcomes? by P. Falkai (S711).
C.06.03 Choosing between antipsychotics – can patient outcomes be improved with new agents? by A. Schreiner (S710-S711).
C.09.01 Optimising outcome in bipolar disorder by I.N. Ferrier (S711).
C.09.02 Understanding patient needs in the acute setting by M. Berk (S711-S712).
C.10.01 Life-long treatment in patients with schizophrenia by F. Cañas (S712-S713).
C.09.03 The patient-psychiatrist goal: maintaining stability in bipolar disorder by J. Calabrese (S712).
C.13.01 Electrophysiological characteristics and regulation of SWS by D.J. Dijk (S716).
C.13.02 Role of SWS in synaptic plasticity by M. Massimini (S716).
C.16.01 Overview of key challenges in the long-term health management in psychiatric patients by H. Möller (S719).
C.15.03 Symptom relief achieved at every stage of depression treatment by S. Kennedy (S719).
C.16.02 Long-term management of schizophrenia by S. Potkin (S720).
C.16.03 Long-term management of bipolar disorder by H. Grunze (S720).
Keyword index (S743-S750).
Author index (S721-S742).
C.15.02 Agomelatine: demonstrated efficacy on the complete range of depressive symptoms by G. Goodwin (S719).
C.15.01 Circadian rhythms: strong evidence on how to treat the core of depression by M. Popoli (S718-S719).
C.13.04 Clinical implications of increasing SWS in insomnia by J.K. Walsh (S717).
C.13.03 Memory processing: SWS is a key factor by J. Born (S716-S717).
C.14.01 Ensuring data quality in multi-national clinical trials by C. Höschl (S717).
C.14.02 Evaluating the relationship between severity and efficacy in placebo-controlled trials by S. Montgomery (S718).
C.14.03 Designing and implementing global CNS development programs: disease-specific considerations by W. Fleischhacker (S718).
C.06.02 Early effective treatment in schizophrenia – what are the options? by R. Emsley (S710).
C.06.01 Is schizophrenia a progressive brain disease? by R. Kahn (S709-S710).
P.8.a.012 Psychiatric comorbidity in females with vaginismus by E.A. Yildirim; S. Cavas; M. Hacioglu; M. Yanik (S700-S701).
P.8.a.01l Survey of psychiatrists' practices when prescribing psychotropic medication for women of reproductive age by B. Iankov; N. Zaman; S. Chapman; A. Sule (S699-S700).
P.8.a.013 Psychotropic drug use evaluation after a therapeutic guide in a long term care centre by L. García-Sánchez; G. Porta-Rius; B. Pascual-Arce; M. Blanca-Tamayo; M.C. Pérez-Navarro; A. Sicras-Mainar; N. Muro-Perea (S701).
P.8.a.014 Serum lipid profiles and schizophrenia: ratio of LDL/HDL cholesterol as predict factor for acute phase schizophrenia by V. Slavkovic; S. Tosic Golubovic; G.D. Gugleta Dragoslava; Z.O. Zikic Olivera (S701-S702).
P.8.b.002 Disorders of neurotic and affective level in assessment of cardio-vascular risk in patients with aterial hypertension by N.P. Garganeyeva; A.I. Rozin; S.Y.U. Shtarik; D.S. Kaskayeva; V.N. Masunov; E.V. Ryabova (S702-S703).
P.8.b.001 Age-dependent plasticity changes of personality profile by J.S. Yi; H.S. Lee; Y.W. Jeon; S.H. Kim (S702).
P.8.a.010 Signal enhancement system identifies inaccurate ratings and quality of clinical interview conducted in a CNS trial by G. Richa; M. Sajatovic; S. DeSanti (S699).
P.8.a.009 The association between mental functioning and conversion disorder by D. Sakarya; V. Senturk; E. Arslan; A. Cevik (S698-S699).
P.8.a.004 Pharmacological treatment prescribed to emergency psychiatric patients over 65 years by J. Arcega; D. Corcoles; J.M. Gines; A. Malagon; A. Merino; A. Bulbena (S695-S696).
P.8.a.003 Clinical and cost-effectiveness analysis of using atorvastatin for secondary stroke prevention: a Spanish perspective by J. Mar; J. Vivancos; J. Rejas; A. Arrospide; J. Caro (S695).
P.8.a.005 Dimensions of burnout syndrome in caregivers of psychiatric outpatients by E. Ozel-Kizil; A. Yilmaz (S696-S697).
P.8.a.006 Consultation-liaison psychiatry service in obstetrics and gynecology, in Athens, Greece by I. Mourikis; A.V. Kouzoupis; M. Antoniou; A. Spyropoulou; A. Leonardou; M. Vogiatzi; I. Zervas; G.N. Papadimitriou (S697).
P.8.a.008 Social adaptation and subsyndromal affective symptoms in bipolar disorder: a cross-sectional and a prospective study by C. de Dios-Perrino; E. Ezquiaga; A. García-López (S698).
P.8.a.007 The effect of Korean red ginseng on psychological symptoms and β-adrenergic receptor function in a normal population by H.B. Sim; E.H. Kang; W.Y. Shin; Y.J. Song; K.J. Kim; B.H. Yu (S697-S698).
P.8.b.003 Affective symptoms, body mass index and metabolic syndrome: a life course approach by D. Gaysina; M. Richards; M. Hotopf; I. Colman; D. Kuh; R. Hardy (S703).
C.01.01 Importance of a good night's sleep by A. Williams (S705).
C.04.03 Treating the whole patient: understanding the complexities of bipolar disorder by C. Bowden (S708).
C.04.02 Understanding the full potential of treatments informed by evidence by J. Cookson (S707-S708).
C.05.01 Neurobiology of circadian systems by P. Schulz (S708).
C.05.02 Disruption of the circadian timing systems in depression by J. Mendlewicz (S708-S709).
C.05.04 New strategies to resynchronise circadian rhythms in depression by G. Hajak (S709).
C.05.03 The sleep-wake cycle and vulnerability to recurrence in depression by E. Frank; D. Buysse; D.J. Kupfer (S709).
C.04.01 Improving care through course of illness approaches by R. Licht (S707).
C.03.04 Integrating clinical treatment strategies for major depressive disorder by G.I. Papakostas (S707).
C.01.03 Melatonin agonism in the treatment of sleep-wake disturbances by L. Leissner (S705-S706).
C.01.02 Treating insomnia by C. Espie (S705).
C.03.01 Serotonergic dysfunction – implications for treatment of mood and anxiety disorders by P. Blier (S706).
C.03.02 Comorbid depression and anxiety – understanding and treating complex patients by B. Bandelow (S706).
C.03.03 Is real-life functionality the new goal of treatment? by R.W. Lam (S706-S707).
P6.d.001 Changes in glutamatergic transmission in rat frontal cortex induced by morphine and methadone treatments by B. Bobula; G. Hess (S657-S658).
P.6.c.013 Prodromal symptoms and neurocognitive profile of 3 groups of dependent drug users: cannabis, ketamine and cocaine by C. Morgan; O. Mason; S. Duffen; S. Hunt; L. Monaghan; H.V. Curran (S657).
P.4.c.008 Benzodiazepines and salivary cortisol: the Netherlands study of depression and anxiety (NESDA) by L. Manthey; E.J. Giltay; T. Veen; S.A. Vreeburg; F.G. Zitman; B.W.J.H. Penninx (S608-S609).
P.4.c.007 Effect of escitalopram treatment on the relationship of pre- to postsynaptic serotonin-1A receptors in anxiety disorders by A. Hahn; R. Lanzenberger; M. Fink; P. Stein; L.K. Mien; M. Savli; E. Ammova; M. Mitterhauser; W. Wadsak; S. Kasper (S607-S608).
P.4.c.009 Dose-dependent effects of a clinically effective and non-effective dose of lorazepam on 7.5% CO2-induced anxiety by J.E. Bailey; A. Diaper; A.S. Rich; G.R. Dawson; D.J. Nutt (S609).
P.4.c.010 Effects of diazepam on the processing of aversive faces: a fMRI study by C.M. Del-Ben; C.A. Queiroz; T.A. Sanchez; W.C. Alves-Neto; V.G. Guapo; D.B. Araujo; F.G. Graeff (S609-S610).
P.4.d.002 The putative anxiolytic and antidepressant-like effect of Achillea millefolium L. extract in mice by I.P. Baretta; R.A. Felizardo; V.F. Bimbato; A. Gasparotto Júnior; C. Kassuya; R. Andreatini (S610-S611).
P.4.d.001 Spironolactone enhances extinction of contextual fear: a potential therapeutic for post-traumatic stress disorder? by R. Andreatini; E.M. Ninomiya; B.J. Martynhak; C. Da Cunha (S610).
P.4.c.006 Anger experiences in patients with depressive disorder and anxiety disorder by J. Kim; S. Wang; I. Chee; Y. Kim (S607).
P.4.c.005 The cardiovascular effects of a subtype selective and non-selective benzodiazepine agonist in healthy volunteers by J.E. Bailey; A. Rich; S. Wilson; D.J. Nutt (S606-S607).
P.4.b.013 Cannabinoids receptors gene polymorphisms and anxiety traits by R. Martin-Santos; J. Undurraga; A.B. Fagundo; I. Royo; M. Gratacos; J.A. Crippa; M. Torrens; M. Farré (S603-S604).
P.4.b.012 Assessment of striatal dopamine release in obsessive-compulsive disorder using positron emission tomography by M. Figee; F. de Vries; N. Vulink; D. Cath; T. van der Doef; D. Veltman; T. van Balkom; A.A. Lammertsma; B.N.M. van Berckel; D.A.J.P. Denys (S603).
P.4.C.001 Drug prescriptions for treating insomnia in hospitalized patients by M.T. Amboage-Paz; J.A. Díaz-Peromingo; E. Fontela-Vivanco; S. González-Bardanca; M.J. Ávila-González; Y. Prieto-Paredes (S604).
P.4.c.002 Clinical suitability of GAD-7 scale compared to hospital anxiety and depression scale-A for monitoring treatment effects in generalized anxiety disorder by B. Bandelow; M. Brasser (S604-S605).
P.4.c.004 Paroxetine in the treatment of panic disorder: a comparison between slow and standard up-titrations by M. Buoli; B. Dell'Osso; F.L. Lopes; S. Bortolussi; B. Benatti; A.C. Altamura (S606).
P.4.c.003 Mother's little helper: prescribing practice of anxiolytics and hypnotics in a community mental health team by K. Naidoo; M. Bohra; O. Mathurine (S605-S606).
P.4.d.003 Increase in nociception and articular diameter after the dorsolateral periaqueductal gray chemical stimulation in rats by L.J. Bertoglio; C.R. Tonussi; E. Bressan; M.A. Martins; C.A.J. Stern (S611-S612).
P.4.d.004 Bilateral infusion of capsazepine in the rat hippocampus: effects on anxiety and spatial learning/memory by L.J. Bertoglio; F.H.M. Do Monte; A.S. Aguiar; C.J.P.A. Santos; R.S. Silva (S612).
P.4.e.010 The comorbidity of metabolic syndrome in patients with obsessive compulsive disorder by I. Erensoy Sacak; O. Karamustafalioglu; G. Alpak; R. Onem; O. Tankaya (S618).
P.4.e.009 Efficacy of trazodone in patients diagnosed with generalised anxiety disorder and benzodiazepine dependence by M. Zavoianu; A. Luchian; C. Tudor; G. Grigorescu; D. Vasile (S617-S618).
P.4.f.001 The impact of changing diagnostic criteria in posttraumatic stress disorder (PTSD) by M. Van Ameringen; C. Mancini; B. Patterson (S618-S619).
P.4.f.002 The absence of one-trial tolerance on a new animal model of anxiety by L.H.F. Zanlorenci; R. Wuo-Silva; R.P. Souza; T.F. Trombin; C.S. Oliveira; L.T.C. Ribeiro; D.F. Fukushiro; M.B. Calzavara; R. Frussa-Filho (S619).
P.5.a.002 Imaging of muscarinic acetylcholine receptors with 11C-3NMPB in vascular dementia and Alzheimer's disease by K. Nagata; D. Takano; T. Maeda; T. Nakase; T. Yamazaki; H. Saitoh (S620).
P.5.a.001 Dropouts due to other reasons than adverse events during clinical trials in Alzheimer's disease by C. Kani; A. Pehlivanidis; K. Papanikolaou; Z. Papadopoulou-Daifoti (S619-S620).
P.4.e.008 The factors that influence the therapeutic response to paroxetine in patients with panic disorder: longitudinal study by M. Ueda; T. Watanabe; Y. Saeki; A. Saito; K. Akiyama; Y. Inoue; S. Morita; G. Hirokane; N. Yamada; K. Shimoda (S617).
P.4.e.007 Psychopharmacotherapy anxiety disorders of patients suffering from different cancer localization by A. Vasylyeva; S. Tabachnikov; S. Bugaytsov (S616).
P.4.e.002 Changes in brain perfusion in the drug-naive panic patients with SPECT following cognitive-behavioural therapy by J. Kim; W. Nam; J. Chae; E. Chang; S. Ryu; K. Won; S. Zeon; Y. Chung (S613).
P.4.e.001 Transcranial electrostimulation of the brain and afobazol in treatment of anxiety disorders in breast cancer patients by V. Sushko; V. Sushko (S612-S613).
P.4.e.003 Comparison of sexual function in two groups of patients with social anxiety disorder and obsessive-compulsive disorder by Y. Cengiz; O. Tankaya; M. Cevik; O. Karamustafalioglu (S613-S614).
P.4.e.004 Agoraphobia treatment: antidepressant monotherapy and combined treatments by C.T. Pitti; M.L. Villaverde; W. Peñate; J.M. Bethencourt; J. de la Fuente; R. Gratia (S614-S615).
P.4.e.006 Does the inhalation of CO2 activate neurosteroids in healthy participants? A pilot study by J.E. Bailey; S. Phillips; A. Diaper; A. Rich; S. Lightman; D.J. Nutt (S615-S616).
P.4.e.005 Personality factor and defense mechanism of non-offensive and offensive type of social phobia patients in Korea by S.B. Baek; S.J. Yang (S615).
P.4.b.01l Corticosterone levels in mice exposed to different types of elevated plus-maze: influence of nociceptive stimulation by J. Mendes-Gomes; V.C.S. Amaral; R.L. Nunes-de-Souza (S602-S603).
P.4.b.010 Internal mood induced by pentylenetetrazole as an unconditioned stimulus in olfactory fear conditioning paradigm by A. Carobrez; J. Cavalli; L.J. Bertoglio (S602).
P.4.a.009 Symptom improvement and functional recovery in patients with anxiety disorders by D.S. Baldwin; B. Bandelow; O.T. Dolberg; H.F. Andersen; D.J. Stein (S590-S591).
P.4.a.008 Stability and persistence of anxiety disorders among youth: a prospective-longitudinal community study by K. Beesdo; S. Knappe; M. Hofler; R. Lieb; H.U. Wittchen (S590).
P.4.a.010 Burnout syndrome among physician of central, surgery and medical departments in a general hospital by M. Serrano Vazquez; M.C. Serrano Carton; M.M. Serrano Carton (S591).
P.4.a.01l Quetiapine monotherapy in chronic posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial by M. Hamner; S. Robert; J. Canive; L. Caleis (S591-S592).
P.4.a.013 Efficacy of repetitive transcranial magnetic stimulation in patients with social anxiety disorder – a preliminary study by U. Uzun; O. Karamustafalioglu; G. Alpak; O. Tankaya (S592-S593).
P.4.a.012 Female reproductive cycle events in symptom worsening and onset of obsessive-compulsive disorder by G. Alpak; O. Karamustafalioglu (S592).
P.4.a.007 Alprazolam/venlafaxine versus venlafaxine in the treatment of mixed depression and anxiety by M. Jakovcevska-Kujundziska; V. Lazarova; V. Filovska; N. Cadikovska (S589).
P.4.a.006 Internet-based screening of anxiety disorders by M. Van Ameringen; C. Mancini; W. Simpson; B. Patterson (S588-S589).
P.4.a.001 Clinical and sociodemographic features of patients with obsessive-compulsive disorder by E.A. Yildirim; M. Kasar; E. Ozcan; E. Albayrak; R.P. Gokalp; S. Ozer (S585-S586).
P.3.f.007 Microglia is widespread activated in recent onset schizophrenia: evidence from PET and post mortem studies by B. van Berckel; M. Yaqub; M. Bossong; R. Boellaard; A. Schuitemaker; A.A. Lammertsma; A.D. Windhorst; A. Rozemuller; W. Cahn; R.S. Kahn (S585).
P.4.a.002 Prevalence of PTSD in a sample of victims of Gwangju democratic uprising by S.h. Kim; H.r. Kim; S.h. Park; M.i. Lee (S586).
P.4.a.003 Sex differences in susceptibility to adverse effects of prenatal stress on birth weight: study of 2516 Belgrade newborns by B. Dunjic; N.P. Maric; D.J. Stojiljkovic; D. Britvic; M. Jasovic Gasic (S587).
P.4.a.005 Outcome predictors in patients with obsessive compulsive disorder: a prospective naturalistic study by B. Dell'Osso; M. Buoli; G. Colombini; S. Bortolussi; B. Benatti; M.C. Palazzo; A.C. Altamura (S588).
P.4.a.004 Fear of depression? Extention of an emotion dysregulation model of generalised anxiety disorder by S. Schönfeld; B. Granica; S. Herwig; S. König (S587-S588).
P.4.a.014 Efficacy and safety of repeated TMS in the treatment of refractory obsessive-compulsive disorder by J. Chae; S.J. Lee; H.J. Seo; Y.E. Jeong (S593).
P.4.a.015 Adjunctive pregabalin after partial response to SSRI or SNRI in GAD: results of a double-blind, placebo-controlled trial by J. Weaver; J. Miceli; T. Shiovitz; T. Ramey; L. Knapp (S593-S594).
P.4.b.005 Impaired attentional control in high and low anxious healthy volunteers: evidence from the antisaccade task by M. Garner; B. Ainsworth; H. Gould; H. Gardner; D.S. Baldwin (S599).
P.4.b.004 Reduced fear expression following pharmacological blockade of the ventral hippocampus by J.A.V. Kroon; A.P. Carobrez (S598-S599).
P.4.b.006 Atenolol impairs the acquisition and expression of olfactory fear conditioning in rats by E. Pavesi; N.S. Canteras; A.P. Carobrez (S599-S600).
P.4.b.007 Aberrant default mode network in patients with obsessive-compulsive disorder: an fMRI study by J.H. Jang; J.H. Kim; W.H. Jung; D.H. Kang; J.M. Lee; C.H. Choi; J.S. Kwon (S600).
P.4.b.009 Association between obsessive-compulsive disorder and glutamate n-methyl-d-aspartate2b subunit receptor gene by C. Kim; S. Hwang (S601-S602).
P.4.b.008 Are you afraid of the dentist? Validation of an MRI compatible paradigm using video stimulation in dental anxiety by U. Lueken; J. Kruschwitz; J. Hoyer; A.T. Gloster; H.U. Wittchen (S600-S601).
P.4.b.003 Anxiolytic effects of 6-iodonordihydrocapsaicin, a TRPV1 antagonist, injected into the medial prefrontal cortex of rats by D.C. Aguiar; A.L. Terzian; F.S. Guimaraes (S597-S598).
P.4.b.002 Effects of dopamine antagonists on therapeutic action of clomipramine in a spontaneous alternation model of OCD in rats by P. Gruca; M. Lason-Tyburkiewicz; M. Papp (S597).
P.4.a.017 Psychological difference between noncoronary and coronary patients with chest pain by G. Nikolic; S. Tosic-Golubovic; L.J. Samardzic; D. Gugleta (S595).
P.4.a.016 Switching from long-term benzodiazepine therapy to pregabalin in patients with generalised anxiety disorder (GAD) by P. Szczypa; S.J. Hadley; S. Donevan; F.S. Mandel; T. Leon (S594-S595).
P.4.a.018 Quadratic relation of frequent panic attacks with systolic blood pressure – the HUNT study by S.J.C. Davies; O. Bjerkeset; P.R. Jackson; D.J. Nutt; G. Lewis (S595-S596).
P.4.a.019 Carbon dioxide-induced respiratory symptoms and experimental panic in healthy volunteers by A. Colasanti; K. Schruers; R. van Diest; G. Esquivel; E. den Boer; A. Dandachi; E.J. Griez (S596).
P.4.b.00l Endocannabinoids modulate the flight responses induced by a nitric oxide donor in the dorsolateral periaqueductal gray by S.F. Lisboa; F.S. Guimãraes (S596-S597).
P.5.a.003 Effects of BDNF val66met polymorphism on the association between physical activity and incident dementia by J.S. Yoon; K.Y. Bae; J.A. Yoo; J.M. Kim; S.W. Kim; S.J. Yang; T. Youn; Y.H. Lee; L.S. Shin (S621).
P.5.a.004 One-carbon metabolism and cognitive decline in an older Korean population by J.A. Yoo; K.Y. Bae; J.M. Kim; I.S. Shin; S.W. Kim; S.J. Yang; T. Youn; J.S. Yoon; J.H. Lee (S621-S622).
P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy by N. Bokhan; E.V. Zhernova; N.M. Vyalova; S.A. Ivanova (S645).
P.6.b.003 Effect of glutamine dipeptides on the levels of brain tissue amino acids and severity of the alcohol withdrawal in rats by P.S. Pronko; A.H. Shlyakhtun; T.I. Khomich; V.I. Satanovskaya; A.V. Gaishmanova (S644-S645).
P.6.b.005 Effect of N-methyl-D-aspartate glutamate receptor antagonist, memantine, on alcohol intake in C57BL/6 mice by S.G. Kim; H.K. Kim; H.C. Kim; Y.M. Jae; B.M. Choi; S.S. Lee; S.M. Shin (S645-S646).
P.6.b.006 Peripheral benzodiazepine receptor in platelets of alcoholic patients as a test of efficacy of antialcohol drugs by T.V. Shushpanova; V.Y.A. Semke (S646).
P.6.b.008 Prodynorphin gene regulation by epigenetic mechanisms following ethanol and acetaldehyde exposure in SH-SY5Y cells by C. D'Addario; T. Ekstrom; S.O. Ogren; P. Romualdi; L. Terenius (S647).
P.6.b.007 Effects of acute alcohol consumption on alcohol attentional bias by S. Adams; A. Ataya; M.R. Munafò (S646-S647).
P.6.b.002 Matrix metalloproteinase 2 (MMP2) concentration among alcohol dependent inpatient women by B. Augustynska; A. Araszkiewicz; M. Dabkowska; A. Wozniak; E. Oglodek; G. Odrowaz-Sypniewska; W. Kosmowski; M. Kuligowska (S643-S644).
P.6.b.001 The galanin-3 antagonist, SNAP37889, reduces preference for operant-responding for ethanol in alcohol-preferring iP rats by E. Djouma; A.J. Lawrence; S.D. Zanatta; S.J. Williams (S643).
P.6.a.009 Zonisamide versus diazepam in the prevention of alcohol withdrawal syndrome by G. Rubio; G. Ponce; J.M. Arriazu; I. Martinez-Gras; F. Ferre (S640-S641).
P.6.a.008 A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol dependent subjects by B.J. Watson; B. Bowsher; S. Wilson; L.G. Taylor; N.J. Kalk; L. Griffin; A.R. Lingford-Hughes; M. Munafo; D.J. Nutt (S640).
P.6.a.010 Effects of zonisamide in the treatment of alcohol dependence by G. Rubio; F. Ferre; I. Martinez-Gras; G. Ponce; J.M. Pascual (S641).
P.6.a.01l Sexual dysfunction and alcohol abuse by T. Paparrigopoulos; T. Zabelis; E. Tzavellas; D. Karaiskos; R. Zaloni; X. Stachtea; G. Persefonis; J. Liappas (S641-S642).
P.6.a.013 Decision making, impulsivity and personality traits in alcohol dependent subjects by F. Struglia; A. Tomassini; P. Stratta; D. Spaziani; A. Rossi (S642-S643).
P.6.a.012 Public view of mental illness and alcohol abuse in Slovenia by B. Avgustin; R. Kobentar; B. Novak Sarotar; M. Radovanovic; M. Zorko (S642).
P.6.b.009 Alcohol dehydrogenase gene polymorphism in Korean alcohol addicted patients by C. Shin; S. Choi (S647-S648).
P.6.b.010 Rimonabant repeated treatment inhibits behavioural sensitisation previously developed to ethanol in mice by E.A.V. Marinho; M.A. Baldaia; A.J. Oliveira-Lima; R. Wuo-Silva; H.A. Fernandes; R. Santos; A.W. Hollais; C.A. Gerardi-Junior; L.A. Ferreira; R. Frussa-Filho (S648).
P6.c.008 Pharmacogenetic modulation of neurocognitive deficits in MDMA users: The role of catechol-O-methyltransferase, serotonin transporter SERT and 5HT2A polymorphisms by A.B. Fagundo; E. Cuyàs; A. Verdejo-Garcia; O. Khymenets; K. Langohr; J. Peña-Casanova; S. de Sola; R. Martín-Santos; M. Farré; R. de la Torre (S654).
P.6.c.007 Association between opioid receptor availability and anxiety in healthy controls but not in substance dependence by T.M. Williams; S.J.C. Davies; L.G. Taylor; D.J. Nutt; A. Lingford-Hughes (S653-S654).
P.6.c.009 Psychiatric co-morbidity among patients with amphetamine and methamphetamine dependence in Malaysia by A. Hatim; M. Ayu; H. Habil (S654-S655).
P.6.c.0101 Pharmacodynamic response patterns to ketamine, zolpidem, and diazepam in abuse liability studies by D. Milovan; S.J. Kovacs; M.K. Rotnach; E.M. Sellers (S655).
P6.c.012 Efficacy of melatonin in methadone maintained patients with insomnia: results from an open comparison study by K.R. Stoychev; K.M. Ivanov; M.G. Alexandrova; R.D. Stoychev; L.Z. Tumbev; D.K. Kirov (S656-S657).
P6.C.0111 Effectiveness of the benztropine analogs in preventing the neurochemical and behavioural effects of psychostimulants by C. Velázquez-Sanchez; A. Ferragud; V. Hernandez-Rabaza; A. Arcusa; H.G. Gumus; A. Nácher; V. Merino; M. Cardá; J. Murga; J.J. Canales (S656).
P.6.c.006 Personality disorders in a dual diagnosis unit by D. Martínez-Sanvisens; G. Mateu-Codina; L. Díaz-Digón; L. Morro-Fernández; A. Martínez-Fernández; A. Muñoz-Champel; G. Vallecillo-Sánchez; M. Torrens-Mélich (S652-S653).
P.6.c.005 Benzodiazepines use withdrawal tapering gradually with pregabalin: findings from the medical practice by G. Rubio; J. Bobes; G. Cervera; A. Terán; M. Pérez; V. López-Gómez; J. Rejas (S652).
P.6.c.001 Is attention affected by cocaine use? A case-control study by E. Ochoa; A. Madoz-Gúrpide (S649-S650).
P.6.b.01l The catechol-O-methyltransferase va1158Met genotype in prefrontal dopamine sensitivity in alcohol dependent patients and healthy controls by A. Schellekens; S. Hoppenreijs; A. Oosterwijck; B. Franke; J. Buitelaar; C. Jong; A. Cools; R. Verkes; B. Ellenbroek (S649).
P.6.c.002 Differences in cortical activity between methamphetamine abusers and healthy subjects performing an empathy task by Y.T. Kim; S.H. Joe; D.H. Kwon; B.J. Chae; Y. Chang (S650).
P.6.c.003 Negative affect in depressed versus non-depressed smokers after brief nicotine abstinence by N. Kilzieh; S. Rastam; W. Maziak; A. Tapp; T. Eissenberg (S651).
P.6.c.004 History of consumption of toxic substances in psychiatric inpatients by M. Vidal Millares; M.C. García Manía; C. Armas Barbazan; P. De Usabel Guzman (S651-S652).
P.6.a.007 Clinical characteristics of alcoholics with a childhood history of attention-deficit hyperactivity disorder by M.H. Kim; J.S. Ahn; S.H. Min; Y.R. Lee (S639).
P.6.a.006 Biomedical status of alcohol-dependent patients with erectile dysfunction: a study of vardenafil versus placebo by L. Ortega; A. Gual; S. Matrai (S638-S639).
P.5.b.005 Combination of memantine and donepezil reverses cognitive deficits in transgenic mice with Alzheimer-type pathology by H. Martinez-Coria; K.N. Green; P.K. Banerjee; F.M. LaFerla (S627).
P.5.b.004 Comparative study of the effects of tacrine, donepezil and galantamine on scopolamine-induced impaired memory in rats by D. Dimitrova; D. Getova (S626-S627).
P.5.c.00l Treatment of sex offenders with the long-acting GnRH analogue triptorelin – a case series by P.J. McNally; R. Brock; P. Chabra; R. Kaler; M. Das; M. Kamal (S628).
P.5.c.002 Pregabalin, venlafaxine extended release or their combination in chronic neuropathic pain treatment by V. Jamie; D. Ravanic; S. Djukic Dejanovic; D. Ignjatovic Ristic; Z. Bukumiric (S628-S629).
P.5.d.002 Level of oxidative stress in patients with multiple sclerosis in process of therapy by S.A. Ivanova; N.V. Krotenko; L.P. Smirnova; V.M. Alifirova (S629-S630).
P.5.d.00l Effects of (R)-and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline on rotenone-induced disturbances of dopaminergic system in the rat brain by A. Wasik; I. Romanska; L. Antkiewicz-Michaluk (S629).
P.5.b.003 Inhibition of brain renin-angiotensin system exerts protective effects on memory and oxidative stress in rats by A. Ciobica; L. Hritcu; V. Artenie; M. Padurariu; W. Bild (S626).
P.5.b.002 Plasma levels of monocyte chemotactic protein 3 and beta-nerve growth factor increase in patients with amnestic mild cognitive impairment (MCI) by S. Park; B. Lee (S625-S626).
P.5.a.006 Tolerability of rivastigmine transdermal patch in Alzheimer dementia with psychotic features by D. Vasile; O. Vasiliu; M. Vasile; M. Terpan (S622-S623).
P.5.a.005 Adjunctive use of amisulpride on acetylcholine inhibitors therapy for the treatment of psychotic symptoms in Alzheimer's disease by C. Theleritis; A. Politis; M. Passa; F. LentidaM; E. Stamouli; A. Maillis; G.N. Papadimitriou (S622).
P.5.a.007 Aβ AFFITOPES as active vaccines in the treatment of Alzheimer's disease: preliminary results of two phase I studies by A. Kutzelnigg; A. Schneeberger; M. Brunner; D. Meshkat; P. Dai-Bianco; A. Laggner; D. Winkler; S. Kasper; E. Auff; M. Schmitz; M. Müller (S623).
P.5.a.008 Effects of memantine on functional communication in moderate Alzheimer's disease: results of a 12-week placebo-controlled trial by S. Graham; J. Saxton; M. Woodward; N. Gilchrist; F. Potocnik; R.K. Hofbauer; S.Y. Yu; H. Hsu; J.L. Perhach (S624).
P.5.b.001 Expression of certain apoptotic regulators in a pharmacological experimental model of Alzheimer's disease by S. Hasanagic; Z. Kundurovic; A. Kucukalic; F. Gavrankapetanovic; N. Bilalovic; M. Petrisic-Salkovic; P. Riederer (S625).
P.5.a.009 Validity of general practitioner assessment of cognition as a screening instrument of dementia by D.W. Lee (S624-S625).
P.5.d.003 Decreased striatal dopamine turnover following administration of 7-nitroindazole to rats with L-DOPA-induced dyskinesia by E.A. Del Bel; R.S. Szawka; F.E. Padovan-Neto; C.A. da-Silva; J.A. Anselmo-Franci (S630-S631).
P.5.d.004 Behavioural changes in wistar and spontaneously hypertensive rats in kainate model of epilepsy by J. Tchekalarova; D. Pechlivanova; P. Markova; A. Stoynev (S631).
P.6.a.00l The genetic and psychosocial factors affecting the change of drinking behaviour of male college students by S.I. Lee; S.K. Kim (S636).
P.5.f.003 Loss of NPC1-deficient neurons is associated with altered mevalonate pathway regulation by T. Ohm; K. Kallwellis; F. Albert; V. Meske (S635).
P.6.a.002 The role of rapid glutamate dehydrogenase's kinetics in leukocytes of alcoholics by M. Kravos; I. Maleic (S636-S637).
P.6.a.003 Oxidative stress and role of salivary peroxidase in acute and chronic alcohol intoxication by N. Waszkiewicz; S.D. Szajda; B. Konarzewska; A. Szulc; M. Waszkiewicz; A. Kepka; A. Zalewska; M. Cechowska-Pasko; K. Zwierz (S637).
P.6.a.005 Factors influencing drinking behaviour during pregnancy in Korean women by S.G. Kim; H.C. Kim; S.S. Lee; S.M. Shin; H.K. Kim; Y.M. Jae; B.M. Choi (S638).
P.6.a.004 Maternal problem-drinking and psychopathology of female adolescents by J. Shin; J. Ahn; H. Jang; M. Kim (S637-S638).
P.5.f.002 Involvement of tetrahydrobiopterin in delirium after cardiac surgery by D. Fekkes; R.J. Osse; J.H.M. Tulen; R.C. van der Mast; A.J.J.C. Bogers; M.W. Hengeveld (S635).
P.5.f.001 The facilitatory effects of nicotine on memory and oxidative stress in a 6-OHDA induced lesion of nucleus accumbens by A. Ciobica; L. Hrticu; V. Artenie; M. Padurariu; W. Bild (S634).
P.5.e.002 Polypharmacy in elderly hospitalised patients suffering from delirium in dementia by T. Kratze (S632).
P.5.e.00l Relation between nutritional risk and metabolic syndrome in the elderly by K.Y. Lim; Y.K. Chung; H.J. Kim (S631-S632).
P.5.e.003 Effects of physical, mental, social activity and health concern on cognition in the elderly by K.Y. Lim; Y.K. Chung; H.C. Kim; C.H. Hong (S632-S633).
P.5.e.004 Global surveillance program monitoring raters' administration and scoring of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog by C. McNamara; D. Miller; A. Jones; P. Samuelson; G. Moya; A. Butler (S633).
P.5.e.005 Charles Bonnet Syndrome: a conceptual revision and review of a case report by M. Serrano Vazquez; M.C. Serrano Carton; M.M. Serrano Carton (S633-S634).
P.2.d.019 Effects of chronic agomelatine administration on the expression of a panel of genes in various brain areas of rats by T.J. Varcoe; M. Salkeld; E. Mocaer; L. Seguin; D.J. Kennaway (S440-S441).
P.2.d.018 Mechanisms contributing to the regulation of the different phases of neurogenesis by agomelatine by A. Soumier; S. Lortet; F. Masmejean; C. Gabriel; E. Mocaer; M. Millan; A. Daszuta (S439-S440).
P.1.b.010 The P3a component of the event-related potential from passive visual task in patients with schizophrenia by Y. Jeon; E. Park; J. Yi; S. Kim (S246).
P.1.b.009 Effects of Chlorpromazine on GIRK channel expressed transiently in HEK cells by E. Kim; K. Kim; S. Hyun (S245-S246).
P.1.b.011 Histamine H3 receptor activation decreases gamma oscillation power and causes desynchronization of action potentials by R. Andersson; A. Fisahn; M. Lindskog (S246-S247).
P.1.b.012 Locus coeruleus and dorsal raphe nucleus neuron activity in control, parkinsonian and dyskinetic animals by C. Miguelez; L. Ugedo (S247).
P.1.b.014 Lasting effect of associative pairing of sensory stimuli and the group I metabotropic glutamate antagonist AIDA on inhibitory transmission in mice barrel cortex by J. Wabno; G. Hess (S248).
P.1.b.013 Chronic sleep deprivation and pain perception by L. Sahin; M. Ascioglu; E. Taskin; A.S. Arris (S247-S248).
P.1.b.008 Hypothalamic-pituitary-thyroid (HPT) axis and personality traits in attempted suicide by J. Jokinen; C. Sinai; P. Nordstrom (S245).
P.1.b.007 Developmental expression and activity of carboxylesterase 1 and carboxylesterase 2 in mouse and human by H.J. Zhu; D.I. Appel; J.L. Donovan; C.L. DeVane; J.S. Markowitz (S244-S245).
P.1.b.002 Night-time/daytime and daytime/daytime patterns of melatonin levels by A.L. Morera; P. Abreu-Gonzalez; A. Orozco-Sanmartin; M. Henry; A. Guerra-Reyes; A. Garcia-Hernandez; L. Fernandez-Lopez; C.R. Morales-García; E. Diaz-Mesa; J. Monzon-Diaz (S241-S242).
P.1.b.00l Digital EEG recording during hallucinatory behaviour in a sample of patients with paranoid schizophrenia by M. Rabie; H. Zalá; A. Gaber; H. Alkhawas (S240-S241).
P.1.b.003 Is diurnal variation in plasma brain-derived neurotrophic factor level sex-related? by S. Choi; J. Ahn; S. Bang (S242).
P.1.b.004 Ultradian regulations: relationships between sleep EEG power spectra and REM-NREM sleep cycles by D. Neu; O. Le Bon; L. Staner; P. Linkowski (S242-S243).
P.1.b.006 The change of laterality to non-dominant handedness during sleep night in obstructive sleep apnea syndrome by D.H. Park; H.J. Jeon (S244).
P.1.b.005 Significance of fatigue and insomnia complaints in the psychiatric emergency room by D. Neu; P. Minner; O. Le Bon; L. From; P. Linkowski; P. Verbanck (S243-S244).
P.1.b.015 Chronic social stress decreases cerebral oxidative metabolism in rats with persistently high sucrose consumption by M. Kanarik; D. Matrov; K. Koiv; J. Harro (S248-S249).
P.1.b.016 The influence of repeated administration of the selective mGluR7 allosteric agonist AMN082 on GABA synthesis and GABA-B receptor expression in mice by J.M. Wieronska; P. Branski; G. Nowak; A. Pile (S249-S250).
P.1.c.008 D-serine adjuvant treatment alleviates motor and behavioural symptoms in idiopathic Parkinson's disease by U. Heresco-Levy; D.C. Javitt; Y. Gelfin; Y. Kaufman; R. Levin; I. Korn-Lubetzki; B. Bloch; H. Wolosker; I. Kremer (S255-S256).
P.1.c.007 The antinociceptive effects of sertraline and duloxetine in cutaneous and visceral pain models in mice by L. Tartau; E.V. Sindrilar; C.E. Lupusoru (S255).
P.1.c.009 A randomized, double-blind, comparison of risperidone versus risperidone plus haloperidol treatment in schizophrenia by C.H. Lin; C.C. Kuo; L.S. Chou; S.J. Wang; M.C. Chen; C.C. Chen (S256).
P.1.c.010 Effect of JNJ-10181457, a selective H3 receptor antagonist, on dopamine release in the rat nucleus accumbens by P. Bonaventure; L. Aluisio; I. Fraser; T. Lovenberg (S257).
P.1.c.012 Efficacy and safety of duloxetine 60-mg and 120-mg daily in patients hospitalised for severe depression by S. Brecht; D. Desaiah; E. Marechal; A. Santini; J. Podhorna; J.D. Guelfi (S258).
P.1.c.011 The changes in cortical BDNF level upon chronic administration of venlafaxine, olanzapine and nicotine by E. Nowakowska; A. Czubak; K. Kus; K. Burda (S257-S258).
P.1.c.006 Targeted delivery of PEGylated liposomes to gap junction protein Connexin-43 (Cx43) positive C6 glioma cells by V.P. Baklaushev; O.I. Gurina; N.F. Grinenko; Y.U.A. Jhyrkov; V.P. Chekhonin (S254-S255).
P.1.c.005 Copper overloading impairs the rewarding effects of morphine evaluated by conditioned place preference by D. Ciubotariu; D.I. Chelarescu; M. Pascu; M. Nechifor (S254).
P.1.b.018 Functional reorganization of dorso-medial medullar local neural networks and ECG alteration under pain influence by H. Prudnikau (S250-S251).
P.1.b.017 Projection of subtypes of aggression to event related brain potentials in healthy adults with a tendency to aggression by E.A. Yildirim; T. Demiralp; M. Ergen; E. Yurdakos (S250).
P.1.c.001 Electrophysiological studies in the rat brain as the basis for aripiprazole augmentation in major depressive disorder by O. Chernoloz; M. El Mansari; P. Brier (S251).
P.1.c.002 Cannabidiol lowers body weight gains in rats by B. Ignatowska-Jankowska; M. Jankowski; W. Glac; A.H. Swiergiel (S252).
P.1.c.004 Repeated citalopram administration counteracts kainic acid-induced plasticity in adult mouse hippocampus by M. Helmdorf; D. Sastin; K. Jaako; A. Zharkovsky (S253).
P.1.c.003 Opiates and SSRI's: risk for serotonin syndrome by L. Timmerman; A.V.D. Hoek-Mensink (S252-S253).
P.1.a.026 Impaired neurogenesis in schizophrenia: results from a multiarray study with schizophrenics and normal controls by P. Belmonte-de-Abreu; H.M. Brentani; M.I. Lobato; C.S. Gama; D. Carraro; J.A. Palha (S240).
P.1.a.025 Association study of rs6916861 polymorphism of the FYN gene in bipolar disorder and it subtypes by A. Leszczynska-Rodziewicz; A. Rajewska-Rager; A. Szczepankiewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Hauser (S239-S240).
P.1.a.005 DRD4 gene polymorphism association and response to methylphenidate in attention deficit hyperactivity disorder by M.H. Lim; K.K. Lee; K.C. Paik; H.W. Kim (S227-S228).
P.1.a.004 Modulation of presynaptic and postsynaptic plasticity by chronic mild stress and decreased vesicular glutamate transporter VGLUT1 levels by N. Elizalde; P.M. Pastor; A.L. Garcia-Garcia; F. Serres; J. Huarte; J. Del Rio; T. Sharp; R.M. Tordera (S227).
P.1.a.006 Genetic interaction of the serotonin transporter and the cannabinoid receptor 1 affects the anxious phenotype by J. Lazary; X. Gonda; A. Benko; E. Molnar; G. Bagdy (S228).
P.1.a.007 The role of insulin receptor substrate-1 Gly972Arg polymorphism in the pathogenesis of Alzheimer's disease by A. Juhasz; A. Fehér; A. Rimanóczy; M. Gálfi; J. Kálmán; Z. Janka (S228-S229).
P.1.a.009 Impulsivity and the C(-1019)G functional polymorphism of the HTR1A gene by A. Benko; J. Lazary; E. Molnar; X. Gonda; D. Pap; G. Juhasz; G. Bagdjr (S230).
P.1.a.008 Menopausal status could modulate the association between 5-HTTLPR and antidepressant efficacy in depressed women by F. Gressier; C. Verstuyfl; E. Bouaziz; P. Hardy; L. Becquemont; E. Comible (S229).
P.1.a.003 Gene-environment interactions predisposing to personality traits: the role of ADRA2A, norepinephrine transporter and COMT gene polymorphisms by A. Kazantseva; D. Gaysina; E. Khusnutdinova (S226).
P.1.a.002 Association study of −1727 A/T and −50C/T GSK-3 beta gene polymorphism with suicidal behaviour in depressed patients by H.K. Yoon; Y.K. Kim; B.H. Lee; J.A. Hwang (S225-S226).
E.05.01 Schizophrenia: when does pharmacogenetics overlap genetic vulnerability? by P. Gorwood; N. Hamdani; C. Dubertret; P. Ramoz (S222).
E.04.04 CANMAT/ISBD collaborative update of guidelines for bipolar disorder by L. Yatham (S222).
E.05.02 Novel insights into the genetics of schizophrenia based on genome-wide association studies by M. O'Donovan (S222-S223).
E.06.02 Process of development of the ICD-11 and DSM-V: first results and cultural perspectives by N. Sartorius (S223).
P.1.a.00l Effect of chronic mild stress on gene expression in raphe nuclei: role of 5-HT (5B) and orphan Gpr88 receptors in stress adaptation in mice by G.R. Juszczak; P. Lisowski; M. Wieczorek; J. Goscik; A.T. Sliwa; A.H. Swiergiel (S225).
E.06.04 Functional impairment as a classification criterion? by M. Linden (S223).
P.1.a.010 The contribution of genetic vulnerability to the multiformity of isotretinoin-induced psychiatric adverse events by V.P. Kontaxakis; P. Ferentinos; B. Havald-Kontaxató; G.N. Papadimitriou (S230-S231).
P.1.a.011 Association of the serotonin transporter intron 2 VNTR polymorphism with treatment response to mirtazapine by H.Y. Lee; H.S. Chang; B.J. Ham; S.G. Kang; S.W. Hahn; M.S. Lee (S231).
P.1.a.020 Oxytocin receptor polymorphisms and adult attachment style in patients with depression by M. Abelli; B. Costa; S. Pini; P. Gabelloni; L. Lari; A. Cardini; C. Gesi; A. Lucacchini; G.B. Cassano; C. Martini (S236-S237).
P.1.a.019 Serotonin transporter gene promoter polymorphism, education, depression and relations with partner by T. Kurrikoff; J. Maestu; N. Nordquist; L. Oreland; J. Harro (S236).
P.1.a.021 Genetic association of MTHFR gene with schizophrenia and bipolar disorder by S. Kim; D.C. Jung; Y.M. Ahn; Y.S. Kim (S237).
P.1.a.022 Cytosolic phospholipase A2 Banl and cyclooxygenase-2 G-765C polymorphisms in Alzheimer's disease by A. Feher; A. Juhász; A. Rimanóczy; J. Kálmán; Z. Janka (S238).
P.1.a.024 Association study of rs2289656, polymorphism of the NTRK2 gene with bipolar disorder and it subtypes by A. Rajewska-Rager; A. Leszczynska-Rodziewicz; A. Szczepankiewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Hauser (S239).
P.1.a.023 Association study between WNT2 polymorphisms and the susceptibility to schizophrenia in Korean population by D.K. Hwang; H.J. Kim; S.V. Yim; B.K. Choe; J.K. Park; J.W. Kim; S.J. Hong; J.H. Chung (S238-S239).
P.1.a.018 Admixture analysis in pharmacogenetics: serotonergic system genes and antipsychotic response by V. De Luca; F. Panariello; R. de Souza; D. Muller; H. Meltzer; S.G. Potkin; J. Lieberman; J.L. Kennedy (S235-S236).
P.1.a.017 Association study between IL-10 and TNF-a genes and tardive dyskinesia in Korean schizophrenia by S.G. Kang; I.E. Choi; H.Y. Lee; H.J. Lee; M.S. Lee; L. Kim (S235).
P.1.a.013 Association study of cannabinoid receptor gene with olanzapine-induced weight gain in schizophrenia by S.G. Kang; J.E. Choi; Y.M. Park; H.J. Lee; S.H. Lee; L. Kim (S232-S233).
P.1.a.012 Interaction effects between serotonin-related gene polymorphisms on emotional intelligence by J.I. Kang; K. Namkoong; S.J. Kim (S231-S232).
P.1.a.014 Variations in the catechol-O-methyl-transferase gene are associated with impulsivity by G. Juhasz; J. Lazary; D. Downey; E. Pegg; D. Chase; K. Mekli; A. Payton; G. Bagdy; I.M. Anderson; J.F.W. Deakin (S233).
P.1.a.015 Relationship of MAO-A and catechol-O-methyltransferase gene polymorphisms to plasma monoamine metabolites levels in patients and controls by M. Zumarraga; N. Basterreche; A. Arrúe; M.I. Zamalloa; R. Dávila; M.A. González-Torres; J. Guimón (S233-S234).
P.1.a.016 Negative life events and genes of the serotonergic pathway of suicide victims with previous aggressive behaviour by P. Pregelj; M. Zmuc Tomori; J. Balazic; T. Zupanc (S234-S235).
P.1.c.013 Differences of brain activation by visual erotic stimuli between patients treated with SSRI and mirtazapine by W. Kim; J.H. Chae (S258-S259).
P.1.c.014 The novel antidepressant, agomelatine, blocks cerebral 5-HT2C receptors in vivo: a phMRI challenge study in rats by I. Linnik; S. McKie; J.A. Stark; S. Luckman; L. Seguin; E. Mocaer; M.J. Millan; B. Deakin; S.R. Williams (S259).
P.l.c.055 Acute stressor improves memory retrieval of discriminative avoidance task in mice by A.L. Takatsu-Coleman; C.L. Patti; M.L. Andersen; S. Tufik; R. Frussa-Filho (S283).
P.l.c.054 Opioid receptors of dorsomedial and ventrolateral periaqueductal grey matter modulate the post-ictal antinociception by R.L. Freitas; L.I. Bolognesi; A. Twardowschy; F.M.A. Correa; N.R. Sibson; N.C. Coimbra (S282-S283).
P.l.c.056 The most frequent used drugs at psychiatric clinical centre Kragujevac in 2007 by G. Mihajlovic; S. Djukic Dejanovic; B. Radmanovic; M. Borovcanin (S283-S284).
P.l.c.057 Effects of trazodone on sleep, respiratory and nocturnal movement variables in insomniac somatoform pain patients by W. Prause; B. Saletu; P. Anderer; E. Grátzhofer; G.M. Saletu-Zyhlarz; M. Aigner (S284).
P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons by B. Guiard; F. Chenu; M. El Mansari; P. Blier (S285).
P.l.c.058 Evaluation of an inpatient therapeutic interchange protocol for second generation antidepressants and clinical follow-up by F. Martínez-Granados; E. Climent-Grana; E. Perez-Martinez; J.P. Ordovas-Baines (S284-S285).
P.l.c.053 Valproic acid and thrombocytopenia in Korean psychiatric patients: a retrospective study by H. So; J. Choi; J. Kim; T. Kim; H. Jung; M. Chung (S282).
P.l.c.052 Paclitaxel induced pain and its character by A. Hacimuftuoglu; F. Saruhan; H. Suleyman; Z. Halici; E. Cadirci; D. Cetin; B. Polat (S281).
P.1.c.047 Hippocampal nociceptin receptors and memory: possible implications for "anti-alcohol" effects of nociceptin ligands by B. Johansson; A. Kuzmin; N. Madjid; L. Terenius; S.O. Ógren (S278-S279).
P.1.c.046 Pharmacogenetics of antidepressant drug response – a case report by M. Grgic; D. Degmecic; N. Boina; A. Dujmovic (S278).
P.1.c.048 Brain histamine-3 receptors as a potential target of novel strategies in the treatment of mental disorders by J.H.A. Folgering; G. Flik; E. Dremencov; T.H.I.F. Cremers; B.H.C. Westerink (S279).
P.1.c.049 Relation of proepileptic activity of indomethacin with adrenal gland hormones by H. Suleyman; A. Hacimuftuoglu; E. Cadirci; A. Albayrak; B. Polat; H.H. Alp; Z. Halici (S279-S280).
P.1.c.0511 Heterodimerization of mu opioid receptor and nociceptin/orphanin FQ peptide receptor alters g protein coupling by O. Gunduz; E. Baldini; A. Borsodi; S. Benyhe; M. Corbani (S280-S281).
P.1.c.050 Interferon treatment in patients with multiple sclerosis and correlation with anxiety and depression by G. Moussas; P. Kostaras; A. Tselebis; F. Karra; M. Maltezou (S280).
P.1.c.060 Effect of agmatine on pentilentetrazole-induced kindling in rats by F. Aricioglu; Z. Agalar; M. Kaya; C. Gurses (S285-S286).
P.l.c.06l Effects of repeated citalopram treatment on the kainic acid induced alterations in brain plasticity in adult mouse by K. Jaako; T. Harkovskaja; A. Harkovsky (S286).
P.1.d.008 The effects of fluoxetine on behaviours in an animal model of transient forebrain ischemic in gerbils by B. Son; H. Li; D. Kim; M. Won; J. Yan (S291-S292).
P.1.d.007 Study of the social instigation in the isolation-induced aggression model: effects of the specific and potent mGluRI antagonist JNJ16259685 by S. Infante; M. Martin-Lopez; V. De Castro; J.F. Navarro (S291).
P.1.d.009 Antiaggressive effects of LY354740, a selective agonist of mGlu2/3 receptors, in social encounters between male mice by V. De Castro; S. Infante; M. Martín-López; J.F. Navarro (S292).
P.1.d.010 Peak in the theta power spectrum of EEG shows strong association with voluntary movements in rats by Z. Kátai; T. Kitka; T. Garay; E. Molnár; G. Bagdy (S292-S293).
P.1.d.012 Role of the endocannabinoid system and vanilloid TRPV1 channels in the phenotype of dopamine D3 receptor knock-out mice by V. Micale; L. Cristino; A. Tamburella; S. Petrosino; G.M. Leggio; V. Di Marzo; F. Drago (S294).
P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice by S. Kittel-Schneider; T. Wultsch; S. Chourbaji; E. Grunblatt; M. Gerlach; L. Gutknecht; A. Schmitt; P. Gass; K.P. Lesch; A. Reif (S293).
P.1.d.006 Effects of medial septal nucleus and dentate gyrus neurotoxic lesions on acquisition of a place and cue water maze task by G. Beselia; M. Dashniani; N. Chkhikvishvili (S290).
P.1.d.005 Cannabidiol-mediated modulation of the defensive behaviour evoked by GABA(A) receptor blockade in the inferior colliculus by A. Twardowschy; J.A.S. Crippa; J.E.C. Hallak; N.C. Coimbra (S289-S290).
P.1.d.00l Effects of JNJ16259685, an antagonist of glutamate mGlul receptors, on anxiety tested in the elevated plus maze in mice by V. De Castro; M. Martín-López; J.F. Navarro (S287-S288).
P.l.c.062 Prenatal exposure of selective cholinoblockers disturbs brain neurotransmitter systems and sexual function in rats by A.A. Bairamov; G.Y.U. Yukrna; N.S. Mamina; P.D. Shabanov (S286-S287).
P.1.d.002 Absence of tolerance to the antiaggressive action of the mGlul R antagonist JNJ16259685 after repeated administration to mice by V. De Castro; M. Martín-López; D. Suárez; A. Rivera; J.F. Navarro (S288).
P.1.d.003 Experimental researches on the modulatory effects of some dopaminergic agents in visceral nociception by L. Tartau; R.V. Lupusoru; C.M. Ghiciuc (S288-S289).
P.1.d.004 Effects of green tea extract on behaviour in chronic lead intoxicated rats by O. Rebai; N.E. Djebli; S. Douichene (S289).
P.l.c.045 Effects of catechin and epicatechin on rat phrenic nerve-hemidiaphragm preparation by A. Zengin; A. Nurten (S277-S278).
P.l.c.044 Paradoxical effects of GABA on the in vivo uptake of the partial inverse GABA agonist [3H]Ro15-4513 in rat brain by R.J. Tyacke; E.S.J. Robinson; A. Harris; A.R. Lingford-Hughes; D.J. Nutt (S276-S277).
P.1.c.024 Aripiprazole augmentation for treatment of patiens with major depression refractory to antidepressants by C. Leotsakou; A. Sardis; A. Kalogeropoulou; C. Labiris; F. Kapsali; K. Papadopoulos; P. Pelka; M. Giovanoglou; E. Mantzari; P. Paterakis (S265).
P.1.c.023 GABA-A receptor-mediated neurotransmission in ventromedial hypothalamus modulates fear and antinociception by R.L. Freitas; M.A. Castiblanco-Urbina; A. Uribe-Mariño; D.H. Elias-Filho; N.C. Coimbra (S264-S265).
P.1.c.025 Differential effects of aripiprazole, amisulpride and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells by M.K. Seo; S.W. Park; J.G. Lee; H.Y. Cho; Y.H. Kim (S266).
P.1.c.026 Opioid and nonopioid stress-induced analgesia are mediated by spinal 5-HT7 receptors by A. Dogrul; M. Seyrek; M.S. Deveci; S. Kahraman (S266-S267).
P.1.c.028 Systemically and spinally administered etanercept, a TNF-alpha antagonist, blocks allodynia in diabetic mice by A. Dogrul; H. Gul; O. Yesilyurt; U.H. Ulas; O. Yildiz (S267-S268).
P.1.c.027 Effects of modafinil on contextual spatial memory retrieval in sleep-deprived mice by C. Piérard; P. Liscia; C. Tronche; M. Coutan; B. Poly; D. Béracochéa (S267).
P.1.c.022 Antipsychotic agents attenuate dopamine fear response in the basolateral amygdala by modulating basal dopamine release by H. Oshibuchi; K. Inada; H. Sugawara; J. Ishigooka (S264).
P.1.c.021 The effect of pharmacological manipulation of endocannabinoid tone in the ventral hippocampus on expression of fear-conditioned analgesia in rats by G.K. Ford; K. Dolan; D.P. Finn (S263-S264).
P.1.c.016 Neuropharmacological activity of new l-valine peptidomimetics – in vitro and in vivo studies by E. Encheva; L. Tancheva; M. Novoselski; V. Petkov; J. Chakalarova; G. Gorneva; D. Tsekova; I. Gurt; E. Katz (S260-S261).
P.1.c.015 Fentanyl and SNC-80 upregulate p25, an activator of cdk5, in rat brain: functional interaction with the MEK-ERK pathway by A. Ramos-Miguel; J.A. Garcia-Sevilla (S259-S260).
P.1.c.017 Neuropsychiatric adverse drug reactions (ADRs) and neuropsychiatric drugs-induced ADRs in a tertiary care hospital by M. Ponte; P.F. Garcia Merletti; S. Cráneo; P. Staltari; M.L. Dupont; A. Wachs; A. Noel (S261).
P.1.c.018 Different neurochemical effects of R and S enantiomers of tetrahydroisoquinoline on dopamine metabolism in rat brain by L. Antkiewicz-Michaluk; I. Romanska; J. Boksa; A. Bojarski; J. Michaluk (S261-S262).
P.1.c.020 Histological outcome after oxcarbazepine treatment in the asphyxiated neonatal rat brain by G. Papazisis; D. Kapoukranidou; I. Kalpidis; M. Albani; D. Kouvelas (S263).
P.1.c.019 Vulnerability to major psychiatric disorders, response to treatment and medical comorbidity – shared genetic factors? by H.H. Stassen; I.G. Anghelescu; S. Braun; K. Hoffmann; D. Rujescu; C. Scharfetter; A. Szegedi; A. Tadic (S262).
P.1.c.029 Acute and chronic exposure to intravenous cocaine affects lymphocyte subsets distribution in peripheral blood of rats by M. Jankowski; B. Ignatowska-Jankowska; W. Glac; A.H. Swiergiel (S268).
P.1.c.030 Effect of dopamine and nitric oxide systems manipulation on spontaneous prepulse inhibition disruption in Wistar rats by A. Issy Pereira; M. Lazzarini; E.A. Del Bel (S268-S269).
P.1.c.039 The effects of valproic acid on the pancreas of rats by J.H. Chung; B.K. Choe; S.V. Yim; J.K. Park; S.J. Hong; J.W. Kim (S274).
P.l.c.038 Modulation of dopaminergic activity in the mesolimbic system by trace amine-associated receptor 1 (TAAR1) modification by E.G. Revel; A. Bradaia; G. Trube; H. Stalder; L. Ozmen; J.G. Wettstein; B. Bettler; M.C. Hoener (S273).
P.l.c.040 Neuroprotective effect of timing for vinpocetine treatment on cerebral ischemia/reperfused rats by C. Kayacilar; D. Tekin; A. Zengin; A. Nurten; I. Kara (S274-S275).
P.l.c.041 The role of pro-inflammatory cytokines IL-ip and IL-6 on proliferation of human hippocampal neural stem cells by P. Zunszain; C. Anacker; L. Carvalho; S. Thuret; J. Price; C.M. Paríante (S275).
P.l.c.043 ACR325: a dopaminergic stabiliser that displays state-dependent effects in-vivo by H. Pontón; T. Dyhring; M. Edling; F. Pettersson; C. Sonesson; B. Svanberg; L. Swanson; J. Tedroff; S. Waters; N. Waters (S276).
P.l.c.042 Antihyperalgesic and antiallodynic effect of chronic lactoferrin administration in neuropathic pain by A. Onal; G. Kayalioglu; A. Parlar; A. Keser; S. Ulker (S275-S276).
P.1.c.037 Efficacy of intramuscular aripiprazole in the management of agitated patients by S. De Filippis; I. Cuomo; S. De Persis; M. Parisi; C. Di Pasquale; L. De Vecchis; L. Penna; A. Sciarretta (S272-S273).
P.1.c.036 From a single target to promiscuity; CB1 receptor-independent actions of rimonabant (SR141716) on G-protein signalling by R. Cinar; M. Szücs (S272).
P.1.c.032 Ropinirole as a coadjuvant treatment in the management of refractory patients with fibromyalgia: a case series by J.S. Vilchez; E.P. Calandre; F. Rico-Villademoros; R. Molina-Barea; C.M. Rodriguez-Lopez; J. Garcia-Carrillo (S270).
P.1.c.031 Tolerance effect to pregabalin in a subpopulation of fibromyalgia by K. Kosma; K. Kontoangelos; K. Roumbou; G. Papadopoulos; M. Anastasiou (S269-S270).
P.1.c.033 Effects of carnosine on long-term plasticity of perforant pathway/dentate gyrus synapses in rats: an in vivo model by N. Dolu; C. Süer; S. Artis; S. Aydogan (S270-S271).
P.1.c.034 Effect of topiramate on valproic acid clearance in adult patients with epilepsy: a population pharmacokinetic study by K. Vucicevic; B. Miljkovic; M. Pokrajac; I. Grabnar (S271).
P.1.c.035 Celecoxib, a cyclooxygenase-2 inhibitor enhances pentylenetetrazole induced seizure threshold in mice by A. Mesdaghinia; A. Heydari; P. Khazaee (S271-S272).
E.04.02 The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines by H. Grunze; E. Vieta; G. Goodwin; C. Bowden; R. Licht; H.J. Moeller; S. Kasper (S221-S222).
E.03.04 Drug treatments for insomnia: why, when, and for how long? by S. Wilson (S221).
S.07.07 Slow frequency oscillations of response-time intra-subject variability in children with ADHD by N. Adamo; A. Di Martino; C. Peddis; E.X. Castellanos; A. Zuddas (S189).
S.07.06 Aripiprazole and risperidone improve working memory in healthy volunteers; an fMRI study by A. Murphy; S. McKie; J.F.W. Deakin (S188-S189).
S.07.08 Erythropoietin modulates emotional processing in biomarker models of antidepressant drug action in depressed patients by K. Miskowiak; E. Favaron; S. Hafizi; B. Inkster; P.J. Cowen; G.M. Goodwin; C.J. Harmer (S189-S190).
S.08.02 Role of Arc/Arg3.1 in the actions of psychostimulant drugs by F. Fumagalli; L. Cafflno; C. Franchi; M. Pasini; G. Racagni; M.A. Riva; L. Cervo (S190).
S.08.04 Learning about Arc/Arg3.1 and long-term memories by D. Kuhl; C. Gross; X.S. Mao; O. Ohana (S190-S191).
S.08.03 Arc/Arg3.1 synthesis and control of LTp consolidation in the adult dentate gyrus in vivo by C. Bramham; D. Panja; A. Tiron; R. Nair; K. Wibrand; S. Kuipers (S190).
S.07.05 Cannabis co-administration potentiates MDMA effects on temperature and heart rate by G. Dumont; C. Kramers; F. Sweep; D. Touw; J. van Hasselt; M. de Kam; J. van Gerven; J. Buitelaar; R.J. Verkes (S188).
S.07.04 Specific deletion of AMPA-R GluR1 subunits in D1 expressing neurons: cocaine-addiction related behavioural consequences by B. Halbout; M. Mameli; J. Rodriguez Parkitna; A. Bilbao; G. Schiitz; C. Lüscher; R. Spanagel (S188).
S.06.04 The dopamine system in adult ADHD – findings from the IMpACT study by B. Cormand; M. Ribasés; J.A. Ramos-Quiroga; C. Sánchez-Mora; M. Casas; S. Johansson; J. Haavik; A. Reif; B. Franke; M. Bayés (S186).
S.06.03 Replication of a genome wide association study on adult ADHD in the IMpACT sample by C. Freitag (S185).
S.06.05 From synthesis to uptake – serotonergic genes in adult ADHD by J. Haavik; S. Johansson; P.M. Knappskog; I. Winge; J.A. McKinney; A. Halmeiy; E.T. Landaas (S186).
S.07.01 Quantification of corticosterone and corticotrophin releasing factor in amygdala dialysates: modulation by stress by G. Bouchez; A. Gobert; J.M. Rivet; M.J. Millan (S186-S187).
S.07.03 Effects of varenicline on dopamine D2/3 receptor binding in rats using ex vivo phosphor storage imaging by C.L. Crunelle; M.L. Miller; K. De Bruin; W. Van den Brink; J. Booij (S187).
S.07.02 The role of GABA in rat basolateral amygdala and periaqueductal gray on the behavioural expression of fear and pain by K. Rea; Y. Lang; D.P. Finn (S187).
S.08.05 Arc/Arg3.1: an important molecule affected by novel cognitive-enhancing drugs by J.D. Mikkelsen (S191).
S.09.01 New opportunities to treat addictive disorders by F. Vocci (S191).
S.12.04 Aging-related decline in relational/declarative and working memory: a translational approach from mice to humans by A. Marighetto; L. Brayda-Bruno; N. Etchamendy; N. Mons (S195).
S.12.03 Phosphodiesterase inhibitors as a target for enhanced cognition by A. Blokland; K. Rutten; O. Reneerkens; E. Bollen; J. Prickaerts (S195).
S.12.05 Therapeutic use of peroxisome proliferator-activated receptors (PPAR) gamma agonists in the treatment of Alzheimer's disease by G. Landreth (S195-S196).
S.14.01 Is there a typical premorbid Parkinsonian personality? by T. Witjas; J.P. Azulay; A. Eusebio; J. Cohen; D. Magalon (S196).
S.14.04 Impulse control disorder: prevalence and possible risk factors by D. Weintraub (S196-S197).
S.14.02 Addicted to dopamine – the dopamine dysregulation syndrome in Parkinson's disease by A.H. Evans (S196).
S.12.02 The glycine transporter 1 and its involvement in memory by P. Singer; D. Boison; H. Mohler; J. Feldon; B.K. Yee (S194-S195).
S.12.01 Does more long-term-potentiation mean better memory? Studies of genetically modified mice with altered NMDAR function by D. Bannerman (S194).
S.09.04 The nociceptin/orphanin FQ system as a potential target to reduce alcohol dependence by A. Kuzmin; S. Liljeqvust; G. BakalMn (S192).
S.09.03 Long acting naltrexone implants for heroin dependence by E. Krupitsky; E.E. Zvartau; G. Woody (S192).
S.09.05 Modulators of glutamate transmission for the treatment of nicotine and cocaine dependence by A. Markou (S192-S193).
S.10.01 A dual role for mineralocorticoid receptors in the limbic brain by M. Joels; H. Karst (S193).
S.10.03 Modulating the mineralocorticoid receptor as add-on therapy in antidepressant treatment with SSRI: a randomised controlled trial by C. Otte; K. Hinkelmann; S. Moritz; A. Yassouridis; H. Jahn; K. Wiedemann; M. Kellner (S193-S194).
S.10.02 Using prednisolone to test mineralocorticoid receptor function in depressed patients by C. Paríante (S193).
S.06.02 From childhood to adulthood – testing the IMAGE candidates in IMpACT by B. Franke; S. Johansson; B. Cormand; J.A. Ramos-Quiroga; P. Asherson; S.V. Faraone; J.K. Buitelaar; K.P. Lesch; J. Haavik; A. Reif (S185).
S.06.01 Diagnostic assessment and multilevel phenotyping in the IMpACT study group by J.A. Ramos-Quiroga; R. Bosch; M. Casas (S184-S185).
S.02.02 Mood effects of DBS of the subthalamic nucleus: a role for 5-HT by T. Sharp; H. Hartung; S. Tan; P. Magill; A. Blokland; V. Visse-Vandevalle; H.W.M. Steinbusch; Y. Temel (S177).
S.02.01 Neurochemical mechanisms underlying DBS of the subthalamic nucleus in a rat model of Parkinson's disease by M. Savasta (S177).
S.02.04 Deep brain stimulation in obsessive compulsive disorder by D. Denys; R. Schuurman (S177-S178).
S.02.05 Deep brain stimulation for treatment resistant depression – predictors of response by T.E. Schlaepfer; H.E. Bewernick; S. Kayser; D. Lenartz; V. Sturm (S178).
S.03.02 Maternal exposure to bacterial endotoxin during pregnancy in rats: implications for aetiopathogenesis of schizophrenia by J. Borrell (S179).
S.03.01 Do virus infections cause schizophrenia? by H. Karlsson; L. Asp; S.O. Ögren; S. Erhardt; M. Holtze; K. Kristensson; C. Dalman (S178).
S.01.05 Is psychological treatment effective in bipolar disorders? by J. Scott (S176).
S.01.04 Management of the difficult-to-treat bipolar patient: a systematic approach by K. Fountoulakis (S176).
PL.02.01 New mechanism responsible for drug addiction: uncoupling between noradrenergic and serotonergic neurons by J. Tassin (S173).
Editorial Board (ii).
PL.03.01 The schizophrenia paradigm: a hundred-year challenge by W. Carpenter (S173-S174).
S.01.01 Protein kinase C inhibitors in mania by A. Yildiz; D. Öngür; P.F. Renshaw (S175).
S.01.03 Treatment of bipolar disorders in children and adolescents by C. Moreno; J. Merchan-Naranjo; M. Alvarez; M. Giraldez; M. Parellada; D.M. Moreno; C. Arango (S176).
S.01.02 Meta-analytic comparison of antipsychotics versus mood-stabilisers in mania by E. Vieta; A. Yildiz; J.R. Baldessarini (S175).
S.03.03 The effect of Toxoplasma gondii on host behaviour: studies on mechanism of action using psychotropics, anti-parasite medication and parasite genes by J.P. Webster; G.A. McConkey (S179).
S.03.04 Inflammation and the glutamate system by N. Müller; A.M. Myint; M.J. Schwarz (S179-S180).
S.04.08 Serotonin-1A receptor binding potential in dorsal raphe nuclei predicts orbitofrontal reactivity in healthy subjects by A. Hahn; M. Savli; P. Stein; L.K. Mien; A. Holik; M. Mitterhauser; C. Windischberger; W. Wadsak; R. Lanzenberger; S. Kasper (S182-S183).
S.04.07 Interaction between ethanol and the cannabinoid system at GABA-ergic synapses on basolateral amygdala principal neurons by G. Talani; D.M. Lovinger (S182).
S.05.01 Understanding individual variability in response: a review of the evidence by S. Leucht (S183).
S.05.02 Early response as a response predictor: use of individual variability in clinical trials by B.J. Kinon; L. Chen; H. Ascher-Svanum; V. Stauffer; S. Kollack-Walker; W. Zhou; S. Kapur; J. Kane (S183).
S.05.04 Pharmacogenetics of antipsychotic response: how much of the variance can be explained? by A. Meary (S184).
S.05.03 The inherent trajectories in antipsychotic response: beyond simple responders and non-responders by S. Kapur; O. Arenovich; O. Agid; B. Muthen; L. Chen; B. Kinon (S184).
S.04.06 The role of serotonin in memory-related cortices for cocaine-induced place preference and hyperlocomotion by C.P. Muller; M.E. Pum; R.J. Carey; J.P. Huston (S182).
S.04.05 Effects of early exposure to ethanol and/or a cannabinoid receptor agonist on alcohol preference at adult age in mice by J. Molet; M. Hamon; L. Lanfumey (S181-S182).
S.04.01 The brain noradrenergic and serotonergic systems as unknown factors regulating the activity of cytochrome P450 by M. Kot; W.A. Daniel (S180).
S.03.05 CNS infections during childhood and risk for schizophrenia: a historical-prospective study on 3,500 children hospitalised for CNS infections in childhood by M. Weiser; N. Werbeloff; A. Levine; G. Livni; S. Schreiber; D. Halperin; M. Davidson (S180).
S.04.02 M- and T-tropic HIVs cause apoptosis in rat neuronal cell culture by F. Biggio; A. Bachis; I. Mocchetti (S180-S181).
S.04.03 Sarizotan stimulates cell proliferation in neurogenic regions in experimental Parkinsonism by M. Egeland; X. Zhang; P. Svenningsson (S181).
S.04.04 Transient expression of phospho-acetylated form of histone H3 in medial prefrontal cortex of rats treated with MK-801 by R. Guzik; M. Mackowiak; D. Dudys; K. Wedzony (S181).
S.15.01 Heart rate dynamics during conditioned fear in mice and its implications for affective disorders by O. Stiedl; J. Youn; R.F. Jansen; A.W. Pieneman; S.O. Ögren; M. Meyer (S197).
S.15.02 The impact of social stressors on cardiac function and structure in rodents by A. Sgoifo (S197).
S.25.03 Off-label use of antipsychotics: when is the benefit/risk ratio favourable? by R. Anand (S212).
S.25.01 Cardiovascular risks of antipsychotics: focus on QT modifications by M.D. Drici (S212).
S.26.03 Translational imaging in the development of psychopharmacological drugs by A. Bifone (S212-S213).
S.26.04 Modulatory effects of cannabinoids on memory-related brain activity: a pharmacological MRI study by G. Jager; M.G. Bossong; H.H. Van Hell; N.F. Ramsey (S213).
S.27.01 From animals to man: overview and main findings from the NewMood project by J.F.W. Deakin; G. Juhasz; I.M. Anderson; A. Payton; H. Platt; E. Pegg; D. Downey; I. Koychev; R. Elliott; K. Mekli (S214).
S.26.05 Multimodal imaging of receptor expression and function by M. Rudin (S213).
S.24.03 Amyloid plaque imaging in vivo by J. Seibyl; K. Marek (S211-S212).
S.24.02 The cell biology of Abeta generation by G. Multhaup; L. Muenter; A. Harmeier (S211).
S.22.05 Effects of stimulant treatment on subsequent substance use disorders and other psychiatric disorders in ADHD youth grown up: a prospective 10 year follow-up study by J. Biederman (S209).
S.22.04 Psychopharmacological treatment of impulsivity in personality disorders by S. Bellino; C. Rinaldi; P. Bozzatello; F. Bogetto (S209).
S.23.01 Genetic dissection of mouse avoidance behaviour: relevance for mood disorders by M.J.H. Kas; J.G. de Mooij-van Malsen; H.A. van Lith; G. Breen; D.A. Collier; B. Olivier (S210).
S.23.02 Role of hippocampus in the cognitive control of anxiety by C. Gross; A. Gruart (S210).
S.24.01 Paradigm shift in Abeta toxicity by T.A. Bayer; O. Wirths (S211).
S.23.03 Gene-environment interactions: relevance to the genetics of depression and anxiety disorders by K.P. Lesch (S210-S211).
S.27.02 Regulation of the raphe: adaptive and maladaptive responses to stress by L. Lanfumey; R. Mongeau; C. Martin; E. Paizanis; M. Hamon (S214).
S.27.03 Decreased VGLUT1 levels and long-term chronic mild stress: animal models addressing specific aspects of major depression by R.M. Tordera; A.L. Garcia-Garcia; N. Elizalde; E. Vénzala; M.J. Ramirez; J. Del Rio (S214-S215).
E.01.02 Clinical aspects of GABA by D. Nutt (S219).
E.01.01 Basic neuroscience focus on GABA by H. Mohler (S219).
E.02.03 Efficacy markers in depression by C. Harmer (S219-S220).
E.02.04 PET and investigation of brain neurobiology by G. Knudsen; S.G. Hasselbalch (S220).
E.03.03 Cognitive behavioural treatment for insomnia: which patients respond? by C. Espie (S220-S221).
E.03.02 Physiopathology of circadian rhythm and depression by G. Hajak (S220).
S.28.05 Gene-environment interaction and the serotonin transporter gene polymorphism by T. Canli (S217).
S.28.04 Serotonin transporter gene polymorphism and susceptibility to depression by L. Pezawas (S216-S217).
S.27.05 From gene to brain: neurotransmitter pathways to depression in humans by I.M. Anderson; G. Juhasz; R. Elliott; L.E.W. Deakin (S215).
S.27.04 Molecular mechanisms of individual vulnerability to depression in animals and humans by J. Harro (S215).
S.28.01 Serotonin, fertility and early embryonic development by F. Cote (S215-S216).
S.28.02 Serotonergic regulation of the development of specific neurons by M. Ugrumov (S216).
S.28.03 Serotonin control over neuronal migration by A. Dayer (S216).
S.22.02 Impulsivity and neurocognitive functioning in addiction by A. Verdejo-Garcia (S208-S209).
S.22.01 Translational research – from basic science of impulsivity to clinical implications by C.A. Winstanley (S208).
S.17.03 Do changes in 5HT function underlie CBT efficacy in panic disorder? by C. Bell; J. Potokar; S. Hood; J. Nash; C. Frampton; D. Hince; S. Argyropoulos; D. Nutt (S201).
S.17.01 Neuroimaging of cognitive behavioural therapy for depression and anxiety: towards personalised treatment by G. Siegle (S200-S201).
S.17.04 Oxytocin and social behaviour: implications for psychotherapy by M. Heinrichs (S201).
S.18.02 HPA stress axis functioning and delinquent behaviour in adolescents by L.M.C. Jansen; A. Popma (S201-S202).
S.18.04 Shared and disorder-specific brain dysfunctions in conduct disorder compared to ADHD by K. Rubia; R. Halari; M.J. Brammer; E. Taylor (S202).
S.18.03 Monoamine oxidases: relationship to personal traits and antisocial behaviour by L. Oreland; J. Hallman; K.W. Nilsson (S202).
S.16.05 Animal models of cognitive flexibility by S. Granon; J.P. Changeux; P. Serreau (S200).
S.16.04 DISC1 mouse model of gene-environment interactions in schizophrenia by M. Pletnikov; Y. Ayhan; B. Abazyan; C. Pardo; A. Sawa; M. Vogel; C. Ross (S200).
S.15.04 Defensive mobilisation and autonomic responding in anxiety disorders patients by A. Hamm (S198).
S.15.03 Neuroendocrine function and sub-clinical atherosclerosis in healthy adults by M. Hamer; K. O'Donnell; A. Steptoe; A. Lahiri (S198).
S.15.05 The intriguing interplay between depression and cardiovascular disease by I. Skoog (S198-S199).
S.16.01 Overview on animal models of schizophrenia by M.A. Geyer (S199).
S.16.03 Infection-based neurodevelopmental animal models for schizophrenia-like brain and behavioural pathology by U. Meyer (S199).
S.16.02 Prefrontal cortex and attention by V.J. Brown; D.S. Tait (S199).
S.18.05 Molecular-genetics of aggression and antisocial behaviour in clinical populations by R. Anney; J. Lasky-Su; The Image Consortium (S203).
S.19.01 Neurophysiology of histaminergic neurons in the brain by H.L. Haas; O.A. Sergeeva (S203).
S.21.01 Introduction: recent finding from ongoing NIMH studies by B. Vitiello (S206-S207).
S.20.05 Peripheral and brain BDNF as a marker of mood disorder by F. Karege; J.M. Aubry; R. La Harpe; G. Bertschi; A. Malafosse (S206).
S.21.02 Efficacy and safety of antipsychotics in early onset psychosis by M. Parellada; C. Arango; D. Moreno; M. Alvarez; C. Moreno; D. Fraguas (S207).
S.21.03 Antipsychotics for non-psychotic disorders by A. Zuddas; S. Paba; T. Usala (S207).
S.21.05 Influences of European regulatory issues on the development of new therapies in children by C.C. Gispen-de Wied; B.J. van Zwieten-Boot (S208).
S.21.04 Patient and parent reported outcome: quality of life (QoL) as effective measure by D. Coghill (S207-S208).
S.20.04 Consequences of altered BDNF protein levels on hippocampal serotonin neurotransmission and behaviour by A. Gardier; T. Deltheil; K. Tanaka; C. Reperant; R. Hen; D.J. David; B. Guiard (S205-S206).
S.20.03 Isoform expression and intracellular trafficking of BDNF following stress and antidepressant drug treatment by M.A. Riva; F. Calabrese; F. Macchi; G. Racagni; R. Molteni (S205).
S.19.03 Implications of histaminergic neurons heterogeneity in cognitive enhancement elicited by H3 antagonists by P. Blandina; M.B. Passani; L. Munari; P. Giannoni (S204).
S.19.02 Preclinical and clinical pharmacology of H3-receptor inverse agonists by J.C. Schwartz; J.C. Schwartz (S203-S204).
S.19.05 Results of clinical trials of tiprolisant in narcolepsy and Parkinson's disease by I. Arnulf (S204).
S.20.01 Neuronal plasticity, neurotrophins and antidepressants by E. Castren (S204-S205).
S.20.02 Functional analysis of BDNF polymorphism in a mouse model by Z.Y. Chen; H. Yu (S205).
P.1.d.013 Prenatal stress increases an anxiety, and alters corticosterone response to 5-HT2A/C agonist in adult female offspring by N. Ordyan; S. Pivina; T. Shamolina; J. Fedotova (S294-S295).
P.1.d.014 Reaching and grasping motor behaviours to study attention in mice: a pharmacological investigation by B. Greco; G. Lassi; V. Tucci (S295).
P.2.a.052 Use of antidepressants in the treatment of major depressive disorder in an outpatient mental health center by C. Gamier; B. Díaz; P. Alvaro; R. Sanchís; J. Castaño; D. Coreóles; L.M. Martín; A. Bulbena (S390-S391).
P.2.a.051 A systematic review and meta-analysis of sertraline for the treatment of depression in older people by A. Byrne; S. Curran (S389-S390).
P.2.b.001 Abnormalities of trace elements in depressed patients using hair analysis by H.M. Sung; J.B. Kim; S.W. Jung; I.H. Shin; Y.W. Kim (S391).
P.2.b.002 Chronic stress changes expression of the axonal membrane glycoprotein M6a in the brain by G. Flügge; B. Cooper; J. Alfonso; E. Fuchs (S391-S392).
P.2.b.004 Common structural features of the serotonin transporter identified by protein homology mapping by W. Kaschka (S392-S393).
P.2.b.003 Endothelial dysfunction in a rodent model of depression may underlie atherosclerosis formation by E. Isingrini; J.L. Freslon; M.C. Machet; V. Camus; C. Belzung (S392).
P.2.a.050 Post traumatic brain injury major depression and primary major depression: psychopathological and neuropsychological profiles by M.C. Mauri; A. Colasanti; S. Paletta; L.E. De Gaspari; D. Moliterno; G. Panza; G. Miserocchi; A.C. Altamura (S389).
P.2.a.049 Functional outcome after 12 months of deep brain stimulation for treatment resistant major depressive disorder by S.J. Rizvi; S.H. Kennedy; H. McNeely; P. Giacobbe; H.S. Mayberg; A.M. Lozano (S388-S389).
P.2.a.044 Efficacy of trazodone in primary insomnia; a double-blind randomised placebo controlled polysomnographic study by L.M. Paterson; D.J. Nutt; C. Durant; S.J. Wilson (S385-S386).
P.2.a.043 Psychoticism dimension in a population of patients with non-psychotic major depression disorder by V. Mantua; S. Calugi; E. Schiavi; M. Miniati; G.B. Cassano (S385).
P.2.a.045 Depressed patients show altered neural responses to an emotional Stroop task after response to citalopram treatment by E. Pegg; D. Amone; S. McKie; R. Elliott; J.F.W. Deakin; I.M. Anderson (S386).
P.2.a.046 Abnormal brain responses during social inclusion in depressive illness and effect of acute anti-depressant medication by P. Kumar; G. Waiter; T. Ahearn; M. Milders; I. Reid; J.D. Steele (S387).
P.2.a.048 NAtional Patient Sleep Assessment Questionnaire III (Napsaq-lll) in depression; a survey for psychiatrists by L. Paterson; S.J. Wilson; D.J. Nutt (S388).
P.2.a.047 A comparison of rating quality between subtitled and spoken Hamilton depression rating scale interviews by B. Friedmann; E. Braxton; H. Riordan; C.J. Weber; M.F. Murphy; N.R. Cutler (S387-S388).
P.2.b.005 Magnetisation imaging in major depressive disorder by N. van der Wee; C. Boersma; M. van Buchem; J. Milles; M.J. van Tol; A. Alemán; R. Demanescu; D. Veltman; F. Zitman (S393-S394).
P.2.b.006 Valence-specific frontal hypoactivation during word recognition in major depressive disorder by N. van der Wee; M.J. van Tol; L. Melby; M. Nielen; A. Alemán; L. Demenescu; M. van Buchem; F. Zitman; D. Veltman (S394).
P.2.b.016 Differential effect of serotonergic and noradrenergic antidepressants on brain activation during cognitive control task by G. Wagner; U. Pietsch; G. Peikert; C. Schachtzabel; K. Koch; J.R. Reichenbach; H. Sauer; R.G. Schlosser (S400).
P.2.b.015 Whole brain resting-state analysis reveals decreased connectivity in major depressive disorder by I. Veer; N. van der Wee; C. Beckmann; E. Baerends; M. van Tol; L. Ferrarini; J. Milles; A. Alemán; D. Veltman; S. Rombouts (S399-S400).
P.2.b.017 Differences in 5-HT1A neurotransmission between rats displaying a persistent high or low exploratory phenotype by K. Kõiv; J. Harro (S400-S401).
P.2.b.018 Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype by E. Aso; A. Ozaita; A. Busquets; M.A. Serra; R. Maldonado (S401-S402).
P.2.b.020 5-HT2C receptor activation inhibits stress-induced increase in 5-HT transmission: relevance of receptor desensitization to the anxiolytic effect chronic antidepressant drugs and mutation in mice by R. Mongeau; C. Martin; C. Chevarin; R. Maldonado; M. Hamon; P. Robledo; L. Lanfumey (S402-S403).
P.2.b.019 Different modulation of transcription profiles in hypothalamus of mice bred for high and low stress-induced analgesia following chronic mild stress by P. Lisowski; G.R. Juszczak; J. Goscik; M. Wieczorek; A.H. Swiergiel (S402).
P.2.b.014 Four days of citalopram increase in vitro glucocorticoid receptor function in healthy volunteers by L. Carvalho; M.F. Juruena; A.S. Papadopoulos; L. Poon; A.J. Cleare; C.M. Paríante (S399).
P.2.b.013 Social isolation and "depressed" Flinders Sensitive Line rats: behaviour, steroids, and neuronal plasticity markers by M. Bianchi; N. Ladurelle; P. Liére; A. Pianos; A.A. Mathé; E.E. Baulieu (S398).
P.2.b.008 Metabotropic glutamate receptor 5: role in depression? by A. Deschwanden; S.M. Ametamey; A. Johayem; G. Westera; Y. Auberson; A. Buck; G. Hasler (S395-S396).
P.2.b.007 Pain and depression: occurrence of pain among patients with mild and moderate depression by K. Krysta; K. Pasternak; P. Prucnal; I. Irena Krupka-Matuszczyk (S394-S395).
P.2.b.009 The association of pain vigilance and awareness with subclinical depression by D. Pap; G. Xenia; J. Lazary; A. Benko; E. Molnar; G.Y. Bagdy (S396).
P.2.b.010 Evaluating nociceptive behaviour in the Wistar Kyoto rat model of depression by P. Calpin; N. Burke; D.P. Finn; M. Roche (S396-S397).
P.2.b.012 Long-term neurobiological changes by chronic mild stress and residual alterations after antidepressant discontinuation by N. Elizalde; A.L. Garcia-Garcia; S. Totterdell; N. Gendive; E. Vénzala; M.J. Ramirez; J. Del Rio; R.M. Tordera (S397-S398).
P.2.b.01l A new preclinical model of vulnerability to depression-like behaviours by A. Blugeot; B. Zeau; C. Rivat; C. Becker; J.J. Benoliel (S397).
P.2.a.042 Comparison of six antidepressants in terms of time to discontinuation by V. Karabulut; Y.C. Cengiz; B. Ozcelik; R. Onem; A. Tekin; O. Tankaya; G. Alpak; O. Karamustafalioglu (S384-S385).
P.2.a.041 Duration of untreated illness (DUI) in first-depressive episodes: the earliest treatment, the better outcomes by J. De Diego-Adeliño; M.J. Portella; D. Puigdemont; R. Pérez-Egea; R. Morgan-Ferrando; E. Álvarez; V. Pérez (S384).
P.2.a.021 Insomnia as a predictor of depression in UK primary care by F. de Vries; A.M. Gallagher; M.H. Lader; A.T. Tylee; J. Donoghue; S.M. Cockle; T.P. van Staa; D.J. Nutt (S372-S373).
P.2.a.020 The catechol-O-methyltransferase gene might be associated with males major depression by S.Y. Huang; M.J. Shih; C.L. Lin; W.C. Lin (S371-S372).
P.2.a.022 Comorbidity between depression, anxiety disorders and infertility: effect on quality of life in Egyptian women by D.N. Radwan; H. Ramy; A. Elmissiry; K.H. Moussa; M. Elsayed; M. Mansour; A. Khalil (S373).
P.2.a.023 Gender differences in symptoms and comorbidity patterns in Dutch depressive outpatients: the Leiden Routine Outcome Monitoring (ROM) Study by N. van der Wee; M.S. van Noorden; E. Giltay; M. den Hollander-Gijsman; R. van der Lem; Y. Rood; E.G. Zitman (S373-S374).
P.2.a.025 Neural effects of 7-day anti-depressant treatment on reward by C. McCabe; P.J. Cowen; C.J. Harmer (S374-S375).
P.2.a.024 Alcohol use disorder and its associations with polymorphisms on ALDH2, BDNF, 5-HTTLPR and MTHFR in older Korean men by J.M. Kim; K.Y. Bae; J.A. Yoo; I.S. Shin; S.W. Kim; S.J. Yang; T. Youn; K.H. Chung; J.S. Yoon (S374).
P.2.a.019 Decreased fronto-limbic gray matter volume associated with recurrent major depressive disorder by D. Arnone; E.J. Pegg; S. McKie; D. Downey; R. Elliott; S.R. Williams; J.F.W. Deakin; I.M. Anderson (S371).
P.2.a.018 Persistence and compliance to antidepressant treatment in patients with depression: a chart review by N. Sawada; H. Uchida; T. Suzuki; K. Watanabe; T. Kikuchi; S. Nio; T. Tsuboi; T. Handa; H. Kashima (S370-S371).
P.2.a.013 Dynamic of electroencephalography indicators in non-psychotic depressions of late age in the course of treatment with an SSRI by S. Odarchenko (S368).
P.2.a.012 Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine by A. Suwa; M. Wakeno; A. Tajika; M. Kato; Y. Takekita; T. Kinoshita (S367).
P.2.a.014 The triallelic 5-HTTLPR polymorphism may be associated with major depression in male Han Chinese population by S.Y. Huang; M.J. Shy (S368-S369).
P.2.a.015 Effects of extended release quetiapine fumarate on long-term functioning and sleep quality in patients with major depressive disorder by H. Svedsater; D. Sheehan; C. Datto; J. Locklear (S369).
P.2.a.017 Fatigue questionnaire: sensitivity to changes in depression severity in depressed patients by P. Ferentinos; V.P. Kontaxakis; B. Havaki-Kontaxaki; D. Dikeos; G.N. Papadimitriou (S370).
P.2.a.016 Increased neural responses to sad facial expressions in current but not remitted major depression by D. Amone; E.J. Pegg; S. McKie; D. Downey; R. Elliott; S.R. Williams; I.M. Anderson (S369-S370).
P.2.a.026 Meta-analysis of region of interest studies in unipolar depression and bipolar disorder by D. Arnone; A.M. Mclntosh; K.P. Ebmeier; J.M. Anderson (S375).
P.2.a.027 Effect of bupropion for nicotine dependece in patients with major depressive disorder: an open clinical trial by H. Kim; K.J. Lee (S375-S376).
P.2.a.036 Depression and anxiety among couples presenting for In-Vitro-Fertilization and Embryo Transfer (IVF/ET) by S. Sonawalla; R. Parikh; F. Parikh (S381).
P.2.a.035 Persistence with hypnotics in depressed patients treated in UK primary care by A.M. Gallagher; F. De Vries; J. Donoghue; D.J. Nutt; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S380-S381).
P.2.a.037 The efficacy and safety of milnacipran 50 mg bid in patients with major depression: the results of a clinical trial by A. Gogus; T. Oral; O. Berksun; O. Karamustafalioglu; S. Vahip; Z. Tunca; O. Yazici (S381-S382).
P.2.a.038 The prevalence of major depressive disorder and bipolar disorder in freshmen assessed by self reported screening test by K.J. Min; W.M. Bahk; Y.C. Shin; B.H. Yoon; D.I. Jon; J.H. Song; E.H. Hur; B.S. Choi (S382).
P.2.a.040 Effects of magnetic seizure therapy and electroconvulsive therapy in treatment-resistant depression by S. Kayser; B.H. Bewernick; C. Grubert; B. Hadrysiewicz; A. Koch; J. Grofle Bley; N. Axmacher; T. Schlaepfer (S383).
P.2.a.039 Comparison of two different intensities of repetitive transcranial magnetic stimulation in drug resistant depression by O. Karamustafalioglu; U.E. Uzun; O. Tankaya; G. Alpak (S382-S383).
P.2.a.034 The risk of suicide and suicidal ideation in depressed patients with sleep disturbance by A.M. Gallagher; F. De Vries; A.T. Tylee; M.H. Lader; J. Donoghue; S.M. Cockle; T.P. van Staa; D.J. Nutt (S379-S380).
P.2.a.033 Initiation of hypnotics or anxiolytics in depressed patients treated in UK primary care by A.M. Gallagher; F. De Vries; D.J. Nutt; J. Donoghue; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S379).
P.2.a.029 Comparison of treatment adherence between antidepressants monotherapy and antipsychotics augmentation with depression by Y.M. Jae; S.H. Jang (S376-S377).
P.2.a.028 Acute and chronic effects of naturalistically smoked cannabis on depression and anxiety by T.P. Freeman; C.J.A. Morgan; G. Schafer; H.V. Curran (S376).
P.2.a.030 Decreased BDNF mRNA in blood peripheral mononuclear cells of patients with unipolar major depression, who had a lack effect on plasma BDNF by B.H. Lee; H.K. Yoon; Y.K. Kim (S377-S378).
P.2.a.03l A cross-cultural, comparative study of the prevalence and symptom patterns of depression among college students by R. Parikh; S. Sonawalla; S. Sharma-Pandey; A. Farabaugh; A. Yeung; S. Safren; M. Fava (S378).
P.2.a.032 Resource use in depressed patients with sleep disturbance by A.M. Gallagher; F. De Vries; D.J. Nutt; J. Donoghue; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S378-S379).
P.2.b.021 First characterisation of tryptophan hydroxylase-2 (Tph2) knockout mice by L. Gutknecht; J. Waider; S. Merker; L. Lanfumey; M. Hamon; K.P. Lesch (S403).
P.2.c.001 Paroxetine for the treatment of old age depression: a systematic review by S. Curran; R. Rampat; R. Spencer; V. Minogue; J. Wattis (S403-S404).
P.2.c.043 Modeling and simulation to optimise efficacy and tolerability for a once-a-day trazodone formulation by V. Lemaire; C. Benquet; D. Le Garree; S. Robertson; D. Smith; S. Stahl (S428).
P.2.c.042 Effects of escitalopram on the modulation of the identification of facial expressions by healthy women: a fMRI study by C.M. Del-Ben; A. Sponholz; R. Shuhama; S. McKie; J.F.W. Deakin; F.G. Graeff (S427-S428).
P.2.c.044 Developing guidelines for the treatment of resistant unipolar depression across primary and secondary care by M. Agius; R. Zaman; K. Klepacka (S428-S429).
P.2.c.045 Outcome of escitalopram treatment based on baseline severity of depression by S. Stamouli; V. Lagari; A. Liakouras; P. Grigoriou; P. Piperos; D. Giailoglou (S429).
P.2.d.002 The phosphodiesterase 2 inhibitor BTT5001 demonstrates anxiolytic, anti-depressive and pro-cognitive efficacy in vivo by B. Langen; T. Hage; H. Stange (S430-S431).
P.2.d.001 Dose-dependent effects of caffeine in a chronic mild stress model of depression in ICR mice by J. Tchekalarova; D. Pechlivanova; V.V. Petkov; R. Nikolov; K. Yakimova (S430).
P.2.c.041 Biomarkers for the combined efficacy of cognitive behavioural therapy in antidepressant treatment in depression by A. Nocon; K. Hackmann; H. Pfister; B. Heldmann; M. Rosenhagen; S. Lucae; M. Ising (S427).
P.2.c.040 A randomised, double-blind, placebo-controlled, active-referenced study of Lu AA21004 in patients with major depression by F. Artigas; M. Dragheim; H. Loft; V. Perez; E. Álvarez (S426-S427).
P.2.c.034 Prefrontal metabolic abnormalities in major depressive disorder: a proton magnetic resonance spectroscopy study by M.J. Portella; R. Morgan-Ferrando; B. Gómez-Ansón; J. De Diego-Adeliño; D. Puigdemont; R. Pérez-Egea; E. Álvarez; J. Ruscalleda; V. Pérez (S423-S424).
P.2.c.033 Psychotropic medication in Spanish population setting: treatment adequacy for major depressive disorder by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pascual-Arce; M.C. Pérez-Navarro; R. Navarro-Artieda; L. García-Sánchez; N. Muro-Perea (S422-S423).
P.2.c.035 Fitness to drive under selective antidepressants by G. Laux (S424).
P.2.c.036 Increase of 5-HTT occupancy during escitalopram or citalopram treatment correlates with antidepressant efficacy in major depressive disorder by E. Akimova; M. Savli; D. Haeusler; M. Fink; A. Hahn; W. Wadsak; M. Mitterhauser; R. Lanzenberger; K. Kletter; S. Kasper (S424-S425).
P.2.c.038 Duloxetine versus placebo in patients with major depressive disorder (MDD): assessment of energy and vitality in MDD by T.M. Myers-Oakes; M.E. Thase; A.L. Meyers; J. Ahl; A. Prakash; L.B. Marangell (S425-S426).
P.2.c.037 Assessing the pharmacokinetics of venlafaxine er 75 mg and desvenlafaxine 50 mg in CYP2D6 extensive and poor metabolisers by C. Kane; A. Nichols; K. Focht; Q. Jiang; S. Preskorn; M. Burczynski (S425).
P.2.d.003 Acute and chronic antidepressants downregulate FADD in rat brain: involvement of monoamine receptors by J.A. Garcia-Sevilla; M.J. Garcia-Fuster (S431).
P.2.d.004 S41744, a dual NK1 antagonist/5-HT reuptake inhibitor and antidepressant: a comparison to aprepitant and paroxetine by M. Broceo; A. Gobert; C. Mannoury la Cour; A. Dekeyne; G. De Nanteuil; B. Olivier; T.R. De Jong; T.I. Cremers; G. Flick; M.J. Millan (S432).
P.2.d.013 Electrophysiological study of the effects of the novel antidepressant Lu AA21004 on the rat 5-HT neuronal activity by N. Haddjeri; A. Etievant; N. Moore; S. Miller; C. Sánchez; C. Betry (S437).
P.2.d.012 Ketamine, memantine and traxoprodil for treatment of depression: in vivo neurochemical mechanism of action by G.N. Smagin; D. Song; H. Wang; J.J. Doherty; V.S. Palamarchouk (S436-S437).
P.2.d.014 Evaluation of the antidepressant effect of new synthesized alpha2-adrenoceptor antagonists by C. Muguruza; F. Rodriguez; J.E. Ortega; L. Urigiien; J.J. Meana; I. Rozas; L.F. Callado (S437-S438).
P.2.d.015 Tissue type plasminogen activator gene polymorphisms and mirtazapine responses in Koreans with major depression by M.S. Lee; H.S. Chang; H.Y. Lee; J.H. Paik; B.J. Ham; R.H. Kang; Y.J. Jeong; H.M. Kim (S438).
P.2.d.017 Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders by A. Mørk; L.T. Brennum; S. Fallón; S. Bisulco; K. Frederiksen; B. Bang-Andersen; A.B. Lassen; H. Zhong; C. Sanchez; T.B. Stensbøl (S439).
P.2.d.016 The beta3 adrenoceptor agonist amibegron counteracts stress-induced behavioural and neurobiological changes by A. Tamburella; V. Micale; G.M. Leggio; F. Drago (S438-S439).
P.2.d.01l Anxiety profile and arginine vasopressin receptor 1B (AvpMb) expression in male and female flinders rats after chronic antidepressant treatment by I. Sotiropoulos; N. Kokras; P.M. Pitychoutis; O.F.X. Almeida; Z. Papadopoulou-Daifoti (S436).
P.2.d.010 Single and chronic agomelatine treatment differently affect cerebral a1-adrenergic receptors by I. Nalepa; K. Wieczerzak; M. Kowalska; D. Nawrat; J. Vetulani (S435-S436).
P.2.d.006 Use of antidepressants and the risk of the metabolic syndrome: the Netherlands Study of Depression and Anxiety (NESDA) by A.K.B. van Reedt Dortland; E.J. Giltay; T. van Veen; F.G. Zitman; B.W.J.H. Penninx (S433).
P.2.d.005 Effects of chronic treatment with 7-nitroindazole on rat hippocampal gene and protein expression after swimming stress by F. Ferreira; S. Joca; D. Pinheiro; A. Santos; W. Silva; A. Catalan; L. Greene; F. Guimaraes (S432-S433).
P.2.d.007 Reversible inactivation of the medial prefrontal cortex induces antidepressant-like effects in rats by F.S. Guimaraes; A.A. Scopinho; M.A. Scopinho; F.M.A. Correa; S.R.L. Joca (S433-S434).
P.2.d.008 Platelet markers before and after trazodone in depressed patients by D. Marazziti; G. Consoli; M. Picchetti; F. Golia; S. Silvestri; S. Baroni; I. Másala; M. Carlini; L. Dell'Osso (S434).
P.2.d.009 Differential effects of fluoxetine or venlafaxine treatment on maternal separation, an experimental model of depression by E. Martisova; B. Aisa; R. Tordera; B. Lasheras; J. Del Rio; M.J. Ramirez (S434-S435).
P.2.c.032 Young patients with type 2 diabetes mellitus are frequently depressed by L. Berge; T. Riise; A. Lund; O. Hundal (S422).
P.2.c.031 Safety and tolerability of adjunctive aripiprazole in major depressive disorder: pooled data from 3 short-term studies by J.Y. Loze; R. Gismondi; R. McQuade; W. Carson; R. Berman (S421-S422).
P.2.c.011 Duloxetine modulates pain-related brain response in patients with major depressive disorder by N. Cardoner; M. López-Sola; J. Pujol; R. Hernández-Ribas; J. Deus; H. Ortiz; B.J. Harrison; C. Soriano-Mas; E. Martinez_Amoros; J.M. Menchon (S409-S410).
P.2.c.010 Duloxetine for pathological laughing and crying in amyotrophic lateral sclerosis by P. Ferentinos; T. Paparrigopoulos; M. Rentzos; V. Zouvelou; I. Evdokimidis (S409).
P.2.c.012 Chronic SSRI treatment modifies blood oxygen level-dependent (BOLD) responses to emotional face expressions by D. Downey; K.E. Davies; S. McKie; G. Juhasz; I.M. Anderson; M.A. Smith; J.F.W. Deakin; S.R. Williams (S410).
P.2.c.013 Two generic antidepressant medications and their bio-equivalence or bio-inequivalence by F. Chenu; L. Batten; G. Zernig; E. Ladstaetter; C. Hebert; P. Blier (S411).
P.2.c.015 Efficacy of SSRIs in treating depression in patients with ischaemic heart disease, a meta-analysis by A.K. Barakzai; A.E. Ades; G. Lewis; X. Qian; S.J.C. Davies (S412).
P.2.c.014 Duloxetine in the treatment of depression comorbid with anxiety: a pilot study with 12-month outcomes by R. Bassetti; M.F. Bosi; A. Colombo; A. Roaro; R. Truzoli; G. Ba (S411-S412).
P.2.c.009 Duloxetine versus iv citalopram in partial/non responder depressed patients: a randomized placebo-controlled study by B. Dell'Osso; M. Buoli; A. Albano; S. Bortolussi; B. Benatti; I. Balossi; L. Oldani; A.C. Altamura (S408-S409).
P.2.c.008 Serotonin transporter gene polymorphisms, personality and response to serotonergic and noradrenergic antidepressants by R. Tranter; P. Muthuvelu; D. Bell; G. Juhasz; I.M. Anderson (S407-S408).
P.2.c.003 Mecamylamine improved disability of depressed subjects who did not respond adequately to citalopram by D. Hosford; R. Kuchibhatla; G. Dunbar (S404-S405).
P.2.c.002 Serotonin or noradrenalin reuptake inhibition in seasonal affective disorder: escitalopram versus reboxetine by E. Pjrek; A. Konstantinidis; E. Assem-Hilger; N. Praschak-Rieder; M. Willeit; S. Kasper; D. Winkler (S404).
P.2.c.004 Basic fibroblast growth factor (FGF2) gene polymorphisms could contribute to SSRIs treatment response and tolerability by M. Kato; G. Okugawa; M. Wakeno; Y. Takekita; S. Nounen; S. Tetsuo; J. Azuma; A. Serretti; T. Kinoshita (S405-S406).
P.2.c.005 Tolerability of combination of low-dose amisulpride with antidepressants in clinical practice by E. Ceskova; J. Suchopar; Z. Priborska (S406).
P.2.c.007 Benefits of switching antidepressants following early nonresponse by S. Nakajima; H.U. Uchida; T.S. Suzuki; H.T. Takeuchi; K.N. Nomura; K.W. Watanabe; H.K. Kashima (S407).
P.2.c.006 Analysis of longitudinal clinical scores in major depressive disorder trials: comparison of linear and non-linear mixed effect modelling by L. Iavarone; R. Gomeni (S406-S407).
P.2.c.016 Superior efficacy results of agomelatine versus main current SSRI/SNRI antidepressants in a pooled-analysis by S. Kasper; A. Hale; P. Lemoine (S412-S413).
P.2.c.017 Patients' behaviours towards side effects of antidepressants with a focus on gender-difference by T. Kikuchi; H. Uchida; T. Suzuki; R. Kitahata; J. Hirano; M. Tomita; K. Watanabe; H. Kashima (S413-S414).
P.2.c.026 Superior antidepressant efficacy of agomelatine vs fluoxetine in severe major depressive disorder patients: a randomised, double-blind study by A. Hale; R. Corral; O. Mencacci; J. Saiz Ruiz; C. Albarran Severo; V. Gentil (S418-S419).
P.2.c.025 Early pain response associated with better outcome in emotional symptoms in depressive patients treated with duloxetine by E. Schneider; U. Hegerl; M. Linden; D. Quail; T. Wagner; H.P. Hundemer (S418).
P.2.c.027 Daily treatment of patients with major depressive disorder: an exploratory study evaluating milnacipran and venlafaxine by D. Gourion; M.F. Poirier; J.P. Olié (S419).
P.2.c.028 Agomelatine antidepressant: advantages over sertraline and venlafaxine in "clinical effectiveness" by S.H. Kennedy (S419-S420).
P.2.c.030 Short-term antidepressant effectiveness and safety in bipolar non-rapid cycling depression: a naturalistic study by A. Tundo; F. Marchetti; I. Lega; P. Cavalieri; L. Borgioni (S421).
P.2.c.029 Suicide risk and choice of antidepressant by M. Agius; R. Zaman; M. Gilhooley; A. Davis (S420-S421).
P.2.c.024 024 Association study between BDNF genetic polymorphism and treatment responses of SSRI in major depressive disorder by Y. Lee; Y. Jung; J. Park; S. Kim; J. Kim; C. Kang; B. Lee; D. Lee (S417-S418).
P.2.c.023 Discerning the etiology of sexual dysfunction in Turkish patients with major depressive disorder: a preliminary study by A. Tufan; E. Ozten; S. Isik (S416-S417).
P.2.c.019 Lamotrigine use for unipolar depression in Korea by H. Sim; E. Kang; D. Lee (S414-S415).
P.2.c.018 Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy by A. Rakic Igniatovic; B. Miljkovic; D. Todorovic; I. Timotijevic; M. Pokrajac (S414).
P.2.c.020 Hidden partial non-compliance with antidepressants and its effect on treatment response by M. Reis; A.C. Åkerblad; L. von Knorring; L. Ekselius (S415).
P.2.c.021 Efficacy and safety of combined therapy with moclobemide and valproic acid or carbamazepine in depressive patients by M. Todorovic; A. Rakic Ignjatovic; B. Miljkovic; D. Todorovic; I. Timotijevic (S415-S416).
P.2.c.022 Efficacy of trazodone in patients with primary insomnia with and without concomitant depressive symptomatology by A. Wichniak; W. Jernajczyk; A. Wierzbicka; A. Sobianska; E. Szatkowska; K. Czasak; I. Musinska (S416).
R2.a.01l Risk factors of treatment resistance in major depression: results of multicenter TRES-DEP study by D. Dudek; J.K. Rybakowski; M. Siwek; T. Pawlowski; D. Lojko; A. Kiejna (S366-S367).
P.2.a.010 Simultaneous measurement of 23 plasma cytokines in late-life depression patients by Y. Chung; K. Lim; K. Lee; C. Hong (S366).
P.1.e.033 Subgenual cingulate volumes in offspring of bipolar parents by T. Novak; T. Hajek; M. Kopecek; E. Gunde; M. Alda; C. Hoschl (S319).
P.1.e.032 Gray matter volume reduction in right middle temporal gyrus and orbitofrontal cortex in panic disorder – a voxel-based morphometry MRI study by T. Sobanski; G. Wagner; G. Peikert; U. Gruhn; R.G. Schlosser; H. Sauer (S318-S319).
P.1.f.00l Prenatal exposure to alcohol changes the development of brain vessels in human embryos and fetuses by A.V. Solonsky; S.V. Logvinov; V.Y.A. Semke (S319-S320).
P.1.f.002 Plasma BDNF levels of patients with somatisation disorder and their alterations after pharmacotherapy by J.C. Yang; T.W. Park; Y.C. Chung; S.K. Chung; A.J. Jung; Y.K. Kim (S320).
P.1.g.002 Early course of disease, current cognitive and clinical status in chronic schizophrenia by A. Kalwa; M. Rzewuska; A. Pirog- Balcerzak; M. Luks; J. Skalska (S321).
P.1.g.00l Switch to lamotrigine due to adverse events following antiepileptic treatment by P. Corti; M.E. Gaspard; P. Bousquet; D. Strubel (S321).
P.1.e.031 Effect of EMDR treatment in PTSD patients: clinical and biological outcomes are stable in 1-year follow-up by M. Tavanti; L. Bossini; S. Calossi; F. Fanetti; D. Marino; G. Vatti; F. Pieraccini; P. Castrogiovanni; A. Fagiolini (S318).
P.1.e.030 Structural and metabolic abnormalities in bipolar I vs II disorder from combined voxel-based morphometry MRI and (18)F-fluorodeoxyglucose PET brain imaging by T. Su; C.T. Cheng-Ta Li; L.F. Li-Fen Chen; Y.S. Yong-Shen Chen; S.J. Shyh-Jen Wang; J.C. Jen-Chuen Hsieh (S317-S318).
P.1.e.025 Effects of the Amazonian psychoactive plant beverage ayahuasca on prefrontal and limbic regions during a language task: a fMRI study by D. Almeida Prado; J. Pinto; J. Crippa; A. Santos; S. Ribeiro; D. Araujo; A. Zuardi; C. Chaves; J. Hallak (S314-S315).
P.1.e.024 D2 receptor occupancy with HC-raclopride PET following single and multiple dose: does steady state make a difference? by M. Schmidt; E. Mannaert; P. De Boer; D. William; M. Neyens; T. van Iersel; A. Willemsen (S314).
P.1.e.026 Resting state connectivity between amygdala and orbitofrontal cortex reflects state anxiety in social phobia by P. Stein; A. Weissenbacher; A. Hahn; F. Gerstl; C. Windischberger; E. Moser; S. Kasper; R. Lanzenberger (S315).
P.1.e.027 Psychotic symptoms and relation to periventricular brain lesions in patients with multiple sclerosis by P. Kostaras; G. Moussas; A. Tselebis; F. Karra; M. Maltezou (S315-S316).
P.1.e.029 Cerebral volumetry in patients with systemic lupus erythematosus presenting neuropsychiatric manifestations by P. Louzada-junior; R. Oliveira; M.s. Carlos; L. Wichert-ana; A.c. Santos (S317).
P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients by S. Potkin; D. Keator; J. Mukherjee; A. Preda; D. Highum; A. Gage; J. Xie; P. Ghahramani; I. Laszlovsky (S316).
P.1.g.003 Theory of mind deficits in unaffected relatives of patients with schizophrenia and bipolar disorder by M.O. Yucel; H. Devrimci-Ozguven; E.T. Ozel-Kizil; S. Haran; M.C. Saka; E.C. Atbasoglu (S322).
P.1.g.004 Developing assessment tool of competency to consent to psychiatric admission treatment in the mentally ill by S. Kim; J. Yi; Y. Jeon; M. Rhee; M. Seo; S. Cho (S322-S323).
P.1.g.014 Effectiveness of cognitive behavioral therapy for comorbid obsessive compulsive disorder in patients with psychosis by A. Tundo; L. Salvati; D. Di Spigno; A. Parena; L. Cieri; S. Sciortino (S327-S328).
P.1.g.013 Neural correlates of the impaired response inhibition in obsessive-compulsive disorder: an event-related fMRI study by D. Kang; J.Y. Han; W.H. Jung; J.H. Jang; J.S. Kwon (S327).
P.1.g.015 Specific cognitive profile in depression remitters following electroconvulsive therapy: a comparison to nonremitters by M. Semkovska; D.M. McLoughlin (S328-S329).
P.1.g.016 Sleep deprivation-induced memory deficits in mice: role of state-dependency by C.L. Patri; L. Sanday; K.A. Zanin; J.M.C. Leite; T.F. Trombin; S.R. Kameda; M.L. Andersen; S. Tufik; R. Frussa-Filho (S329).
P.1.g.018 Tenses can have different effects on declarative processes by O.M. Koçak; S. Yüksel; A. Yilmaz; E. Eren-Kocak; K. Sayar (S330).
P.1.g.017 Sodium fluoride induced memory impairment is associated with changes in striatal monoaminergic levels by E.M. Losso; M. Pereira; P.A. Dombrowski; C. Da Cunha; R. Andreatini (S329-S330).
P.1.g.011 Chronic rapid eye movement sleep deprivation deteriorates long-term potentiation in the rat hippocampus by A.S. Artis; C. Suer; N. Dolu; L. Sahin; M. Ascioglu (S326-S327).
P.l.g.010 Noradrenaline re-uptake inhibition improves impulse control in the forced-choice serial reaction time task by E.S.J. Robinson; S. Cundy; F. Byrne; D. Ferguson (S326).
P.1.g.006 TMS over the dorsal visual pathway generates schizophrenia-like visual-deficit in healthy controls by R. Amiaz; A. Gershon; D. Vainiger; M. Weiser; M. Lavidor; D.C. Javitt (S323-S324).
P.1.g.005 Protective effect of new l-valine derivatives on brain function in experimental model of aggression in mice by E. Encheva; M. Novoselski; L. Tancheva; V.V. Petkov; S. Stancheva; L. Alova; D. Tsekova (S323).
P.1.g.007 Preliminary analysis of the functional consequences of the CACNA1C gene polymorphism in Bipolar Disorder by S. Frangou; G. Ruberto; E. Vassos (S324-S325).
P.1.g.008 Vitamin E ameliorates memory and changes the expression of nitric oxide-producing neurons in the brains of diabetic rats by R. Oliveira; D. Cornin; L. Gazarini; J.N. Zanoni; H. Milani (S325).
P.1.g.009 Psychomotor performance, fatigue, sleepiness and cognitive function in in-patients with major depression by D. Neu; X. Montana; Y.M. Vandriette; C. Kornreich; P. Peigneux; P. Verbanck; P. Linkowski; O. Le Bon (S325-S326).
P.1.e.022 Effect of bupropion on extracellular dopamine levels in the striatum: a translational PET approach by A. Egerton; J.P. Shotbolt; P.R. Stokes; O.D. Howes; P.M. Grasby (S313).
P.1.e.023 Longitudinal assessment of presynaptic dopamine function in the striatum: a F-DOPA PET test-retest study by A. Egerton; A. Demjaha; P.M. Grasby; P.K. McGuire; R.M. Murray; O.D. Howes (S313-S314).
P.1.e.002 Changes in brain perfusión in drug-naive panic patients with SPECT following cognitive-behavioural therapy by J.B. Kim; W.H. Nam; J.H. Chae; E.J. Chang; S.Y. Ryu; K.S. Won; S.K. Zeon; Y.A. Chung; H.M. Sung (S300-S301).
P.1.e.00l A dynamic [18F]-fally pride PET study: measuring dopamine neuromodulation in the extrastriatal reward circuit by E. Vrieze; J. Ceccarini; D. Pizzagalli; G. Bormans; K. Demyttenaere; K. Van Laere; S. Claes (S300).
P.1.e.003 Disorder-specific right inferior prefrontal dysfunction during inhibition in boys with ADHD compared to boys with OCD by K. Rubia; A. Cubillo; A. Smith; J. Woolley; M. Brammer (S301-S302).
P.1.e.004 Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier by O. de Klerk; F.J. Bosker; J.A. den Boer; A.T.M. Willemsen; A. van Waarde; P. Meerlo (S302).
P.1.e.006 Regional increase in P-glycoprotein function in the blood-brain-barrier of patients with chronic schizophrenia by O.L. de Klerk; A.T.M. Willemsen; F.J. Bosker; A.L. Bartels; N.H. Hendrikse; J.A. den Boer (S303).
P.1.e.005 Reduced activation and functional interconnectivity within fronto-striatal systems in adults with childhood ADHD by A. Cubillo; R. Halari; E. Taylor; K. Rubia (S302-S303).
P.1.d.022 Lipoxin A4 exerts neuroprotective effects mediated by the endocannabinoid system in mice by R.N. Takahashi; F.A. Pamplona (S299-S300).
P.1.d.021 Preliminary experimental data regarding the effect on spontaneous activity of systemically administered cobalt by B.I. Tamba; I.M. Jaba; D.G. Ionescu; O.C. Mungiu (S299).
P.1.d.016 Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alphal and alpha5 than alpha2 and alpha3 subunits by M.M. Milinkovic; M.M. Savic; S. Huang; R. Furtmüller; S. Majumder; J. Samardic; J.M. Divljakovic; B.L. Roth; W. Sieghart; J.M. Cook (S296).
P.1.d.015 Behavioural and molecular correlations in the rat chronic mild stress model of depression by O. Wiborg; K. Henningsen; E. Bouzinova; T. Christensen; S. Christiansen (S295-S296).
P.1.d.017 Blockade of 5-alpha reductase reduces compulsive behaviors in mice by V. Bini; R. Frau; M. Collu; S. Paba; P. Devoto; F. Marrosu; M. Bortolato (S296-S297).
P.1.d.018 WYS-8, a novel ligand at GABAA receptors: a step forward to linking in vitro with in vivo selectivity? by S.M. Joksimovic; M.M. Savic; M.M. Milinkovic; M. Van Linn; J. Ramerstorfer; S. Majumder; W. Yin; B.L. Roth; W. Sieghart; J.M. Cook (S297).
P.1.d.020 Object recognition and location memory in rats with electrolytic lesions of the dorsal and ventral striatal regions by G. Maglakelidze; M. Burjanadze; T. Naneishvili (S298-S299).
P.1.d.019 The effects of atrial natriuretic peptide on the emotional activity in rats exposed to chronic immobilization stress by E.A. Yildirim; M. Mengi; S. Turhan; E. Yurdakos (S297-S298).
P.1.e.007 Fronto-cerebellar brain dysfunction in adults with childhood ADHD during sustained attention and reward by A. Cubillo; R. Halari; A.B. Smith; E. Taylor; K. Rubia (S303-S304).
P.1.e.008 Methylphenidate modulates inferior and orbitofrontal brain activation in ADHD during sustained attention and reward by K. Rubia; R. Halari; A.I. Cubillo; E.T. Taylor (S304-S305).
P.1.e.017 Chronic SSRI treatment induces adaptive changes in brain 5-HT phMRI responses by D. Downey; K.E. Davies; S. McKie; G. Juhasz; I.M. Anderson; M.A. Smith; J.F.W. Deakin; S.R. Williams (S309-S310).
P.1.e.016 Proton magnetic resonance spectroscopy study in first-episode and chronic schizophrenic patients by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; B. Konarzewska; N. Waszkiewicz (S309).
P.1.e.018 Neural substrates of major depressive disorder: A voxel-based morphometric imaging study by B.J. Ham; M.S. Lee; S.H. Joe; I.K. Jung (S310-S311).
P.1.e.019 Imaging gender differences in serotonin-1A receptor lateralization in language areas of healthy subjects using PET by M. Fink; M. Lanzenberger; M. Savli; C. Spindelegger; M. Mitterhauser; W. Wadsak; P. Stein; A. Hahn; K. Kletter; S. Kasper (S311).
P.1.e.02l The effects of cognitive-behavioural therapy on brain regional cerebral blood flow in obsessive compulsive disorder by G. Berk; B.M. Ergun; Y. Narin; C. Basoglu; A.S. Gonul; S. Ebrinc; M. Cetin; M.Z. Sungur (S312).
P.1.e.020 Brain metabolite alterations in subjects at ultra-high risk for psychosis: magnetic resonance spectroscopy study by M. Byun; J. Choi; S. Yoo; D. Kang; C. Choi; D. Jang; W. Jung; J. Lee; J. Kwon (S311-S312).
P.1.e.015 Involvement of the endocannabinoid system in associative memory: a pharmacological MRI study by M.G. Bossong; H.H. Van Hell; G. Jager; A. Brouwer; R.S. Kahn; N.F. Ramsey (S308-S309).
P.1.e.014 The acute effects of delta-9-tetrahydro-cannabinol (THC) on brain activity during working memory by H.H. van Hell; M.G. Bossong; G. Jager; E. Saliasi; R.S. Kahn; N.F. Ramsey (S308).
P.1.e.010 Understanding postpartum blues: a time course of MAO-A levels in the living human brain during the postpartum period by J. Sacher; A.A. Wilson; P. Rusjan; S. Hassan; L. Jacobs; P.M. Bloomfield; D.E. Stewart; S. Houle; J.H. Meyer (S305-S306).
P.1.e.009 The disrupted-in-schizophrenia-1 ser704cys polymorphism and brain morphology in schizophrenia by M. Suzuki; T. Takahashi; M. Tsunoda; N. Maeno; Y. Kawasaki; S. Zhou; H. Tsuneki; S. Kobayashi; M. Kurachi; N. Ozaki (S305).
P.1.e.011 Clinical correlates of brain metabolite measures in chronic schizophrenia by A. Szulc; B. Galinska; E. Tarasow; B. Kubas; B. Konarzewska; N. Waszkiewicz; R. Poplawska (S306).
P.1.e.012 Switching off the human basolateral amygdala with the beta-noradrenergic antagonist propranolol by R. Hurlemann; O.A. Onur (S307).
P.1.e.013 Lorazepam impairs processing of frequency changes andnovel sounds: combined MEG/EEG study by S. Kahkonen; E. Pekkonen; P. Horn; J. Huttunen; R. Kivisaari; M. Korostenskaja (S307-S308).
P.1.h.001 Delayed sleep phase syndrome in burn patients by B.C. Lee; B.W. Lee; J.E. Park; I.Y. Kim (S331).
P.1.h.002 Cognitive functioning in childhood and adulthood risk for depressive symptoms in the 1970 British birth cohort by V. Matei; A. Reichenberg (S331-S332).
P.1.i.036 Genetic association with impaired decision-making and personality traits in suicide attempters by A. Szkaliczki; E. Krivek; B. Ando; A. Fehér; Z. Janka; P. Almos (S355).
P.1.i.035 Objective and subjective efficacy of ramelteon 4mg in adults with chronic insomnia by G. Hajak; L. Ferini-Strambi; S. Wang-Weigand; E. Waldron; T. Roth (S354-S355).
P.1.i.037 Rater training on SANS and monitoring of rater performance during clinical trials by G. Richa; S. DeSanti; J. Schoemaker (S355-S356).
P.1.i.038 Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder by R. Lasser; R. Weisler; J. Young; G. Mattingly; J. Gao; L. Adler; L. Squires (S356).
P.1.i.040 Increased expression of diabetic autoantigen PTPR-N in basal ganglia of Tourette's syndrome patients by A. Morer; W. Chae; Z. Tobiasova; O. Henegariu; F. Vaccarino; A. Bothwell; J.F. Leckman; I. Kawikova (S357).
P.1.i.039 Differences in melatonin therapy response in elderly patients with various ages at the onset of insomnia by S. Nastase; L. Nastase (S356-S357).
P.1.i.034 Efficacy outcomes during longterm prolonged-release methylphenidate treatment of adults with ADHD by L. Imhof; H.J. Nyerod; H.J. Filipe; J. Dejonckheere; S. Wachter; B. Schauble; J. Buitelaar; S. Kooij; M. Casas; J.C. Van Oene (S353-S354).
P.1.i.032 Improved trophic efficacy of glial cell-derived neurotropic factor (GDNF) after combination with TGF-beta 1 both in vitro and in vivo models of parkinsonism by E. Fernandez-Espejo; R. González-Aparicio (S353).
P.1.i.025 Vasopressin as stimulator of the cancerous growth metastases by A. Amikishieva; S.I. Ilnitskaya; N.A. Popova; V.P. Nikolin; M.D. Belyaev; T.G. Tolstikova; V.I. Kaledin (S350).
P.1.i.024 Arnold-Chiari type I malformation with psychiatric symptoms: a case report by F.O. Orhan; Z. Yuksel; O. Altunoren; I. Altun; S. Berk; O. Akman; M.F. Karaaslan (S349-S350).
P.1.i.026 The relationships between second to fourth digit length ratio (2D:4D) and psychological characteristics by D. Kang; H. Kim; W. Lee; Y. Lee (S350-S351).
P.1.i.029 Pharmacist interventions involving psychotropic medication in inpatient pharmacotherapy by B. Pascual Arce; N. Muro-perea; M. Blanca-tamayo; M.c. Pérez-navarro; L. García-sánchez; A. Sicras-maynar (S351-S352).
P.1.i.0311 Predictors of treatment outcome with long-acting methylphenidate in attention deficit hyperactivity disorder in adults by J.A. Ramos-Quiroga; S. Kooij; G.E. Trott; J.R. Medori; J. Dejonckheere; J.C. van Oene; B. Schauble; M. Casas; J. Buitelaar (S352-S353).
P.1.i.030 Eplivanserin in healthy participants: psychomotor and cognitive performance, alone and in combination with zolpidem by C. Roy; J. Micallef-Roll; A. Delfolie; J.L. Pinquier; O. Blin (S352).
P.1.i.041 Sport, physical health and lyfestyle in psychiatric illness by L. Ferrannini; C. Venturino; C. Pitto; M. Ferrari; P. Greco (S357-S358).
P.1.i.042 Quetiapine versus placebo in the treatment of delirium: a randomized controlled trial by T. Tahir (S358).
P.2.a.005 Serum BDNF levels correlate with hippocampal volumes in first episode, medication-free depressed patients by M. Eker; O. Kitis; F. Taneli; O.D. Ekec; E. Ozan; K. Yucel; K. Coburn; A.S. Gonul (S363).
P.2.a.004 A comparative study on alexithymia in depressive, somatoform, anxiety, and psychotic disorders among Koreans by S.J. Lee; H.D. Rim; H. Jo; S.H. Jeong; Y.H. Lee; U.S. Chung; J.J. Lee; J.M. Woo; Y.W. Park (S362-S363).
P.2.a.006 Sexual function in depressed outpatients with enduring personality change (F62.0) taking mirtazapine by M. Stojakovic; B. Stojakovic; S. Vukadinovic; V. Pandzic (S364).
P.2.a.007 Screening for depression during pregnancy by A. Bunevicius; L. Kusminskas; V.J. Pop; C. Pedersen; R. Bunevicius (S364-S365).
P.2.a.009 Prediction of response to serotonin reuptake inhibitors in patients with depression: QEEG cordance value as a predictor by M. Bares; M. Brunovsky; T. Novak; M. Kopecek; P. Stopkova; P. Sos; V. Krajca (S365-S366).
P.2.a.008 Right-sided, 1-Hz repetitive TMS compared with venlafaxine extended-release in the treatment of resistant depression: a double-blind study by M. Bares; M. Kopecek; T. Novak; P. Stopkova; P. Sos; J. Kozeny; M. Brunovsky; C. Hóschl (S365).
P.2.a.003 Prescription pattern and side effect profiles of bupropion by W.M. Bahk; K.U. Lee; D.I. Jon; K.J. Min; Y.C. Shin; Y.S. Woo; C.H. Kim (S362).
P.2.a.002 An audit on informed choice in the treatment of depression by B. Luft (S361-S362).
P.1.i.044 Evaluation of cognitive functioning in young, professionally active men after coronary bypass by A. Woznica; L.J. Krzych; A. Pawlak; J. Skarysz; Z. Eysymontt; I. Krupka-Matuszczyk; K. Krysta; A. Bochenek; M. Cisowski (S359).
P.1.i.043 Protective personality factors associated with premenstrual symptomatology in healthy women by X. Gonda; T. Telek; D. Pap; G. Csukly; K.N. Fountoulakis; H.G. Kiss; G. Bagdjr (S358-S359).
P.1.i.045 Lesion and stimulation of the mesolimbic motivational dopamine system influence peripheral blood lymphocyte number by K. Plucinska; B. Grembecka; W. Glac; P. Badtke; G. Jerzemowska; D. Myslinska; D. Wrona (S359-S360).
P.1.i.046 C-reactive protein gene polymorphisms are associated with cortisol awakening response by G. Veen; E.J. Giltay; R.H. de Rijk; I.M. van Vliet; E.G. Zitman (S360).
P.2.a.00l Antidepressive therapy effects on emotional cognition in elderly depressed patients by E. Savaskan; S.E. Miiller; A. Bohringer; A. Schulz; H. Schachinger (S361).
P.1.i.023 Anxiety and depressive symptoms in bone marrow transplantation patients:impact on quality of life by M. Abd el Meguid; M. Moussa (S349).
P.1.i.022 High level of TV viewing is associated with silent inflammation by J. Korkeila; J. Markkula; P. Korhonen (S348-S349).
P.1.i.002 Potential in vitro and in vivo teratogenicity of selective and mixed monoaminergic re-uptake inhibitors by W. Sloot (S337).
P.1.i.001 A year in the psychiatric clinic of general hospital Thriasio; statistical analysis of the patients characteristics by E. Neroutsos; G. Vagionis; G. Andreou; M. Fiste (S336-S337).
P.1.i.003 Chain reactions: polyunsaturated fatty acids and the depressive phenotype in maternally separated rodents by G. Clarke; S.M. O'Mahony; P. Ross; C. Stanton; J.F. Cryan; T.G. Dinan (S337-S338).
P. 1.i.004 Characterization of conditioned fear-induced c-Fos and phosphorylated CREB-positive cells in the basolateral amygdala by T. Izumi; T. Inoue; K. Konno; T. Yamaguchi; T. Yoshida; M. Watanabe; T. Koyama; M. Yoshioka (S338).
P.1.i.006 Comparison of characteristics of Korean patients with narcolepsy or obstructive sleep apnea syndrome by S. Lee; S. Hong; H. Lee; J. Jeong; J. Han (S339).
P.1.i.005 Influence of psychotropic medication on sexual experiences of patients suffering from schizophrenia or depression by M. Vucic Peitl; V. Peitl; E. Pavlovic; D. Ljubicic (S338-S339).
R1.h,010 Quality of life in young and professionally active men undergoing on-pump coronary artery bypass grafting by L.J. Krzych; A. Woznica; A. Pawlak; J. Skarysz; Z. Eysymontt; I. Krupka-Matuszczyk; A. Bochenek; M. Cisowski (S336).
P.1.h.009 Treatment of manic patients during hospitalisation – a retrospective chart review in 2004-2008: what has changed? by O. Yazici; O. Aydemir; S. Guloksuz; F. Akdeniz; C. Yenilmez; C. Akkaya; P. Cetinay; N. Ozpoyraz; A. Bozkurt; N. Kalkan Oguzhanoglu (S335).
P.1.h.004 Socio-demographic and clinical characteristics of elderly patients in acute psychiatric unit during ten year follow up by M. Serrano Vazquez; M.M. Serrano Carton; M.C. Serrano Carton; E. Bobadilla Perez (S332-S333).
P.1.h.003 Psychotropic medication consumption evaluation in hospitalized patients: comparison between 2004 and 2008 by B. Pascual Arce; A. Sicras-Mainar; M.C. Pérez-Navarro; L. García-Sánchez; N. Muro-Perea; M. Blanca-Tamayo (S332).
P.1.h.005 Incidence rate and prevalence of obsessive-compulsive disorder in treatment-seeking primary care patients by J.H. Veldhuis; T. Wohlfarth; J. Dieleman; J.G. Storosum; W. van den Brink; M.C.J.M. Sturkenboom; D.J.A.P. Denys (S333).
P.1.h.006 Frequency of insomnia symptoms and their ‘day-after’ consequences in Mexican patients treated by primary care physicians by J. Espinosa-Avila; G. Equinox Study Group (S333-S334).
P.1.h.008 Prevalence of chronic obstructive pulmonary disease among those with serious mental illness by A. Karkanias; A. Kapsokaliva; G. Moussas; M. Lerikou; L. Stournara; G. Pavlakou; O. Anagnostopoulou (S334-S335).
P.1.h.007 Association of reported nighttime sleep and daytime nap with 19-year mortality in older adults by K. Jung; C. Song; J. Kim; E. Barrett-Connor (S334).
P.1.i.007 The effects of providing verbal and translated psychiatric medication information to non-English speaking (CALD) patients with a mental illness by N. Tran; D. Castle (S339-S340).
P.1.i.008 Identifying patients with high pharmacy consumption by using the adjusted clinical groups in a primary care setting by A. Sicras-Mainar; R. Navarro-Artieda; S. Velasco-Velasco; J. Serrat-Tarrés; A. Prados; J. Estelrich (S340-S341).
P.1.i.017 Amelioration of affective disorders and quality of life in obstructive sleep apnea (OSA) patients following continuous positive airway pressure (CPAP) therapy by T.J. Paparrigopoulos; N.T. Economou; I. Koutsourelakis; H. Giannakopoulou; I. Kritikou; E. Perraki; F. Christidi; I. Zalonis; E. Vagiakis; C.R. Soldatos (S345-S346).
P.1.i.016 Serotonin, impulsivity and gender by D. Marazziti; S. Baroni; I. Másala; G. Consoli; M. Picchetti; F. Golia; M. Catena Dell'Osso; G. Giannaccini; L. Betti; A. Lucacchini (S345).
P.1.i.018 Clinical semantics, semiology and auto-evaluation. The challenging case of fatigue and sleepiness by D. Neu; D. Pieters; E. Morel; X. Montana; G. Hoffmann; P. Verbanck; R. Cluydts; P. Linkowski; O. Le Bon (S346-S347).
P.1.i.019 Social support and high-sensitivity C-reactive protein (hCRP) in a representative, stratified population sample by S. Runsten; K. Korkeila; O. Vainio; J. Korkeila (S347).
P.1.i.02l Neuroendocrine and psychological factors in chronic fatigue syndrome by J. Bushnell; J.A. Harvey; P.M. Ellis (S348).
P.1.i.020 Psychopathology during pregnancy and postpartum: characterization of a selected high risk Italian sample by G. Petrilli; R. Anniverno; C. Mencacci; J.M.C. Blom (S347-S348).
P.1.i.015 Serum folate, vitamin B12, and homocysteine in acute patients with schizophrenia, depression, or bipolar disorder by F.J. Trujillo; J.M. Raya; J. Monzón; T. Rodriguez-Martos; M. Salinas; T. Martin-Santos; M. Sanginés; M. Henry; A. Jiménez-Sosa; R. Gracia (S344-S345).
P.1.i.014 Serum levels of vitamin B12, folate, and homocysteine in patients with persistent suicidal ideation or suicide attempt by F.J. Trujillo; J.M. Raya; J. Monzón; T. Rodriguez-Martos; A. Renshaw; L. Morabito; M. Henry; R.M. Morales; A. Jiménez-Sosa; R. Gracia (S343-S344).
P.1.i.010 Social and cognitive functioning as risk factors for suicide: a historical-prospective cohort study by N. Werbeloff; M. Weiser; G. Lubin (S341-S342).
P.1.i.009 Methylphenidate for adults with attention deficit-hyperactivity disorder, a systematic review by T. Epstein; N.A. Patsopoulos; M. Weiser (S341).
P.1.i.01l A standardisation of the Korean version of reaction inventory to measure anger by I.S. Chee; J.L. Kim; S.K. Wang; S.Y. Kim; Y.W. Cho (S342).
P.1.i.012 Treatment of insomnia in patients with schizophrenia by O. Dimova; V.F. Filovska; K.M. Kujundziska (S342-S343).
P.1.i.013 Neuropsychiatric drugs consumption: a pharmacoepidemiological study by M. Ponte; P.F. Garcia Merletti; E.L. Jurisic (S343).
PL.01.01 The neurobiological basis of addictive behaviour: a genetic perspective by G. Schumann (S173).